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Abstract 
Asthma, a chronic inflammatory disease of the airways, is associated with 
mucus hypersecretion by airway epithelium. Accumulated mucus in the airways 
contributes to airway obstruction, airway hyperresponsiveness and sometimes 
death. In a murine model of asthma, chronically blocking β2-adrenoceptors (β2-
ARs) or genetic ablation of β2-ARs causes a reduction in mucus secretion, an 
index of inflammatory responses, in response to allergen. The detailed molecular 
components of these effects remain to be elucidated.  
We examined the β2-AR signaling pathways involved in mediating mucin 
production in response to IL-13 in airway epithelial cells. The expression of 
MUC5AC, the predominant mucin-producing gene in asthma, and mucin content 
were induced by IL-13 in normal human bronchial epithelial (NHBE) cells as 
compared to control cells only in the presence of epinephrine. Blocking β2-ARs, 
but not β1-ARs, attenuated the IL-13 effect. The three members of MAPK family, 
ERK1/2, p38 and JNK, were all involved in inducing mucin production in 
response to IL-13 in the presence of epinephrine.  
Since β2-ARs signal through the canonical Gs-adenylyl cyclase or β-
arrestin signaling cascade, we examined each pathway separately. Elevating 
intracellular cAMP levels was associated with enhanced IL-13 response, either in 
the presence or absence of epinephrine and increased epithelial cell number. 
Moreover, inhibiting the activity of PKA and PDE4 resulted in attenuated IL-13 
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response. Stimulating β-arrestin-2 signaling did not alter the IL-13 response in 
NHBE cells, either in the presence or absence of epinephrine. However, the 
absence of β-arrestin-2 from mouse airway epithelial cells attenuated the 
response to IL-13 as compared to cells expressing β-arrestin-2.  
β2-ARs did not seem to affect IL-13 mediated mucuciliary shift from 
ciliated to goblet cells or cell proliferation. We conclude that, in human bronchial 
epithelial cells, epinephrine-induced β2-AR signaling is required to enhance 
mucus production in response to IL-13. Moreover, MAPKs, cAMP and cAMP-
dependent protein kinases are all involved components of β2-AR signaling in 
mediating the effect of IL-13 in NHBE cells. 
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1. Introduction and statement of the problem 
Approximately 300 million people worldwide currently suffer from asthma 
and the number may grow an additional100 million by 2025 (Masoli, Fabian et al. 
2004; 2007). Despite advances in health care, asthma accounts for 250,000 
death cases per year worldwide (2007).  
The Global Initiative for Asthma ((GINA) 2012) defines asthma as: 
“A chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness, and coughing, particularly at night or in the early 
morning. These episodes are usually associated with widespread, but variable, 
airflow obstruction within the lung that is often reversible either spontaneously or 
with treatment” ((GINA) 2012). 
Understanding airway inflammation and establishing better treatment 
regimens have been the focus of research for decades (Djukanovic, Roche et al. 
1990; Barnes 2008). Airway inflammation in asthma is characterized by an 
amplified T-helper-2 (TH2) response at the expense of TH1 responses (Kidd 
2003). Therefore, there is an increase in TH2 cytokines, such as interleukin (IL)-4, 
IL-5 and IL-13 in the airways (Kips 2001). To target the two main changes that 
are associated with asthma, inflammation and airway obstruction, inhaled 
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corticosteroids (ICS) and β2-AR agonists (Fanta 2009) have been the drugs of 
choice for the last half-century . 
ICS are the most effective anti-inflammatory medication used in asthma 
and   they are effective in the majority of adults and children (Kupczyk, Dahlen et 
al. 2011; van Aalderen and Sprikkelman 2011). However, besides the existence 
of ‘steroid-resistant’ asthmatics, inhaled corticosteroids also have numerous 
adverse effects. Growth impairment in children (Dahl 2006; Kelly, Sternberg et al. 
2012) and reduction in bone density (Kelly and Nelson 2003) are few of their side 
effects.  Though these effects are usually dose related and more thus common 
when used at high doses in severe persistent asthma, they can be observed in 
what are typically moderate doses of ICS (Kelly, Sternberg et al. 2012). 
All asthmatic patients are prescribed short acting β2-AR agonists to 
provide acute bronchodilation for asthma attacks. Some patients develop a 
disease state that affects their daily life activities (moderate persistent asthma), 
and ICS are usually the first controller medications added in this circumstance. If 
additional control is needed long acting β2-AR agonists (LABAs) are added 
(Fanta 2009). However, the use of β2-AR agonists chronically is associated with 
increased risk of severe exacerbations and overall asthma related death (Nelson, 
Weiss et al. 2006). Several studies have shown that chronic use of β2-AR 
agonists resulted in AHR exacerbation (van Schayck, Graafsma et al. 1990), 
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increased inhaled antigen load (Broadley 2006), increased allergen induced 
bronchial inflammation (Boulet, Chakir et al. 2001), enhanced sputum eosinophils 
(Gauvreau, Jordana et al. 1997) and eventually increased airway inflammation 
(Rider and Craig 2006). Therefore, according to the current asthma therapy 
guidelines, long acting β2-AR agonists should never be used as monotherapy 
and should always be prescribed with ICS (Giembycz and Newton 2006). The 
restricted use resulting from the long term side effects of ICS and β2-AR agonists 
creates a subset of patients who have uncontrolled disease, leading to learning 
disabilities and depression, in children and adults (O'Byrne, Pedersen et al. 
2013). Several therapeutic agents have been developed recently to meet the 
need of patients with uncontrolled disease. Of these agents, leukotriene 
modifiers, mast cell stabilizers and a long list of monoclonal antibodies that 
neutralize several inflammatory mediators have been tested, and in some cases, 
marketed (Holgate and Polosa 2008; Holgate and Davies 2009). Unfortunately, 
these approaches are expensive and effective only in specific subpopulations. 
Therefore, there is a need to discover better therapeutic agents.  
In summary, short-acting β2-AR agonists are incredibly valuable 
bronchodilators acutely, but chronic use of LABAs can exacerbate airway 
inflammation, and cause a small but significant increase in asthma mortality. 
These agents should be used only if the addition of ICS still does not provide 
adequate asthma control. This scenario is analogous to congestive heart failure 
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(CHF) where the acute use of β-AR agonists improves the quality of life, but 
chronic use is associated with increased mortality (Weber, Likoff et al. 1982; 
Felker and O'Connor 2001). As ‘beta-blockers’ are negative inotropic agents, this 
class of drugs was contraindicated for many decades (Haber, Simek et al. 1993). 
However, after successful clinical studies, chronic administration of certain β-AR 
blockers became the gold standard medical therapy for CHF (Hunt, Baker et al. 
2001). This temporal difference between acute and chronic use of agonists and 
antagonists in disease treatment may also be applicable to asthma.  Acute 
administration of β-AR blockers can result in airway narrowing in asthmatic 
patients (Singh, Whitlock et al. 1976; Boskabady and Snashall 2000) and in an 
antigen-driven murine model of asthma (Callaerts-Vegh, Evans et al. 2004). 
However, chronically blocking β2-AR signaling by nadolol or genetically ablating 
β2-ARs results in reduction in airway hyperresponsiveness (AHR), inflammatory 
cell recruitment to the airways and mucin content of airway epithelium in allergen 
driven murine model of asthma (Callaerts-Vegh, Evans et al. 2004; Nguyen, 
Omoluabi et al. 2008; Nguyen, Lin et al. 2009).  
Airway smooth muscle (ASM) cells control the airway caliber and hence 
contribute to AHR. Constriction of ASM results in airway narrowing in response to 
nonspecific stimuli or pharmacological agonist. Because of this, ASM cells are 
the predominant cell type studied for control of AHR. ASM cells can also 
contribute to AHR and inflammation through releasing different inflammatory 
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mediators (Johnson, Roth et al. 2001; Borger, Tamm et al. 2006; Hershenson, 
Brown et al. 2008; Zuyderduyn, Sukkar et al. 2008). The role of airway epithelial 
cells, the second most predominant parenchymal lung cell, in asthma has been 
the subject of less intense investigation and initially considered primarily as 
mechanical barrier to maintain the integrity of inhaled substances from entering 
the systemic circulation. However, several recent studies have shown an 
emerging role for epithelium as a tissue orchestrating a sophisticated set of 
responses (review by Holgate). These include a critical role in initiating the 
immune response to inhaled allergens (Lambrecht and Hammad 2012) and 
skewing the inflammatory response toward TH2 (Bulek, Swaidani et al. 2010). 
Moreover, airway epithelial cells, through producing mucus and forming mucus 
plugs, cause airway obstruction. AHR and mucous plugs are the cause of death 
in almost all asthma-related fatalities (Aikawa, Shimura et al. 1992; Fahy 2002). 
Chronic β2-AR activation can result in increased airway inflammation and 
airway epithelial cells respond to inflammatory mediators by increasing mucus 
production (Kuperman, Huang et al. 2002; Evans and Koo 2009). However, 
studies have shown that chronic inhibition of β2-AR signaling can rescue airway 
inflammation and hence attenuate mucus production asthma (Nguyen, Omoluabi 
et al. 2008; Nguyen, Lin et al. 2009). Therefore, studying the β2-AR signaling 
mechanism mediating mucous production and the disease pathophysiology is 
critical in our understanding of asthma. Due to the complexity of the signaling 
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pathways that are involved in mediating mucous production and the involvement 
of diverse inflammatory and parenchymal cells in whole animal models, we 
undertook to study cultured human airway epithelial cells. Many studies have 
established that in vitro cell culture using human airway epithelial cells share 
many morphological and functional distinctive properties with in vivo airway 
epithelial cells (Lin, Li et al. 2007; Stewart, Torr et al. 2012). In our studies we 
investigated the requirement of agonist induced β2-AR signaling for the 
expression MUC5AC, the major mucin producing gene, and intracellular mucin in 
response to IL-13, a TH2 cytokine, in human bronchial epithelial cells. 
Additionally, we investigated the involvement of various potential IL-13 signaling 
components including mitogen-activated protein kinases (MAPKs), canonical Gs-
adenylyl cyclase/protein kinase A (PKA) signaling and β-arrestin-2 signaling in IL-
13 induced mucus changes. Furthermore, we examined the source of goblet cell 
formation and the involvement of β2-AR signaling in mediating the mucociliary 
shift induced by IL-13.  
The results from these studies contribute key findings in our 
understanding of the mechanisms by which chronic use of β2-AR agonists 
deteriorate the disease condition. Also these results influence a change in 
treatment paradigms and may enhance acceptance of chronic use of a subset of 
β-blockers, such as nadolol, in the treatment of asthma. This dramatic departure 
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from the current paradigm, if validated, may help overcome the difficulties in 
managing asthma in general and mucous hypersecretion in particular.  
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2. Literature Survey 
2.1 Asthma: 
Asthma is a chronic inflammatory disorder of the airways (Busse and 
Lemanske 2001; Lemanske and Busse 2003) and is characterized by airway 
hyperresponsiveness (AHR), airway obstruction, airway inflammation and mucus 
metaplasia. Asthmatic patients usually present with shortness of breath, cough 
and wheezing (Busse 2011). Asthma affects around 300 million people 
worldwide and it is estimated that this number will keep growing to reach around 
400 million by year 2025 (Masoli, Fabian et al. 2004; 2007). The increase in 
asthma prevalence is associated with increased financial burden. This economic 
cost is resulted from the direct cost of hospitalization and medications and the 
indirect cost because of work and school absenteeism (Bahadori, Doyle-Waters 
et al. 2009). Despite the presence of different treatment modalities, asthma 
accounts for 250,000 death cases per year (2007). 
 
2.1.1 Airway inflammation in asthma: 
Several inflammatory cells and mediators play a role in asthma 
pathogenesis as outlined in Figure 1.  Asthma is characterized by T-helper-2 
(TH2) response. This preferential skewing toward TH2 is results from different 
factors, in particular, the cytokine environment that promotes the expression of 
transcription factors that drives the differentiation of the naïve T cells to TH2 (Ho 
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and Pai 2007). GATA-binding protein 3 (GATA3) and T-bet are the transcription 
factors that drive TH2 and TH1 differentiation respectively (Barnes 2008). 
Moreover, these two responses downregulate each other. The major biological 
function of TH1 and TH2 responses is to eradicate intracellular pathogens (cellular 
immunity) and extracellular pathogens (humoral immunity) respectively (Kidd 
2003). Based on the TH1/TH2 model, the “Hygiene hypothesis” was introduced 
proposing that lack of exposure to infection early in life alters the TH1/TH2 
balance and causes the preferential programming of naïve T cells to TH2 (Sheikh 
and Strachan 2004). However, hygiene hypothesis is not the only explanation of 
asthma development and prevalence (Maziak 2003; Ramsey and Celedon 2005). 
Moreover, the description of asthma as solely a TH2 response is too simple and 
raised too many concerns that have been reviewed systematically (Salvi, Babu et 
al. 2001; Ngoc, Gold et al. 2005). The involvement of several types of 
inflammatory cells, structural cells and inflammatory mediators are summarized 
below.  
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Figure 1. Overview of the inflammatory cells that are involved in asthma: 
Different inflammatory and structural cells play a role in asthma pathogenesis. 
Mast cells trigger airway smooth muscle bronchoconstriction through releasing 
histamine and cysteinyl leukotrienes. Epithelial cells, through releasing stem-cell 
factor (SCF) and thymic stromal lymphopoietin (TSLP), recruit mast cells to the 
surface of airways and initiate TH2 inflammation respectively. The released TH2 
cytokines (IL-13, IL-4, IL-5 and IL-9) induce eosinophilic inflammation, IgE 
production from B cells and mast cell proliferation as described in the text. 
Adapted from Barnes (2008). 
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2.1.1.1 Inflammatory cells: 
Different inflammatory cells are recruited to the airways and contribute to 
the disease development. Eosinophilic inflammation is a major characteristic of 
asthma (Watt, Schock et al. 2005) and the levels of eosinophils in blood is 
correlated with the disease severity (Griffin, Hakansson et al. 1991). Eosinophils 
contribute to late asthmatic reaction (LAR) (Bradding 2008) through releasing 
pro-inflammatory proteins such, as major basic protein, and several leukotriens  
and cytokines such as cysteinyl leukotriene C4 and IL-4 and 5 (Busse and 
Lemanske 2001; Broadley 2006). The granular proteins that are released by 
eosinophils contribute to epithelial shedding and damage while chemokines and 
cytokines recruit more inflammatory cells and augment the inflammation 
(Broadley 2006). Mast cells contribute to immediate response to allergen through 
releasing their preformed content of histamine (Barnes 2008) upon 
Immunoglobulin E (IgE) cross-linking on the high affinity receptors that present 
on mast cells (Robinson 2004). Moreover, mast cells also release several newly 
synthesized cytokines such as interleukin (IL)-4, IL-5, IL-13 and tumor necrosis 
factor-α (TNF-α) (Bradding 2008). Basophils also possess the high affinity IgE 
receptors, release the stored histamine upon IgE binding and secrete IL-4 and IL-
13 (Hamid, Tulic et al. 2003). Analyzing the sputum of asthmatic patients reveals 
the presence of basophils and mast cells (Gauvreau, Lee et al. 2000). Neutrophil 
numbers are increased in severe asthma and severe sudden exacerbations 
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(Ennis 2003; Macdowell and Peters 2007; Monteseirin 2009). Macrophages also 
contribute to airway inflammation (Hamid, Tulic et al. 2003). Beside TH2 cells, 
regulatory T cells, Th17 (Vock, Hauber et al. 2010) and B cells also play a role in 
asthma (Barnes 2008).  
 
2.1.1.2 Airway Structural cells: 
Airway smooth muscle (ASM) cells are the major structural cell that have 
been studied thoroughly due to their role in controlling airway caliber. ASM cells 
are increased in mass in asthma due to hypertrophy (Benayoun, Druilhe et al. 
2003) or hyperplasia (Woodruff, Dolganov et al. 2004). ASM cells contribute to 
AHR, which is the increase in airway narrowing in response to nonspecific stimuli 
or pharmacological agonist. The contractility of ASM cells from asthmatic patients 
is higher than controls and this results from increased expression of myosin light 
chain kinase (MLCK) (Ma, Cheng et al. 2002). Moreover, ASM cells contribute to 
the inflammatory circuit in asthma by releasing different chemokines such as 
eotaxin, RANTES, IL-8 and cytokines such as interleukin-1β (IL-1β) and GM-CSF 
(Hershenson, Brown et al. 2008). Of interest, pretreating ASM cells with IL-1β 
caused a decrease in relaxation in response to isoproterenol due to β-
adrenoceptor and Gs-adenylyl cyclase uncoupling (Shore, Laporte et al. 1997). 
Thus, ASM cells released inflammatory mediators that eventually impair their 
response to bronchodilators.  
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Airway epithelial cells also contribute to asthma pathophysiology by 
preferentially initiating TH2 response (Bulek, Swaidani et al. 2010), releasing 
different chemokines and cytokines (Barnes 2008) and increasing mucus 
production and secretion (Bai and Knight 2005). The involvement of airway 
epithelial cells in asthma will be discussed in more details in section 2.2.   
 
2.1.1.3 Cytokines and inflammatory mediators: 
In asthma, there is an increase in TH2 cytokines (IL-4, 5, 9 and 13) (Kips 
2001)  and each of these cytokines play a major role in orchestrating the 
inflammation. IL-5 mediates eosinophil differentiation from precursor cells and 
their survival (Barnes 2001) while IL-4, but not IL-13, is involved in the 
differentiation of TH2 cells (Barnes 2008). Moreover, IL-4 promotes the 
production of IgE by B-cells which mediates mast cell degranulation upon 
allergen exposure (Gould and Sutton 2008). IL-13 alone is sufficient to induce 
AHR, mucus metaplasia and airway inflammation in mice (Grunig, Warnock et al. 
1998; Kuperman, Huang et al. 2002; Wills-Karp 2004). Additionally, several other 
cytokines are released in the airways, including TNF-α, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), IL-17, IL-11 and IL‐1β (Kips 2001; Hamid, 
Tulic et al. 2003; Atamas, Chapoval et al. 2013). Several chemokines are 
secreted from structural and inflammatory cells that contribute in recruiting 
inflammatory cells to the airways (Lukacs, Oliveira et al. 1999; Lukacs 2001).  
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2.1.1.4 Airway remodeling in asthma: 
In asthma, the airways undergo several changes (Chetta, Foresi et al. 
1997; Homer and Elias 2000; Bergeron, Al-Ramli et al. 2009), summarized in 
Figure 2, such as thickening of the basement membrane (Shifren, Witt et al. 
2012), mucous metaplasia (Aikawa, Shimura et al. 1992; Fahy 2001; Ordonez, 
Khashayar et al. 2001), increased airway smooth muscle mass (Lambert, Wiggs 
et al. 1993), increased airway vascularity and permeability (Li and Wilson 1997; 
Freyer, Johnson et al. 2001; Tanaka, Yamada et al. 2003), subepithelial fibrosis 
(Roche, Beasley et al. 1989; Minshall, Leung et al. 1997; Hoshino, Nakamura et 
al. 1998) and recruitment of inflammatory cells and the release of different 
cytokines, especially from TH2 cells (Bhakta and Woodruff 2011). Collectively 
these changes lead to AHR and airway obstruction.  
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Figure 2. Airway remodeling associated with asthma: Several changes in all 
structural cells of the airways are induced by the released inflammatory 
mediators from inflammatory cells, as discussed in the text. Adapted from 
Shifren, Witt, et al (2012). 
 
2.1.2 Therapeutic approaches: 
Patients with asthma are diagnosed with intermittent or persistent mild, 
moderate and severe disease, based different parameters such as the frequency 
of the symptoms and the use of short acting bronchodilators as well as lung 
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function (National Asthma and Prevention 2007). The approach to the treatment 
of asthma is based on the severity of the disease.  Short acting β2-Adrenoceptors 
(β2-ARs) agonists are the most effective bronchodilators that are used to control 
acute asthma attacks (Fanta 2009). Inhaled corticosteroids and long acting β2-
AR agonists are among the widely used medications for long term disease 
control (Fanta 2009). Inhaled corticosteroids (ICS) are effective anti-inflammatory 
medications that are used in asthma. However, ICSs, especially at high doses in 
severe persistent asthma, result in serious systemic side effects such as growth 
impairment in children (Dahl 2006) and reduction in bone density (Kelly and 
Nelson 2003).  Chronic use of β2-AR agonists is also associated with serious 
consequences such as increased risk of severe asthma exacerbations and 
possible death (Currie, Lee et al. 2006; Salpeter, Buckley et al. 2006). The 
increase in death associated with β2-AR agonists was first observed with regular 
use of the newly introduced inhaled bronchodilator fenoterol in New Zealand 
(Crane, Pearce et al. 1989). This drug, when used chronically, results in disease 
exacerbation and worsening of lung function (Taylor, Sears et al. 1993). In 
another study, regular use of salbutamol was associated with disease 
deterioration and AHR exacerbation (van Schayck, Graafsma et al. 1990). Even 
though the acute bronchodilatory effect of β2-AR agonists is lifesaving, their 
regular use increases the inhaled antigen load (Broadley 2006) and provokes 
more inflammation. This is reflected by the increased allergen induced bronchial 
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inflammation (Boulet, Chakir et al. 2001) and sputum eosinophils (Gauvreau, 
Jordana et al. 1997) in response to regular use of salmeterol and salbutamol 
respectively. However, a recent review reported that the use of salmeterol 
together with ICS did not result in serious adverse events, either fatal or non-fatal 
(Cates, Jaeschke et al. 2013). In another meta-analysis, salmeterol resulted in 
increased mortality only when it was used as monotherapy while this risk was 
reduced when ICS were added to the treatment regimen (Weatherall, Wijesinghe 
et al. 2010). However, it was not possible to conclude that formoterol in 
combination with ICS did not have any increase in mortality (Cates, Lasserson et 
al. 2009). The recent analysis by FDA demonstrated that the risk asthma related 
deaths of formoterol monotherapy was not reduced by adding ICS (Rodrigo 
2010). Therefore, FDA recommends physician in practice not to use long acting 
β2-AR agonists as monotherapy and it should be combined with ICS (Giembycz 
and Newton 2006). 
The fear of long term side effects of ICS and β2-AR agonists creates a 
subset of patients who have uncontrolled disease. Uncontrolled disease results 
in several negative consequences such as learning disabilities and depression, in 
children and adults (O'Byrne, Pedersen et al. 2013). Additionally, another subset 
of asthmatic patients, (~5% to 10%), are not responsive to conventional 
treatment approaches and exhibit severe disease manifestations (Busse, Banks-
Schlegel et al. 2000; Papiris, Kotanidou et al. 2002). A better understanding of 
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the disease pathophysiology and the critical role of inflammatory mediators in 
disease progression has resulted in the development of a variety of promising 
therapeutic interventions such as leukotriene modifiers, mast cell stabilizers, 
monoclonal antibodies that target IL-13 and TNF-α (Holgate and Polosa 2008; 
Holgate and Davies 2009). These therapeutic approaches are expensive, 
effective only in a specific subset of asthmatic patients and their regular use is 
not risk-free. Thus, more research is required to improve the pharmacological 
approaches in asthma treatment.  
The detrimental effects with long term use of β2-AR agonists in asthma is 
similar to that previously observed in congestive heart failure (CHF), where 
chronic use of β-AR agonists was associated with increased mortality (Weber, 
Likoff et al. 1982; Felker and O'Connor 2001). β-AR blockers resulted acutely in 
serious detrimental effects and thus these agents had been contraindicated in 
patients with CHF for many decades (Haber, Simek et al. 1993). However, after 
successful clinical studies, chronic administration of certain β-AR blockers 
became the gold standard medical therapy for CHF (Hunt, Baker et al. 2001). A 
similar picture is also perceived with β-AR blockers in asthma. These agents are 
associated with airway narrowing when administered acutely (Singh, Whitlock et 
al. 1976; Boskabady and Snashall 2000). However, chronically treatment with the 
β-blocker nadolol, or genetically ablating β2-ARs resulted in reductions in AHR, 
inflammatory cell recruitment to the airways and mucus metaplasia in an allergen 
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driven murine model of asthma (Nguyen, Omoluabi et al. 2008; Nguyen, Lin et al. 
2009). The anti-inflammatory effect of nadolol not only resulted in additive effect 
when combined with glucocorticosteroid at the level of airway inflammation and 
mucus metaplasia, but also had "glucocorticoid-sparing" effect (Nguyen, Singh et 
al. 2012). Moreover, chronic nadolol administration to mild asthmatic patients 
reduced AHR (Hanania, Singh et al. 2008) and these patients still respond to 
salbutamol to reverse bronchoconstriction provoked by methacholine (Hanania, 
Mannava et al. 2010). Therefore, β-blockers are potentially a promising 
therapeutic approach to treat asthma and reduce the adverse effects that are 
associated with chronic use of ICS. 
 
2.2 Airway epithelium: 
Airway epithelium is first line of defense against foreign particles through 
providing functional and physical barriers, initiating immune responses and 
removing inhaled particles (Thompson, Robbins et al. 1995). The barrier function 
is created by the continuous layer of polarized epithelial cells that are connected 
by tight junctions (Vareille, Kieninger et al. 2011). Also, airway epithelial cells are 
covered by a layer of mucus that contains mucins and other proteins, such as 
antimicrobial proteins and cytokines (Nicholas, Skipp et al. 2006). Antimicrobial 
proteins include, but are not limited to, secretory immunoglobulin A, lysozyme, 
lactoferrin and defensins (Eisele and Anderson 2011; Li, Wang et al. 2012). 
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Inhaled particles that are trapped in the viscous mucus layer are cleared from the 
airways by the action of the cilia and cough reflex (Thompson, Robbins et al. 
1995). In addition, airway epithelial cells secrete different cytokines and 
mediators that recruit inflammatory cells to the airway to clear the invading 
agents.  These mediators include thymus and activation regulated chemokine 
(TARC), eotaxin-1 and interleukin-8 (IL-8) (Bloemen, Verstraelen et al. 2007) that 
play a role in recruiting T-cells (Panina-Bordignon, Papi et al. 2001), eosinophils 
(Ying, Robinson et al. 1997) and neutrophils (Nocker, Schoonbrood et al. 1996) 
respectively.  
Airway epithelial cells play a major role in initiating the immune response 
and in connecting both innate and adaptive immunity. Upon allergen exposure, 
allergens are processed primarily by dendritic cells (DCs). Activated DCs migrate 
to mediastinal lymph node (MLNs) and present processed allergen to T cells 
(Lambrecht and Hammad 2009). These T cells become either central memory T 
(TCM) cells or effector T cells and then migrate to non-draining lymph nodes or 
to the lung respectively (Lambrecht and Hammad 2003). In ongoing 
inflammation, naïve T cells preferentially develop into T-helper-2 (TH2) cells 
(Lambrecht and Hammad 2003). Airway epithelial cells play a role in skewing the 
inflammatory response toward TH2 by producing different mediators that are 
called “TH2-driving cytokines” that create a microenvironment that favors TH2 
response (Bulek, Swaidani et al. 2010) such as TSLP (thymic stromal 
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lymphopoietin) (Schleimer, Kato et al. 2007) that activates DCs to regulate the 
release of TH2 cytokines from naïve T helper cells (Bulek, Swaidani et al. 2010), 
including interleukin-25 (IL-25) (Hammad and Lambrecht 2011) and interleukin-
33 (IL-33) (Holgate 2013) that contribute to TH2 cell polarization (Bulek, Swaidani 
et al. 2010). Moreover, these TH2 driving cytokines trigger group 2 innate 
lymphoid cells (ILC2 cells) to secrete TH2 cytokines (Licona-Limon, Kim et al. 
2013). 
The effect of epithelial cells is not restricted to DCs: epithelial cells though 
the release of different mediators also affect and recruit T and B cells. For 
example, TARC recruits TH2 to the airways (Schleimer, Kato et al. 2007) while B 
cell-activating factor of TNF family (BAFF) and a proliferation-inducing ligand 
(APRIL) affect B cell activation and switching to IgE production (Kato, Truong-
Tran et al. 2006).  
 
2.2.1 Types of epithelial cells: 
The epithelial layer is composed of different cell types that vary in their 
distribution along the respiratory tract, as shown in Figure 3. To simplify the 
description of different airway epithelial cells, the airway is divided into two 
zones; the conducting zone that only conducts air, and the respiratory zone 
where gas exchange takes place.  
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Figure 3. The principal cell types comprising the airway epithelium in the 
human respiratory tract: Lower respiratory tract (RT) represents the conducting 
zone and the distal RT represents the respiratory zone. The conducting zone is 
characterized by the presence of goblet, ciliated, basal and Clara cells (club 
cells). The respiratory zone is comprised of type I and II alveolar airway epithelial 
cells.  Adapted from Berube, Prytherch et al. (2010). 
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The distribution of epithelial cell types along the conducting airways varies 
between species, as summarized in the table (Table 1) below. 
 
Table 1. Comparison of the distribution of different types of airway 
epithelial cells in rodents and primates:  NA: unknown or under investigation; 
T: trachea; B: bronchi; Br: bronchioles; NCC: nonciliated, nonsecretory columnar 
cells; SMG: submucosal glands. “a” For pathogen-free animals; in infection or 
cytokine stimulation the abundance of goblet cells is increased. Adapted from 
Liu, Driskell et al. (2006). 
 
2.2.1.1 Basal cells: 
Basal cells are attached to the basement membrane through 
hemidesmosomes (Mary Mann-Jong Chang 2008). Basal cells connect different 
cells of the pseudostratified layer to the basement membrane, control the 
inflammatory response and regulate water trans-epithelial movement (Evans, 
Van Winkle et al. 2001; Knight and Holgate 2003; Mary Mann-Jong Chang 2008). 
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Moreover, basal cells are described as progenitor or stem cells in the airways 
because of their ability to self-renew and differentiate into columnar airway 
epithelial cells (Evans, Van Winkle et al. 2001; Hong, Reynolds et al. 2004; Liu, 
Driskell et al. 2006; Rock, Onaitis et al. 2009). Other evidence suggests that 
basal cells differentiate first to mucous cells and then to ciliated cells (Ayers and 
Jeffery 1988). Regardless which step occurs first, basal cells have the ability to 
differentiate to ciliated and mucous cells. Different markers are used to 
distinguish basal cells such as transcription factor transformation-related protein 
63 (Trp-63) and cytokeratins 5 (Krt5) and Krt14 (Rock, Onaitis et al. 2009; Rock, 
Randell et al. 2010). 
 
2.2.1.2 Ciliated cells: 
Ciliated cells are characterized by their columnar shape and the their 
apical cilia, numbering about 200–250 cilia/cell (Mary Mann-Jong Chang 2008). 
The cilia extends from the inner liquid mucus layer, that is composed mainly of 
water (Cohn 2006), into the outer viscous gel layer (Evans, Kim et al. 2009; Fahy 
and Dickey 2010). These cells are present throughout the conducting zone of the 
airways (Berube, Prytherch et al. 2010). The cilia of neighbor cells share a 
common orientation and their beating rate is highly coordinated (Thompson, 
Robbins et al. 1995). Ciliated cells can be characterized by the presence of 
protein such as tektin, hepatocyte nuclear factor homolog (HFH-4)/ forkhead box 
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protein J1 (FOXJ1) and β-tubulin IV (Blatt, Yan et al. 1999; Yoshisue, 
Puddicombe et al. 2004). 
 
2.2.1.3 Non-ciliated secretory cells: 
The major secretory cells in human are goblet cells, while club cells are 
the predominant secretory cells in mice and rabbits (Liu, Driskell et al. 2006; 
Mary Mann-Jong Chang 2008).  
 
2.2.1.3.1 Goblet cells: 
Goblet cells are characterized by the presence of mucus granules in their 
apical compartment (Rogers 1994). Mucin glycoproteins are the main component 
of these mucus granules. Mucin contributes to the viscoelastic properties of the 
mucus layer and traps inhaled particles that are subsequently removed by the 
action of cilia (Kim, McCracken et al. 1997; Rogers 2002; Fahy and Dickey 
2010). Goblet cells are identified by immunohistochemical detection of mucin 
5AC or MUC5AC expression, the main mucin-producing gene in goblet cells 
(Atherton, Jones et al. 2003; Yoshisue, Puddicombe et al. 2004). 
Goblet cell hyperplasia and metaplasia are two different terms that are 
commonly used to describe hypersecretory diseases, such as asthma and 
chronic obstructive pulmonary disease (COPD). Briefly, goblet cell hyperplasia is 
defined by the increase in the goblet cell numbers in areas where goblet cells are 
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usually present (Rogers 2003; Mary Mann-Jong Chang 2008). On the other 
hand, metaplasia describes the appearance of these goblet cells in areas where 
these cells are not commonly present (Rogers 2003; Mary Mann-Jong Chang 
2008). Goblet cells may develop from ciliated cells by the process of 
transdifferentiation (Tyner, Kim et al. 2006; Turner, Roger et al. 2011).  
 
2.2.1.3.2 Club cells: 
Club cells (known formally as Clara cells) are the main non-ciliated 
secretory cells throughout mouse airways but in humans are only found in 
bronchioles (Table 1). These cells play an important role in xenobiotic 
metabolism (Knight and Holgate 2003; Reynolds and Malkinson 2010), secretion 
of antiproteases (De Water, Willems et al. 1986) and of Clara cell protein (CC10), 
also called Clara cell secretory protein (CCSP) (Singh and Katyal 1997), which 
has anti-inflammatory and anti-oxidant roles (Broeckaert, Clippe et al. 2000). This 
important role of club cells is noted in asthmatic patients, where the reduction in 
CC10 levels is associated with increased mast and T cells numbers in small 
airways (Shijubo, Itoh et al. 1999). Moreover, analysis of protein content in 
bronchoalveolar lavage fluid (BALF) from asthmatic patients revealed low levels 
of CC10 content compared to normal controls (Van Vyve, Chanez et al. 1995).  
Club cells also have the capacity to serve as precursor for ciliated and 
mucus secreting cells (Knight and Holgate 2003; Reynolds and Malkinson 2010). 
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Several studies have shown that club cells are the origin of goblet cells in murine 
model of asthma (Reader, Tepper et al. 2003; Evans, Williams et al. 2004; 
Hayashi, Ishii et al. 2004; Chen, Korfhagen et al. 2009). It has been suggested 
that “metaplasia” term should be used carefully, because club cells are not 
replaced by goblet cells and mucin granules are exclusively present in CCSP-
positive cells in allergen induce murine model of asthma (Evans, Williams et al. 
2004).  
  
2.2.1.4 Alveolar epithelium: 
The two types of alveolar epithelial cells, type I and type II, are 
distinguished by their different physiological roles. The majority of the surface 
area of the lung alveoli is covered by type I cells, while type II cells cover only 5% 
of the lung surface area (Thompson, Robbins et al. 1995; Mason 2006). Type I 
cells form an essential component in gas-exchange barrier (Mary Mann-Jong 
Chang 2008) and enhance innate immunity during infection (Yamamoto, Ferrari 
et al. 2012). Type II cells play a major role in the production of surfactant 
(Fehrenbach 2001), synthesis and secretion of anti-inflammatory and anti-
microbial agents (Mason 2006) and are the progenitor cells (stem cells) for type I 
cells (Mason 2006). Moreover, type II cells have the capacity to proliferate and 
differentiate when type I cells are exposed to injury and death (Liu, Driskell et al. 
2006).  
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2.2.2 Changes of epithelial cells in asthma: 
Besides all the changes that has been described earlier, transcription 
factors that regulate inflammatory genes are upregulated in asthmatic airway 
epithelial cells (Knight and Holgate 2003). Damaged epithelial cells tend to 
desquamate and appear in the sputum and BALF (Naylor 1962; Wardlaw, 
Dunnette et al. 1988) as well as in airways biopsies from asthmatic patients 
(Laitinen, Heino et al. 1985). Epithelial cell shedding also causes the decline in 
epithelial derived relaxing factors and hence could contribute the increase in 
airway hyper-reactivity (Vanhoutte 1989). However, the epithelial cell 
desquamation observed in asthmatic biopsies could be an artifact caused by 
endobronchial sampling processes (Ordonez, Ferrando et al. 2000). 
Furthermore, the barrier integrity of the epithelial layer is also altered in asthma 
(Lambrecht and Hammad 2012).  
  
2.3 Airway Mucus: 
The apical surface of the respiratory tract is covered by mucus. The 
mucus layer protects the respiratory tract from inhaled particles and pathogens 
(Rogers 2002). Mucus is mainly composed of water and a mixture of numerous 
substances such as lipid, proteins and the highly glycosylated mucin particles 
(Rogers 2002; Fahy and Dickey 2010). Mucin is a heavily glycosylated, high 
molecular weight protein and is responsible for the viscoelastic properties of 
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mucus (Kim, McCracken et al. 1997; Rogers 2002; Fahy and Dickey 2010). 
Structurally, as outlined in Figure 4, mucin is composed of a peptide backbone, 
called apomucin (Rogers 2002), which is encoded by MUC genes (Rose and 
Voynow 2006). Mucins are glycosylated on serine/threonine residues of the 
tandem repeats (TR) domains (Kim, McCracken et al. 1997; Rogers 2002; Rose 
and Voynow 2006; Lai and Rogers 2010). Mucins are negatively charged 
proteins because of their terminal carboxyl or sulfate groups (Fahy and Dickey 
2010).  
 
 
Figure 4. Structure of mucin: Mucin is composed of a protein backbone that is 
highly glycosylated as described in the text. Adapted from Rose and Voynow 
(2006). 
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2.3.1 Airway Mucin genes: 
Seventeen MUC genes are present in the human genome (Thornton, 
Rousseau et al. 2008), and based on a backbone that is encoded by these 
genes, mucins are categorized into: 
 
2.3.1.1 Secreted gel forming mucins:  
MUC5AC, MUC5B, MUC2, MUC6 and MUC19 (Fahy 2002; Rose and 
Voynow 2006; Thornton, Rousseau et al. 2008; Evans and Koo 2009; Voynow 
and Rubin 2009) are examples of this category. These secreted polymerized 
mucins contribute to mucus viscosity and form a gel layer that coats the airway 
epithelium (Evans, Kim et al. 2009). Secreted gel forming mucins are 
characterized by their high molecular weight and water absorbent properties 
(Rogers 2002; Evans and Koo 2009). MUC5AC and MUC5B are the main 
mucins present in mucus and sputum (Thornton, Rousseau et al. 2008). 
MUC5AC is produced by goblet cells located on the surface epithelium while 
submucosal glands secrete MUC5B (Thornton, Rousseau et al. 2008; Evans, 
Kim et al. 2009). Under normal conditions, MUC5AC is constitutively expressed 
in proximal human airways while muc5ac is not detectable in mice airways (Fahy 
and Dickey 2010). MUC5AC is the most abundant secreted mucin in asthma and 
muc5ac is upregulated by antigen challenge in murine model (Evans and Koo 
2009). MUC5B and muc5b are both constitutively expressed in the airways 
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(Evans, Kim et al. 2009) and the sputum level of MUC5B is increased in patients 
with asthma as compared to normal individuals (Kirkham, Sheehan et al. 2002). 
Endobronchial biopsy from patients with asthma revealed that MUC2 and 4 are 
also significantly elevated as compared to normal individuals (Fahy 2002).  
 
2.3.1.2 Secreted nonpolymerizing mucins:  
MUC7 (Rose and Voynow 2006; Thornton, Rousseau et al. 2008; Voynow 
and Rubin 2009), MUC8 (Rose and Voynow 2006; Thornton, Rousseau et al. 
2008) and MUC9 (Rose and Voynow 2006) are examples of this family of 
mucins. Due to the absence of cysteine rich domains in their tandem repeats, 
these secreted mucins tend not to polymerize (Rose and Voynow 2006; 
Thornton, Rousseau et al. 2008). 
The secreted mucins are packed into the intracellular granules by virtue of 
high calcium concentrations (Fahy 2002). Following stimulation, the release of 
calcium from the granules upon membrane fusion causes the entrance of 
extracellular water. Consequently, the condensed mucins are no longer packed 
and the large hydrated repulsive macromolecules explode from the cell (Fahy 
2002). 
 
 
 
 
 
32 
2.3.1.3 Membrane associated mucins: 
These mucins include MUC1, MUC4, MUC11, MUC13, MUC15, MUC12, 
MUC3A & B, MUC16, MUC17 and MUC20 (Rose and Voynow 2006; Voynow 
and Rubin 2009). Of these, MUC1, 4 and 16 are known to be expressed 
constitutively in the lung (Evans, Kim et al. 2009). These mucins are present at 
the plasma membrane of the surface epithelium (Evans, Kim et al. 2009) and 
they determine the physical characteristics of the inner liquid layer that covers 
airway epithelium (Fahy and Dickey 2010). Furthermore, membrane associated 
mucins participate in cell signaling either through their cytoplasmic domain or via 
interaction with other surface receptors (Evans and Koo 2009). 
 
2.3.2 Effect of mucus overproduction: 
Decades ago, physicians underestimated the critical role of mucus plugs 
in asthma due to the absence of phlegm in asthmatic cough (Fahy and Dickey 
2010). Autopsies of patients who died of severe asthma attacks revealed goblet 
cell hyperplasia and mucus accumulation in peripheral airways when compared 
to asthmatic patients who did not die of acute attacks (Aikawa, Shimura et al. 
1992; Fahy 2002). Mucus plugs from patients who died of asthma are rich in 
mucin content in contrast to mucus from normal individual (Sheehan, Richardson 
et al. 1995). Moreover, there is an increase in the goblet cell number and 
intracellular mucin in patients with mild-moderate asthma (Fahy 2002). Mucus 
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composition varies between health and disease states. In healthy individuals, 
mucus contains mucin glycoproteins and small amount of inflammatory cells and 
proteins with no RNA, actin or bacteria (Fahy and Dickey 2010). In asthmatic 
individuals, mucus viscosity is increased due to elevated levels of mucin, proteins 
and inflammatory cells combined with DNA and actin (Fahy and Dickey 2010; Lai 
and Rogers 2010). Different cytokines that are released in asthma induce the 
expression of MUC genes, goblet hyperplasia and mucus secretion (Rogers 
2004).  
The accumulation of mucus leads to: 
A) Airway obstruction: Excessive mucus plugs enhances dyspnea as a result of 
ventilation-perfusion mismatch (Cohn 2006). 
B) Airflow resistance: The reduction in the airway’s radius, due to 
bronchonstriction, combined with mucus accumulation in the airway results in 
dramatic increase in airway resistance, as summarized in Figure 5 below (Lai 
and Rogers 2010).  
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Figure 5. The effect of airway mucus accumulation on airway resistance: 
Based on Poiseuille’s law, resistance can be calculated as 1/r4, where r is the 
airway radius. If r is set to one, then the resistance (R) will be 1 unit (c). When 
the radius is reduced by 50% because of bronchoconstriction, then there is 16-
fold increase in the airway resistance (d). Accumulation of mucus in the airway 
causes a small increase in airway resistance (e), but when bronchoconstriction 
takes place on the top of mucus layer, a dramatic increase in the resistance 
results (f). Adapted from Lai and Rogers (2010).  
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2.3.3 MUC5AC and asthma: 
Endobronchial biopsy from asthmatic patients reveals 60% higher levels of 
MUC5AC expression as compared to unaffected individuals (Fahy 2002). In 
healthy and asthmatic individuals, the MUC5AC gene product is restricted to 
airway goblet cells (Rose and Voynow 2006). MUC5B is expressed in 
submucosal glands in healthy individuals and is secreted from goblet and 
glandular neck cells in asthma patients (Kirkham, Sheehan et al. 2002). The 
sputum levels of both MUC5AC and MUC5B are increased in patients with 
asthma as compared to normal individuals (Kirkham, Sheehan et al. 2002).  
The MUC5AC and muc5ac genes are highly regulated at the level of 
transcription. MUC5AC transcription is induced in response to different cytokines 
as demonstrated by increased MUC5AC promoter activity following the 
transfection of cells with a MUC5AC promoter-luciferase construct (Rose and 
Voynow 2006; Fujisawa, Velichko et al. 2009). Examples of these mediators are 
TNF-α (Lai and Rogers 2010), EGF (Zhen, Park et al. 2007), IL-1β (Gray, 
Nettesheim et al. 2004) and most importantly IL-13, which is discussed further in 
the following section. Moreover, other inflammatory mediators such as IL-8 
(Bautista, Chen et al. 2009) and TNF-α (Borchers, Carty et al. 1999) regulate 
MUC5AC expression at posttranscriptional level through increasing mRNA 
stability (Rose and Voynow 2006). 
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2.4 Interleukin-13 (IL-13): 
IL-13 is a major TH2 cytokine that is released in response to allergen from 
CD4+ and CD8+ T cells, non-T cells such as natural killers and eosinophils 
(Schmid-Grendelmeier, Altznauer et al. 2002; Akbari, Stock et al. 2003) and ILC2 
cells in response to TH2-driving cytokines released from airway epithelial cells 
(Licona-Limon, Kim et al. 2013). There is substantial experimental evidence that 
IL-13 is involved in asthma pathogenesis. In the allergen driven murine model of 
asthma, elevated levels of IL-13 are detected in BALF (Taube, Duez et al. 2002) 
and neutralizing IL-13 antibodies attenuates the asthma phenotype (Grunig, 
Warnock et al. 1998). Asthmatic patients have higher levels of IL-13 in plasma, 
sputum, broncheoalveolar lavage fluid and bronchial biopsy as compared to 
normal individuals (Naseer, Minshall et al. 1997; Wong, Ho et al. 2001; Brightling, 
Symon et al. 2003; Berry, Parker et al. 2004; Park, Jangm et al. 2005). Moreover, 
IL-13 levels are raised in patients with severe refractory disease (Saha, Berry et 
al. 2008) and during acute exacerbations (Lee, Lee et al. 2001). Higher IL-13 
levels in sputum are associated with lower concentration of the constrictor agent 
that causes a 20% fall in forced expiratory volume in 1 second (FEV1) (Park, 
Jangm et al. 2005). Additionally, IL-13 may be responsible for the elevated levels 
of produced IgE in asthma patients (Van der Pouw Kraan, Van der Zee et al. 
1998). 
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2.4.1 IL-13 signaling pathways: 
IL-13 binds to IL-13-receptor alpha 1 (IL-13Rα1) at low affinity and this 
binding recruits IL-4-receptor alpha (IL-4Rα) to form a high affinity complex (type 
II IL-4Rα/IL-13Rα1 receptor) (Wills-Karp 2004; Kelly-Welch, Hanson et al. 2005; 
Izuhara, Arima et al. 2006). Each of these receptor chains is composed of 
extracellular, transmembrane and intracellular domains. The intracellular domain 
has several regions that participate in the phosphorylation and activation of 
different signaling molecules that mediate the effect of IL-13 (Izuhara, Arima et 
al. 2006) as shown in Figure 6 below. 
IL-13 also binds to IL-13-receptor alpha 2 (IL-13Rα2) chain, which is 
known as a decoy receptor, at a high affinity (Izuhara, Arima et al. 2006). IL-
13Rα2 has a short cytoplasmic domain and it blocks signaling induced by IL-13 
(Izuhara, Umeshita-Suyama et al. 2000; Andrews, Nordgren et al. 2009). 
However, membrane bound IL-13Rα2 may contribute to cell signaling. Binding of 
IL-13 to IL-13Rα2 in macrophages enhances the release of transforming growth 
factor-beta (TGF-β), (Fichtner-Feigl, Strober et al. 2006), which causes lung 
fibrosis. Moreover, the presence of soluble IL-13Rα2 in interstitial spaces 
sequesters IL-13 and diminishes IL-13 availability (Andrews, Nordgren et al. 
2009).  
IL-13Rα2, IL-4Rα (Lordan, Bucchieri et al. 2002) and IL-13Rα1 (Wills-Karp 
2004) are expressed on the surface of airway epithelial cells. Moreover, the IL-13 
 
 
38 
receptor complex is also expressed on airway smooth muscle (ASM) cells 
(Izuhara, Umeshita-Suyama et al. 2000).  
  
Figure 6. Schematic presentation of IL-13 receptor chains and the 
activation of downstream signaling cascade: IL-13 modulates gene 
transcription through activation of several downstream signaling cascades, such 
as JAK/STAT, PI3 kinase and MAPK pathways. However, binding of IL-13 to IL-
13Rα2 activates AP-1 family of transcription factors and inhibits the 
aforementioned signaling cascades. Adapted from Izuhara, Arima et al. (2006). 
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The binding of IL-13 to IL-4Rα/IL-13Rα1 activates Janus tyrosine Kinase 
(JAK) / signal transducer and activator of transcription-6 (STAT6) signaling 
cascade (Izuhara, Umeshita-Suyama et al. 2000; Wills-Karp 2004). Once STAT6 
is phosphorylated, it translocates to the nucleus as a dimer and binds to specific 
binding sites on target gene promoters to stimulate transcription (Wills-Karp 
2004; Goenka and Kaplan 2011). Many IL-13 effects are mediated by the STAT6 
signaling cascade, such as TH2 cell differentiation and IgE synthesis (Pernis and 
Rothman 2002). In the antigen driven murine model of asthma, STAT6 Knockout 
(KO) mice failed to develop AHR, mucus metaplasia and TH2 response 
(Tomkinson, Kanehiro et al. 1999). Signal transducer and activator of 
transcription-3 (STAT3) is also activated by IL-13 IL-13Rα1 chain (de Vries 1998) 
but its biological contribution is yet to be determined.  
IL-13 binding to type II receptor complex phosphorylates tyrosine residues 
of the IL-4Rα chain, which in turn activates and phosphorylates insulin receptor 
substrate 1 and 2 (IRS-1 and IRS-2) (Jiang, Harris et al. 2000; Hershey 2003). 
Phosphorylated IRS1/2 activates mitogen activated protein kinases (MAPKs) 
through growth factor receptor-bound protein-2 (Grb-2)/ son of sevenless (SOS)/ 
Ras pathway (Jiang, Harris et al. 2000; Hershey 2003).  Moreover, activated 
IRS1/2 activates phosphoinositol-3 (PI3) kinase signaling pathway (Jiang, Harris 
et al. 2000; Hershey 2003). Activated PI3 kinase signals through Akt (survival 
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signaling) (Downward 1998) or p70 ribosomal protein S6 kinase (p70S6K) 
(Alessi, Kozlowski et al. 1998).  
 
2.4.2 Role of IL-13 in asthma pathogenesis: 
IL-13 transgenic mice that overexpress IL-13 in the airways develop 
airway inflammation, AHR and airway remodeling (Zhu, Homer et al. 1999). 
Interestingly, IL-13 KO mice are incapable of developing AHR in response to 
allergen despite the presence of eosinophilic inflammation and other TH2 
cytokines (Walter, McIntire et al. 2001). The development of AHR by IL-13 
treatment appears at earlier time point as compared to the development of 
inflammation (Venkayya, Lam et al. 2002) and is independent of eosinophils 
(Yang, Hogan et al. 2001).  Thus, the effect of IL-13 on AHR appears to be 
mediated through airway resident cells. IL-13 affects different cells that are 
involved in asthma pathogenesis, as summarized in Figure 7. In cultured human 
ASM, IL-13 increases contractility and reduces β-AR responsiveness (Laporte, 
Moore et al. 2001; Tliba, Deshpande et al. 2003). IL-13 transgenic mice that 
express STAT6 in airway epithelial cells develop AHR and mucus metaplasia, 
independent of eosinophilic inflammation (Kuperman, Huang et al. 2002). 
Additionally, IL-13 reduces the release of nitric oxide (NO), through inhibiting 
inducible nitric oxide synthase and inducing arginase I (Wills-Karp 2004).  
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IL-13 induces airway remodeling by different mechanisms. It stimulates 
subepithelial fibrosis by upregulating arginase I synthesis, which contributes to 
collagen synthesis by fibroblasts (Hesse, Modolell et al. 2001), and enhances the 
release of pro-fibrotic TGF-β from epithelial cells (Wen, Kohyama et al. 2002) 
and monocytes/ macrophages (Lee, Homer et al. 2001). Moreover, IL-13 
promotes mucus metaplasia (Atherton, Jones et al. 2003; Fujisawa, Ide et al. 
2008).  
 
Figure 7: Schematic presentation of IL-13 effects on different airway cells. 
IL-13 affects lung parenchymal cells as well as the inflammatory cells that are 
involved in asthma pathogenesis as described in the text. Adapted from Hershey 
(2003). 
 
 
42 
2.4.3 Effects of IL-13 on airway epithelium: 
IL-13 induces the release of several chemokines from airway epithelial 
cells, including macrophage inflammatory protein 3 alpha (MIP-3α) (Reibman, 
Hsu et al. 2003), IL-8 and RANTES (Fujisawa, Kato et al. 2000), MCP-1 (Lee, 
Homer et al. 2001; Oeckinghaus and Ghosh 2009), eotaxins 1,2 and 3 
(Matsukura, Stellato et al. 2001; Komiya, Nagase et al. 2003) and growth-related 
oncogene-α (GRO-α) (Meyer-Hoffert, Lezcano-Meza et al. 2003). These factors 
contribute to airway inflammation through recruiting different inflammatory cells to 
the airways.  
IL-13 drives MUC5AC expression and mucin content in cultured 
differentiated normal human bronchial epithelial (NHBE) cells (Laoukili, Perret et 
al. 2001; Atherton, Jones et al. 2003; Zhen, Park et al. 2007; Kono, Nishiuma et 
al. 2010; Tanabe, Kanoh et al. 2011) through different mechanisms that 
eventually activates transcription factors to translocate to the nucleus and binds 
to MUC5AC promoter region.  A detailed study of human MUC5AC promoter 
region revealed the presence of different binding sites for transcription factors as 
outlined in Figure 8. 
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Figure 8. 5’ flanking region of MUC5AC:  Activation of different signaling 
pathways causes activation or translocation of transcription factors that bind to 
specific binding motifs in human MUC5AC promoter. NF-κB, activator protein 1 
(AP-1), glucocorticoid response elements (GRE), cAMP-response element 
(CRE), Smad4, and Specificity Protein 1 (SP1) are examples of the binding sites 
of transcription factors. Adapted from Thai, Loukoianov et al. (2008).  
 
IL-13 induces the release of TGF-β2 from airway epithelial cells which in 
turn increases MUC5AC expression through SMAD4 dependent mechanisms 
(Chu, Balzar et al. 2004). Moreover, IL-13 stimulates the release of heparin-
binding EGF-like growth factor (HB-EGF) from airway epithelial cells, which 
activates epidermal growth factor receptor (EGFR) (Allahverdian, Harada et al. 
2008). EGFR signaling is involved in IL-13 induced mucin production (Shim, 
Dabbagh et al. 2001; Kim, Shim et al. 2002). This effect is attributed to the 
reduction in forkhead box protein A2 (FOXA2) expression, which is a negative 
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regulator of MUC5AC expression (Zhen, Park et al. 2007). Moreover, EGFR 
signaling enhances ciliated cell survival, through PI3 kinase, and IL-13 induces 
the transdifferentiation of ciliated cells to goblet cells (Tyner, Kim et al. 2006). IL-
13 also reduces the expression and the apical translocation of ezrin, a protein 
that is involved in basal body attachment to the apical surface of ciliated cells 
(Laoukili, Perret et al. 2001). IL-13 upregulates 15-Lipoxygenase-1 (15-LO-1) in 
human airway epithelial cells leading to increased MUC5AC expression (Zhao, 
Maskrey et al. 2009) via the Raf-1/MEK/ERK signaling cascade (Zhao, O'Donnell 
et al. 2011). Moreover, elements of IL-13 signaling pathways, specifically STAT6 
and IL-4R, play a major role in the development of mucus production in murine 
model of asthma (Gavett, O'Hearn et al. 1997; Kuperman, Schofield et al. 1998). 
IL-13 also provokes the secretory phenotype of airway epithelial cells 
through increasing the apical calcium activated anion conductance (Danahay, 
Atherton et al. 2002). This effect is due to increased expression of calcium-
activated chloride channel, mCLCA3 (in mice) and hCLCA1 (in humans) (Zhou, 
Dong et al. 2001). The expression level of hCLCA1 is upregulated in airway 
epithelial cells from asthmatic patients (Hoshino, Morita et al. 2002). Additionally, 
introducing mCLCA3 / hCLCA1 into airway epithelial cells increases mucus 
production and MUC5AC expression (Nakanishi, Morita et al. 2001), pointing 
toward the important role of hCLCA1 in MUC5AC expression. It is important to 
note that IL-13 regulates hCLCA1 and MUC5AC expression at different time 
 
 
45 
points. After 24 hours of IL-13 treatment, hCLCA1, but not MUC5AC, expression 
level is increased through JAK/STAT6 dependent pathway (Thai, Chen et al. 
2005). It is thus possible that MUC5AC expression is regulated by STAT6 
independent pathways (Thai, Chen et al. 2005). In support of this notion, muc5ac 
(and MUC5AC) 5' flanking region lacks STAT6 consensus motif, as outlined in 
Figure 5, so STAT6 may indirectly contribute to MUC5AC expression through 
activation of other transcription factors such as hypoxia-inducible factor-1 (HIF-1) 
and SMAD4 (Young, Williams et al. 2007; Thai, Loukoianov et al. 2008).   
IL-13 also initiates airway epithelial cell proliferation through the release of 
transforming growth factor-alpha (TGF-α) and activation of EGFR signaling 
cascade (Booth, Adler et al. 2001).  
 
2.5   β-Adrenoceptor in airway cells: 
2.5.1 β2-AR signaling pathway: 
β2-ARs belong to the G protein-coupled superfamily of receptors 
(GPCRs), which are characterized by their seven transmembrane domains. 
These receptors transduce their effect through heterotrimeric G protein that 
consists of α, β, and γ subunits (Gilman 1987). There are at least 23 Gα subunits 
grouped into four main classes (Gαi/o, Gαs, Gαq/11, and Gα12), 5 types of Gβ and 
11 types of Gγ (Hermans 2003). When the receptor is not stimulated by a ligand, 
the guanosine diphosphate (GDP) bound-α subunit is associated with βγ 
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subunits and the heterotrimer is coupled to the receptor. Receptor activation by 
agonist binding stimulates the release of GDP, and guanosine triphosphate 
(GTP) subsequently binds the α subunit, which dissociates from βγ subunits. 
Each of the dissociated subunits (α and βγ) activate downstream signaling 
cascades. The GTPase activity of α subunit eventually hydrolyses the terminal 
phosphate of GTP and causes termination of the signaling cascade, re-
association of α and βγ, and recoupling of the heterotrimer to receptors (Neer 
1995). 
The Gαs subunit released upon β2-AR activation activates adenylyl 
cyclase (AC), which increases intracellular cyclic adenosine monophosphate 
(cAMP), consequently activating cAMP dependent protein kinase A (PKA) and 
Exchange Protein directly Activated by cAMP (Epac) (Pierce, Premont et al. 
2002). In mammalian cells, there are at least 9 membrane bound isoforms of AC 
and one soluble AC (Hanoune and Defer 2001; Pierre, Eschenhagen et al. 
2009). In the lung, AC2, 6, 8 and 9 are highly expressed while AC3, 4, 5 and 7 
are expressed at a low level and AC1 is not detected (Pierre, Eschenhagen et al. 
2009). GTP-bound Gαs activates the enzymatic catalytic activity of AC (Pierre, 
Eschenhagen et al. 2009) while Gαi inhibits the catalytic activity (Pierre, 
Eschenhagen et al. 2009). The intracellular level of cAMP is regulated at the 
synthesis level, through AC, and degradation level, through phosphodiesterases 
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(PDEs), which hydrolyze the 3`cyclic phosphate bond in cAMP (Bender and 
Beavo 2006).   
PKA, a downstream target of cAMP, is composed of two regulatory 
subunits bound to two catalytic subunits (Taylor, Kim et al. 2008; Pidoux and 
Tasken 2010). Binding of four cAMP molecules to the regulatory subunits 
induces the dissociation of the regulatory subunits from the catalytic subunits 
(Builder, Beavo et al. 1980). This dissociation activates the catalytic subunits that 
phosphorylate serine threonine residues in numerous cellular substrates. Figure 
9 summarizes cAMP/PKA-signaling pathways downstream of activated GPCR. 
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Figure 9: Schematic diagram of the cAMP/PKA signaling pathway. Activation 
of the G-protein coupled receptors increase intracellular cAMP levels through 
activating adenylyl cyclase. cAMP binds to and activates PKA which in turn 
phosphorylates several downstream substrates. However, intracellular cAMP is 
degraded by phosphodiesterases (PDEs). Adapted from Gerits, Kostenko et al. 
(2008). 
Additionally, PKA phosphorylates the third intracellular loop of β2-AR and 
causes a partial uncoupling of the receptor from Gs (desensitization) (Benovic, 
Bouvier et al. 1988) and switches the receptor to a form that couples to Gi 
(Daaka, Luttrell et al. 1997; Zamah, Delahunty et al. 2002). Released βγ subunits 
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bind to G protein-coupled receptor kinase (GRK) 2/3 and induces its 
translocation to the plasma membrane (Penela, Ribas et al. 2003). GRKs then 
phosphorylate agonist activated β2-AR at serine residues different from those 
phosphorylated by PKA (Ferguson 2001). Activated and phosphorylated 
receptors bind to β-arrestin-2, which fully uncouples receptors and attenuates 
their signaling through a steric effect (Noor, Patel et al. 2011) or by increasing 
cAMP degradation via recruiting PDEs to the activated β2-AR (Perry, Baillie et al. 
2002). Moreover, β-arrestins function as an adaptor protein that bring activated 
receptor into clathrin-coated pits and thus facilitates internalization (Sibley, 
Strasser et al. 1986; Krupnick, Goodman et al. 1997; Pierce and Lefkowitz 2001), 
β-arrestin-2 binds transiently and weakly to the receptor and rapidly dissociates 
after targeting the receptors to clathrin-coated pits (DeWire, Ahn et al. 2007). 
Receptor internalization completes desensitization, and enables receptors to be 
dephosphorylated by intracellular phosphatases before returning to the cell 
surface (Ferguson 2001). The roles of β-arrestins are summarized in Figure 10 
below. 
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Figure 10: The classical roles of β-arrestins in receptor desensitization and 
internalization. Binding of a ligand to the receptor initiates signaling waves 
through G-protein (a). However, β-arrestin recruitment to phosphorylated ligand-
occupied receptor inhibits the G-protein coupling and causes desensitization (b). 
Moreover, β-arrestin also causes receptor internalization through targeting the 
receptors to clathrin-coated pits (c). Adapted from Lefkowitz and Whalen (2004).  
 
Beside the aforementioned classical functions of β-arrestins, these 
molecules initiate a second wave of signaling pathways through their scaffold 
properties, as demonstrated in Figure 11. β-arrestins activate ERK1/2, JNK3 
(Lefkowitz and Shenoy 2005), p38 and Akt (DeWire, Ahn et al. 2007). Activated 
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ERK1/2 by G-protein dependent pathways is translocated to the nucleus while it 
is retained in the cytosol if it is activated through β-arrestins (Defea 2008). The 
activation of ERK1/2 by Gs is rapid whereas β-arrestin mediated activation is 
slow and sustained (Shenoy, Drake et al. 2006). ERK1/2 is activated by β-
arrestins through recruiting Src, a non-receptor tyrosine kinase, to the active β2-
AR (Luttrell, Ferguson et al. 1999). Besides activating ERK1/2, Src transactivates 
EGFR through the release of HB-EGF by matrix metalloproteinase (MMP) 
dependent pathways (Prenzel, Zwick et al. 1999). 
 
Figure 11: Scaffold properties of β-arrestin-2 and their role in initiating a 
second wave of signaling pathways. β-arrestin-2 regulates the activity of 
ERK1/2 (a), JNK3 (b) and Akt (c), through its scaffold properties, and activates 
their downstream signaling cascades. Adapted from DeWire, Ahn et al (2007). 
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2.5.2 Role of β2-AR signaling in airway cells: 
Activation of airway β2-ARs causes several important physiological 
changes in different airway cells. Chronic activation of β2-ARs, by agonists, 
results in several detrimental consequences that will be discussed in conjunction 
with the physiological roles of β2-AR signaling for each cell type.  
 
2.5.2.1 Role of β2-AR signaling in inflammatory cells: 
Several inflammatory cells express β2-ARs, such as mast cells (Chong, 
Chess-Williams et al. 2002), macrophages (Schenkelaars and Bonta 1984), 
eosinophils (Yukawa, Ukena et al. 1990), neutrophils (Galant and Allred 1980) 
and lymphocytes (Brodde, Brinkmann et al. 1985). There is some evidence that 
β2AR-signalling may promote allergic inflammation. 
Stimulation of β2-ARs on peripheral blood mononuclear cell (PBMC) by 
epinephrine or terbutaline resulted in skewing the TH1/TH2 balance toward TH2 
where there is an increase in IL-4, IL-5 and IL-10 besides a reduction in 
interferon-γ (IFN-γ) levels (Agarwal and Marshall 2000). β2-ARs are expressed 
on activated TH1 cells, but not activated TH2 cells, and activation of these 
receptors by terbutaline reduces the release of IL-2. This reduction in IL-2 
disturbs the inhibitory effect of TH1 cytokines on TH2 cell (Ramer-Quinn, Baker et 
al. 1997) and enhances the TH2 response. Moreover, salbutamol and fenoterol 
enhance the production of IgE induced by IL-4 in cultured PBMCs (Coqueret, 
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Dugas et al. 1995). Salbutamol, by shifting the immune response toward TH2, 
potentiated IgE production in response to TH2 cytokines (Fedyk, Adawi et al. 
1996). 
β2-AR agonists also reduce the release of some inflammatory mediators 
(Barnes 1999). Salbutamol inhibits histamine release from mast cells (Chong, 
Chess-Williams et al. 2002) and salmeterol reduces the release of histamine and 
leukotrienes from human lung (Butchers, Vardey et al. 1991). Histamine and 
leukotrienes are immediate inducers of airway smooth muscle contraction. β2-AR 
agonists inhibit lipopolysaccharide (LPS) induced TNF-α and IL-8 production 
from human monocyte cells via cAMP/PKA signaling (Farmer and Pugin 2000), 
suggesting a reduction in TH1 responses that would promote TH2-mediated 
allergy. In addition, the reduction in heparin sulphate release from mast cells by 
β2-AR agonists may contribute to several detrimental effects. Heparin sulphate is 
normally released from mast cells and neutralizes cationic proteins that are 
produced by eosinophils (Broadley 2006). Cationic proteins, such as major basic 
protein, have the potential to damage airway epithelial cells (Motojima, Frigas et 
al. 1989). Moreover, heparin inhibits ASM proliferation (Kanabar, Hirst et al. 
2005). Finally, regular use of salbutamol causes an increase in late asthmatic 
response and eosinophil influx into the airways (Gauvreau, Jordana et al. 1997).  
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2.5.2.2 Role of β2-AR signaling in airway smooth muscle (ASM) cells: 
β2-AR signaling affects ASM and enhances airway relaxation through 
numerous mechanisms. For example, potassium channels phosphorylated by 
PKA tend to open more frequently and thus reduce cell excitability (Giembycz 
and Newton 2006). PKA also inactivates myosin light chain kinase (MLCK) 
(Miller, Silver et al. 1983) while it activates myosin light chain phosphatase 
(MLCP) (Janssen, Tazzeo et al. 2004) leading collectively to muscle relaxation 
(Kassel, Wyatt et al. 2008). 
In addition, activation of β2-AR signaling has anti-inflammatory effects 
through reducing the release of different chemokines from ASM such as 
RANTES (Hallsworth, Twort et al. 2001; Lazzeri, Belvisi et al. 2001), GM-CSF 
(Hallsworth, Twort et al. 2001) and eotaxin (Hallsworth, Twort et al. 2001; Pang 
and Knox 2001), in contrast to the β2-AR effects on leucocytes described above. 
With chronic use of β2-AR agonists, their ability to enhance 
bronchodilation is reduced (Giembycz and Newton 2006). Several mechanisms 
have been proposed to explain this reduction in response, including receptor 
desensitization via uncoupling of β2-AR from Gs, β-arrestin binding followed by 
receptor internalization, sequestration and downregulation (Johnson 1998), 
downregulation of Gαs (Finney, Donnelly et al. 2001) and upregulation of PDEs 
(Torphy, Zhou et al. 1992; Seybold, Newton et al. 1998). The bronchodilatory 
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effect of β2-AR agonists is relatively resistant to desensitization in contrast to 
other responses such as the anti-inflammatory effects (Broadley 2006).  
The loss of bronchodilation with chronic β2-AR agonist is also due to 
upregulation of phospholipase Cβ1 (PLCβ1) (McGraw, Almoosa et al. 2003), the 
signaling molecule that mediates the bronchoconstriction response induced by 
agents such as methacholine and acetylcholine, as outlined in Figure 12. 
Overexpression of β2-AR in ASM cells enhanced acetylcholine-induced 
bronchoconstriction by upregulating PLCβ1 expression (McGraw, Almoosa et al. 
2003). However, the bronchoconstriction response induced by methacholine and 
Gq-coupled receptor agonists was reduced in β2-AR KO (McGraw, Almoosa et 
al. 2003). This mechanism provides an explanation for the AHR induced by 
bronchoconstrictors after chronic administration of β2-AR agonists (Barnes 2011). 
Moreover, chronic β2-AR activation increases cytokine release from ASM and 
consequently airway remodeling via ERK dependent mechanisms (Shore and 
Drazen 2003).  
The inflammatory milieu reduces β2-AR responsiveness due to several 
mechanisms. For example, IL-1β reduces ASM relaxation in response to β2-AR 
stimulation through increasing prostaglandin E2 (PGE2) release in ASM cells. 
PGE2 increased cAMP levels and PKA activation resulted in heterologous 
phosphorylation of β2-AR (Laporte, Moore et al. 1998) and consequently 
uncoupling of β2-AR from Gs (Shore, Laporte et al. 1997; Laporte, Moore et al. 
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1998). TNF-α and IL-1β combination also decreased ASM response to β2-AR 
agonist via the same mechanism (Moore, Lahiri et al. 2001). Moreover, IL-13 and 
IL-4, as a part of TH2 cytokines, attenuate ASM relaxation in response to β2-AR 
agonists (Shore 2002). 
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Figure 12: Detrimental effects of chronic β2-AR agonist stimulation. Binding 
of agonist to β2-AR induces airway relaxation through increasing PKA activity and 
inhibiting ERK signaling (a). However, regular activation of β2-AR enhances the 
expression of chemokines and airway remodeling through increasing ERK 
activation by Gi/β-arrestin coupling (b). In addition, regular activation of β2-AR 
also induces AHR through increasing PLC-β levels. Adapted from Shore and 
Drazen (2003). 
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2.5.2.3 Role of β2-AR signaling in airway epithelial cells: 
The coordinated beating of cilia is necessary for mucociliary clearance. β-
agonists increase the ciliary beat frequency (CBF) (Verdugo, Johnson et al. 
1980; Yanaura, Imamura et al. 1981; Lopez-Vidriero, Jacobs et al. 1985; Devalia, 
Sapsford et al. 1992; Tamaoki, Chiyotani et al. 1993; Wyatt, Spurzem et al. 
1998). The effect β2-AR agonist on CBF is mediated by cAMP/PKA signaling (Di 
Benedetto, Manara-Shediac et al. 1991; Salathe 2002). Interestingly, cAMP 
enhances calcium release from intracellular stores and thus stimulates nitric 
oxide induced CBF (Salathe 2002). In support to this notion, acute β-agonist 
inhalation increases the rate of mucociliary clearance in both normal individuals 
(Lafortuna and Fazio 1984) and in patients with chronic bronchitis (Fazio and 
Lafortuna 1981; Lafortuna and Fazio 1984).  
In many studies, β2-AR agonist causes changes in the release of 
inflammatory mediators. Formoterol, a long acting β2-AR agonist, increases IL-8 
release from airway epithelium and decreases GM-CSF level in response to 
TNF-α (Korn, Jerre et al. 2001). Moreover, salbutamol, salmeterol and formoterol 
enhance the release of IL-8 and IL-6 from airway epithelium in response to IL-1β 
through cAMP-PKA signaling (Holden, Rider et al. 2010). In contrast, another 
study has shown that formoterol did not affect IL-8 or GM-CSF levels in airway 
epithelium from asthmatic patients (Wilson, Wallin et al. 2001). It is noteworthy to 
mention that the inflammatory cytokines that are released in asthma also play a 
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role in altering β2-AR/AC system. For example, IL-1β increases β2-AR levels in 
airway epithelium but also elevates Gαi levels, thus leading to dichotomous effect 
on functional coupling of β2-AR to cAMP production (Kelsen, Anakwe et al. 
1997).  
 
2.5.3 β-Blockers in asthma: 
Based on all of the above-mentioned evidence for the detrimental effect of 
chronically activating β2-ARs, blocking these receptors might have beneficial 
effects. β-AR blockers are contraindicated in asthma because acute 
administration of these agents is associated with airway narrowing (Singh, 
Whitlock et al. 1976; Boskabady and Snashall 2000). Chronic, but not acute, 
administration of nadolol reduces AHR in murine model of asthma (Callaerts-
Vegh, Evans et al. 2004). The decreased AHR after blocking β2-AR is partially 
due to reduction in the levels of PLC-β1, PDE4D and Gi (Lin, Peng et al. 2008). 
Blocking β2-AR chronically, by nadolol administration, or by genetically ablating 
β2-AR reduces AHR, eosinophil recruitment to airways and mucus metaplasia 
(Nguyen, Omoluabi et al. 2008; Nguyen, Lin et al. 2009). These lines of evidence 
point toward the detrimental effect of activating β2-ARs and their pro-
inflammatory role and suggest that blocking these receptors might result in 
attenuating asthma phenotype. 
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3. Methods 
3.1 Cell culture: 
Normal human bronchial epithelial (NHBE) cells were obtained from Lonza 
(Walkersville, MD). Cells were cultured in bronchial epithelial growth medium 
(BEGM; Lonza) and grown in 5% CO2 and 95 % air at 37°C. At 80–90% 
confluence, cells (2 x 104 cells/ cm2) were seeded onto Transwell-culture inserts 
(24.5 mm diameter with 0.45 μm pore size) in a media composed of 50% of 
bronchial epithelial basal media (BEBM) and 50% of Dulbecco’s modified Eagle 
medium (DMEM) high glucose and supplemented with 30 μg/ml bovine pituitary 
extract, 0.5 μg/ml bovine serum albumin (BSA), 0.5 μg/ml epinephrine, 50 μg/ml 
gentamycin, 50 ng/ml amphotericin B, 0.5 ng/ml human EGF, 0.5 μg/ml 
hydrocortisone, 5 μg/ml insulin, 7 ng/ml triiodothyronine, 10 μg/ml transferrin and 
0.1 ng/ml retinoic acid. This media will be referred as “differentiation media” 
throughout the text. Cells were cultured with epinephrine for ~8 days until they 
reached confluence, then the apical medium was removed and air-liquid interface 
(ALI) was established. After establishing ALI, the medium was changed every 
other day.  
In some experiments, cells were grown in the absence of epinephrine for 
72 hours before reaching ALI and throughout the ALI period. This condition will 
be referred as “absence of epinephrine”. The cells were then treated with 20 
ng/ml of IL-13 combined with different agonist/antagonist or inhibitors at the start 
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of ALI for 14 days as demonstrated in Figure (13). All experiments were repeated 
with three independent IL-13-responsive donor cell samples (N=3).  
 
 
Figure 13: NHBE cells culture and treatment protocol.  
 
3.2 NHBE cell treatment: 
Cells were treated with IL-13 (20 ng/ml) combined with one of these 
additions for 14 days after establishing ALI: 1μM ICI-118,551 (selective β2AR 
antagonist), 3μM CGP-20712A ( selective β1AR antagonist), 10 μM Nadolol or 
alprenolol, 3μM FR180204 (ERK1/2 inhibitor), 3μM SB203580 (p38 inhibitor), 
3μM SP600125 (JNK inhibitor), 3μM H89 (PKA inhibitor), 50 or 100 μM Rp-
cAMPS (cAMP-dependent protein kinases inhibitor), 10 μM forskolin with 100 μM 
IBMX, 100 nM roflumilast (PDE4 inhibitor) or 100 nM carvedilol. These reagents 
were applied to the basal media at their final concentrations. The basal media 
was replaced with new media to which was added the reagents at their final 
concentrations every 48 hours. Compound-related toxicity was assessed by 
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observing the dryness of the apical surface of the cultured NHBE cells (Atherton, 
Jones et al. 2003).  
 
3.3 Transepithelial Electrical Resistance (TEER) measurements: 
The transepithelial electrical resistance (TEER) was measured using 
epithelial ohmvolt meter EVOM voltohmmeter device (WPI, Sarasota, FL) 
throughout the culture period to evaluate the monolayer integrity. Briefly, the 
medium was added to the apical compartment and resistance was measured 
from 3 inserts for each treatment group from each donor. Apical medium was 
then removed to maintain ALI conditions. TEER values were then subtracted 
from TEER of an empty insert. The values were then multiplied by the surface 
area and the data presented in units of Ω·cm2.  
 
3.4 Real-Time quantitative PCR Analysis: 
Total RNA was extracted from cells using Trizol® (Invitrogen, CA), 
according to manufacturer’s protocol. cDNA was generated from 5μg of total 
RNA using SuperScript III RT (Invitrogen, CA). MUC5AC, FOXJ1 and 18s mRNA 
was quantified using the Taqman Gene Expression Assay® (Applied Biosystems, 
CA) and analyzed by real time quantitative PCR (ABI PRISM 7000 Sequence 
Detection System, Applied Biosystems, CA). The threshold cycle (Ct) of treated 
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groups was compared to control group and normalized to 18s. Relative MUC5AC 
expression was calculated using Delta-Delta CT method. 
 
3.5 Immunoblotting: 
NHBE cells were lysed in a buffer containing 20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin 
(Cell Signaling, Danvers, MA) combined with protease inhibitor cocktail tablet 
(Roche Applied Sciences, Indianapolis, IN). Total protein concentration was 
determined by BCA Protein Assay Kit® (Thermo Fisher Scientific Inc, Rockford, 
IL), according to the manufacture’s protocols. Protein extracts were subjected to 
SDS-PAGE using 10% Tris-HCl gels (Bio-Rad Laboratories, Hercules, CA) and 
transblotted to polyvinylidene difluoride (PVDF) membrane (EMD Millipore, 
Billerica, MA). Membranes were blocked in 3% BSA for 1 hour at room 
temperature and then incubated with primary antibodies, at the concentrations 
shown in Table 2, overnight at 4oC followed by treatment for 1 hour with HRP 
conjugated antibodies against secondary antibody. The protein bands were 
developed using SuperSignal West Pico chemiluminescent substrate® (Thermo 
Fisher Scientific) according to manufacturer’s recommendations. A CCD camera 
(Fluorochem 8800™) was used to collect the digital images and AlphaEase 
software (ProteinSimple, Santa Clara, CA) to quantify band density. The 
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membranes were then stripped and probed with GAPDH antibody or total-
ERK1/2.  The signal density of the phosphorylated proteins was normalized with 
that of GAPDH or total-protein. The data was presented as fold change as 
compared to control untreated cells to account for donors profile variations. 
 
Primary antibody 
 
Source 
 
Dilution 
Phospho-ERK1/2, Cell Signaling 1:1000 
Total-ERK1/2 Cell Signaling 1:1000 
Phospho-CREB Cell Signaling 1:250 
Total-CREB Cell Signaling 1:1000 
Phospho-p38 Santa Cruz Biotechnology 1:1000 
Phospho-c-Jun Millipore 1:1000 
Phospgo-STAT6 Cell Signaling 1:1000 
GAPDH Millipore 1:1000 
 
Table 2: List of primary antibodies used for immunoblotting. 
 
3.6 Periodic acid fluorescent Schiff’s (PAFS) stain:  
The apical surfaces of NHBE cells were washed with phosphate buffered 
saline (PBS), fixed in 4% paraformaldehyde (PFA) and permeabilized with Triton 
X-100. The inserts were stained with PAFS as described previously (Piccotti, 
Dickey et al. 2012). Red fluorescence of mucin was detected when the slides 
were excited at 380–580 nm and observed at 600–650 nm while the nucleic acid 
and cytoplasm of the cells fluorescence green when observed at a lower 
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wavelength (380–500 nm and 450–475 nm excitation and emission wavelengths 
respectively) (Piccotti, Dickey et al. 2012). Images were captured using an 
Olympus DUS spinning disc confocal microscope maintained in the College of 
Pharmacy Imaging Core. To correct for insert background, empty inserts were 
stained and used as a negative controls. To maintain consistency in subsequent 
image analysis, we used the same channel-specific threshold when capturing all 
images. The ratio of mucin integrated density and nucleic acid/cytoplasm 
integrated density was calculated using Image J software (NIH). The data are 
represented as fold change compared to the correspondent control cells. 
 
3.7 Immunofluorescence labeling: 
The apical surfaces of NHBE cells were washed with PBS, fixed in 4% 
paraformaldehyde (PFA) and permeabilized with Triton X-100. The inserts were 
incubated for 15 minutes with 10% normal goat serum at room temperature 
followed by rabbit polyclonal mucin 5AC antibody (H-160, Santa Cruz) (Fujisawa, 
Velichko et al. 2009) or ZO-1 antibody (Invitrogen) (Stewart, Torr et al. 2012) at 
dilutions of 1:200 overnight at 4oC. After washing the inserts with PBS, they were 
incubated with Alexa 594 goat anti-rabbit secondary antibody at 1:200 for 1 hour 
at room temperature. DAPI, at final concentration of 1 μg/ml, was used to 
counterstain the nuclei for 15 minutes at room temperature. Slides incubated with 
primary antibody diluents were used as negative controls. Images were captured 
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by confocal microscopy and the same channel-specific threshold was maintained 
when capturing the images. The ratio of integrated mucin 5AC density of each 
group to the integrated mucin 5AC density of the corresponding control group 
was calculated using Image J software (NIH).  
 
3.8 Chemokine release: 
Basolateral medium from the correspondent treatment groups were 
sampled at day 5 of ALI. Samples were flash frozen and sent to Aushon 
Biosystems (Billerica, MA) for assay of selected chemokines by indirect ELISA. 
 
3.9 cAMP measurements: 
Intracellular cAMP levels were measured by cAMP complete ELISA kit® 
(Ezo life sciences, NY) competitive immunoassay according to the manufacture’s 
protocols. Briefly, NHBE cells were lysed in 0.1 M HCl to inhibit the activity of 
endogenous phosphodiesterases. The samples were then centrifuged and cell 
suspensions were stored at -80oC. The standards and the samples were run in 
duplicate and incubated with alkaline phosphatase conjugated cAMP and cAMP 
antibody. After incubating the plate with the substrate, the absorbance was 
measured at 405 nm and cAMP concentration was calculated as pmol/ml. The 
cAMP concentration was then divided by the protein concentration (mg/ml) to 
normalize for protein content. Data are represented as pmol/mg of protein. 
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3.10 mouse tracheal epithelial cells (mTECs) Isolation: 
Wild type and β-arrestin-2 knockout mice were provided and genotyped by 
Garbo Mak from Dr. David Corry’s lab (Baylor College of Medicine, Houston, TX). 
Xiaoyi Yuan from Dr. Farrah Kheradmand ‘s lab (Baylor College of Medicine, 
Houston, TX) provided the technical assistance for mTECs isolation.  
mTECs were isolated as described previously (You and Brody 2013). The 
resected trachea was opened longitudinally and rinsed with cold calcium and 
magnesium-free PBS. Then it was kept in cold DMEM/Ham’s F-12 medium 
supplemented with 25 units-µg/ml penicillin/streptomycin. To isolate the mTECs, 
the trachea was incubated for 18-24 hours at 4oC in DMEM/Ham’s F-12 
penicillin/streptomycin media containing 0.15% pronase.  Tracheal epithelial cells 
were detached from the trachea by gentle inversion in DMEM/Ham’s F-12 
medium supplemented with 25 units-µg/ml penicillin/streptomycin and 10% fetal 
bovine serum (FBS). After centrifugation, the cells were suspended in ‘mTEC 
Basic’ medium and incubated at 37oC 5% CO2 for ~6 hours in primary culture 
dishes to remove adherent fibroblasts. Non-adherent cells were collected, 
centrifuged and suspended in ‘mTEC/Plus’ medium.  
 
3.11 In vitro culture of mTEC: 
After isolating mTECs, the cells were seeded into collagen-coated inserts 
and kept submerged in ‘mTEC/Plus’ medium. After 7 days, the medium from the 
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apical compartment was removed and ALI was established. During ALI, ‘mTEC/ 
NuSerum’ medium was added to the basolateral compartment. Fourteen days 
after establishing ALI, the cells were treated with 20 ng/ml mouse recombinant 
IL-13 and 3 µM epinephrine for 14 days. IL-13 and epinephrine were added to 
‘mTEC/ NuSerum’ medium. The compositions of different culture media that were 
used for mTECs are summarized in the table 3. Figure 14 below summarizes the 
culture and treatment protocol.    
    
 
Figure 14: mTECs culture and treatment protocol 
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mTEC medium 
 
Composition 
 
‘mTEC Basic’  
DMEM/Ham’s F-12 (1:1 v/v) supplemented with 4 mM 
glutamine, 0.25 µg/ml amphotericin B, 50 µg/ml 
gentamicin and 10 units-µg/ml penicillin-streptomycin 
 
 
 
‘mTEC/Plus’  
DMEM/Ham’s F-12 (1:1 v/v) supplemented with 5% FBS, 
4 mM glutamine, 0.25 µg/ml amphotericin B, 50 µg/ml 
gentamicin, 10 units- µg/ml penicillin-streptomycin, 5 
mg/ml insulin, 30 µg/ml bovine pituitary extract, 5 µg/ml 
human transferrin, 0.1 µg/ml cholera toxin, 25 ng/ml 
epidermal growth factor and 10-8 M retinoic acid.  
 
 
‘mTEC/NuSerum’  
‘mTEC basic’ medium supplemented with 2% NuSerum 
and 10-8 M retinoic acid. 
 
 
Table3: Composition of different culture media used for mTECs. 
 
3.12 Statistical Analysis:  
Data are presented as means ± SEM. All experiments were done with 
NHBE cells from 3 donors (N=3). One-way ANOVA followed by Tukey's 
multicomparison test for multiple group statistical analysis was performed using 
GraphPad Prism 4® software. p<0.05 was considered statistically significant. 
 
 
 
70 
4. Results: 
4.1 Epinephrine is required for mucin production in response to IL-13 in 
NHBE cells  
In many published studies, epinephrine is routinely added to the medium 
of cultured NHBE cells (Atherton, Jones et al. 2003; Fulcher, Gabriel et al. 2005; 
Zhen, Park et al. 2007). We thus evaluated the requirement of epinephrine in 
inducing mucus production in response to IL-13. When NHBE cells were grown 
in the absence of epinephrine 72 hours before the cells reached ALI and 14 days 
after establishing AL, MUC5AC was expressed at low levels. Treating these cells 
with 20 ng/ml IL-13 for 14 days after establishing ALI did not induce MUC5AC 
expression (Figure 15A).  
However, in the presence of epinephrine, treating NHBE cells with 20 
ng/ml IL-13 for 14 days increased MUC5AC expression by ~ 15 fold as compared 
to control cells (-IL-13) (Figure 15A). To correlate the expression level with 
intracellular mucin 5AC and mucin glycoprotein, NHBE cells were incubated with 
primary antibody that recognize mucin 5AC of human origin or with PAFS 
staining respectively. A similar trend was also observed at the level of 
intracellular content of mucin 5AC and mucin glycoprotein (Figure 15B and 
Figure 16).  
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To determine whether growing NHBE cells in the absence of epinephrine 
compromised their integrity, we evaluated tight-junction formation between the 
cells by measuring transepithelial electrical resistance (TEER) throughout the 
culture period. TEERs increased during ALI, peaked on ~ALI day 7 and then 
decreased. The presence or absence of IL-13 or epinephrine did not greatly 
reduce TEERs values below untreated cells (Figure 17A). The formation of tight 
junctions was also confirmed by showing the presence of ZO-1 on the cell 
peripheries by immunofluorescence on ALI day 14 (Figure 17B).  
We examined if the absence of epinephrine affected cell differentiation 
and whether this is the underlying mechanism for not responding to IL-13 
stimulation. The expression of FOXJ1, a transcription factor expressed early in 
ciliogenesis, and MUC5AC were similar in the absence or presence of 
epinephrine (Figure 18A).  The secretion of a well-studied epithelial cytokine, 
thymic stromal lymphopoietin (TSLP), and other cytokines such as monocyte 
chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein 3 
alpha (MIP3 ), were also not affected by the presence or absence of 
epinephrine. (Figure 18C). 
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Figure 15. Epinephrine is required for mucin 5AC production in response to IL-
13 in NHBE cells: A) NHBE cells were grown in the presence or absence of 3 μM 
epinephrine. At ALI, the cells were treated with 20 ng/ml IL-13 for 14 days, total RNA 
was harvested and then MUC5AC transcripts were measured by qRT-PCR. Data are 
presented as fold change compared to the corresponding treatment control (in the 
absence of IL13). B) The Transwell® membranes were incubated with a rabbit 
antibody against human mucin 5AC (red) and DAPI to counterstain the nuclei (blue). 
The ratio of integrated fluorescence density of each group to the integrated mucin 
5AC density of the corresponding control group was calculated and expressed as 
fold change compared to the corresponding control cells (in the absence of IL-13 
treatment). Representative images of immunofluorescence are shown (scale bar = 
100 μm). Data are presented as means ± SEM from three donors. *, † and ¥ indicate 
p<0.05 significance as compared to +epi, -epi and -epi + IL-13 treated cells 
respectively. 
A B 
 
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Epinephrine is required for mucin production in response to IL-13 in 
NHBE cells: NHBE cells were grown in the presence or absence of 3 μM 
epinephrine. At ALI, the cells were treated with 20 ng/ml IL-13 for 14 days. PAFS 
staining of NHBE cells to quantify total intracellular mucin glycoproteins. 
Representative images are shown (scale bar = 100 μm). The ratio of mucin 
integrated density and nucleic acid/cytoplasm integrated density was calculated and 
the data presented as fold change compared to the corresponding control cells (in 
the absence of IL-13 treatment). Representative image is the inset. Data are 
presented as means ± SEM from three donors. *, † and ¥ indicate p<0.05 
significance as compared to +epi, -epi and -epi +IL-13 treated cells respectively. 
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Epi     - - + + 
IL-13  - + - + 
A 
B 
Figure 17. Role of epinephrine in the integrity of NHBE cells monolayer in 
response to IL-13: NHBE cells were grown in the presence or absence of 3 μM 
epinephrine. At ALI, the cells were treated with 20 ng/ml IL-13 for 14 days. A) 
Trans-epithelial electrical resistance (TEER) was measured throughout the culture 
period. Data are presented as ohm.cm2 of insert surface area. Data are presented 
as means ± SEM from three donors. * and # indicate p<0.05 significance between 
–epi+IL-13 and +epi+IL-13 and –epi and -epi +IL-13 treated cells respectively. B) 
Representative images of immunofluorescence with a rabbit antibody against ZO-
1 (red) (scale bar = 100 μm). The Transwell® membranes were incubated with 
DAPI to counterstain the nuclei (blue). Incubation with antibody diluent showed no 
red fluorescence (negative control). 
100 µm 
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Figure 18. Effect of epinephrine on NHBE cell differentiation:  NHBE cells were 
grown in the presence or absence of 3 μM epinephrine after establishing ALI. For 
cells grown in the absence of epinephrine, epinephrine was removed from the 
differentiation media 72 hours before ALI.  A) After 14 days of growth at ALI, total 
RNA was harvested and then FOXJ1 and MUC5AC transcripts were measured by 
qRT-PCR. Data are presented as fold change compared to cells grown in the 
presence of epinephrine. B) The ratio of integrated fluorescence density (mucin 5AC 
and mucin glycoproteins) of each group to the integrated fluorescence density of the 
corresponding control group was calculated and expressed as fold change compared 
to cells grown in the presence of epinephrine. C) Secretion of thymic stromal 
lymphopoietin (TSLP), monocyte chemoattractant protein-1 (MCP-1) and 
macrophage inflammatory protein 3α (MIP3α) from cells grown in the presence or 
absence of epinephrine (Indira Pokkunuri et al., BPS winter meeting, 2011). Data are 
presented as means ± SEM from three donors. 
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4.2 Epinephrine induced-β2-AR signaling is required for mucin production 
in response to IL-13 in NHBE cells  
To determine the β-AR subtype involved in MUC5AC expression in 
response to IL-13 in the presence of epinephrine, NHBE cells were incubated 
with either a selective β2-AR antagonist (1 μM ICI-118,551) or a selective β1-AR 
antagonist (3 μM CGP-20712A). ICI-118,551 completely abolished (>99%) IL-13 
induced MUC5AC expression (0.039 ± 0.038 fold vs 15.99 ± 1.48 fold increase 
by IL-13. p<0.05). On the other hand, CGP-20712A did not affect the MUC5AC 
expression level (14.75 ± 0.96 fold vs 15.99 ± 1.48 fold increase by IL-13, 
p>0.05) (Figure 19A). CGP-20712A did not affect the intracellular mucin levels 
induced by IL-13 while ICI-118,551 brought the levels back to baseline (Figure 
19B and Figure 20). Neither CGP-20712A nor ICI-118,551 affected the integrity 
of the monolayer as evaluated by TEERs measurement and ZO-1 localization 
(Figure 21). 
We next asked if the increase in MUC5AC expression in response to IL-13 
is due to agonist induced or constitutive β2-AR signaling. NHBE cells were 
treated with 10 μM nadolol, a non-selective β-AR ligand that has inverse agonist 
activity on β2-ARs and blocks both constitutive and agonist-induced receptor 
activity, or with 10 μM alprenolol, a non-selective β-AR antagonist which does not 
have inverse agonist activity, for 14 days in combination with IL-13 and in the 
presence of epinephrine. Treatment with nadolol reduced IL-13 induced 
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MUC5AC expression (3.36 ± 4.10 fold vs 25.37 ± 16.30 fold increase by IL-13, 
p<0.05) (Figure 22A), intracellular mucin 5AC protein and mucin content (Figure 
22B and Figure 23). Treatment with alprenolol reduced IL-13-induced MUC5AC 
expression to a similar extent (3.19 ± 3.73 fold vs 25.37 ± 16.30 fold increase by 
IL-13, p<0.05) as well as intracellular mucin 5AC and mucin content.  
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Figure 19. β2-ARs are required for mucin 5AC production in response to IL-13 
in NHBE cells: NHBE cells were grown in the presence of 3 μM epinephrine, then at 
ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM CGP-20712A (a 
preferential β1-AR antagonist) or 1 μM ICI-118,551 (a preferential β2-AR 
antagonist) for 14 days. A) MUC5AC transcripts were quantified from extracted total 
RNA by qRT-PCR. Data are presented as fold change compared to cells grown in the 
presence of epinephrine only. B) The Transwell® membranes were incubated with a 
rabbit antibody against human mucin 5AC (red) and DAPI to counterstain the nuclei 
(blue). The ratio of integrated fluorescence density of each group to the integrated 
mucin 5AC density of the corresponding control group was calculated and expressed 
as fold change compared to the corresponding control cells (in the absence of IL-13 
treatment). Representative images of immunofluorescence are shown (scale bar = 
100 μm). Data are presented as means ± SEM from three donors. *, # and @ 
indicate p<0.05 significance as compared to +epi, +epi+IL-13 and +epi+IL-13+CGP-
20721A treated cells respectively. 
A B 
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Figure 20. β2-ARs are required for mucin production in response to IL-13 
in NHBE cells: NHBE cells were grown in the presence of 3 μM epinephrine, 
then at ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM 
CGP-20712A (a preferential β1-AR antagonist) or 1 μM ICI-118,551 (a 
preferential β2-AR antagonist) for 14 days. PAFS staining of NHBE cells to 
quantify total intracellular mucin glycoproteins. Representative images are 
shown (scale bar = 100 μm). The ratio of mucin integrated density and nucleic 
acid/cytoplasm integrated density was calculated and the data presented as fold 
change compared to the corresponding control cells (in the absence of IL-13 
treatment). Data are presented as means ± SEM from three donors. *, # and @ 
indicate p<0.05 significance as compared to +epi, +epi+IL-13 and +epi+IL-
13+CGP-20721A treated cells respectively. 
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Epi (3µM) + + + + 
IL-13 (20ng/ml) - + + + 
CGP-20712A (3μM) - - + - 
ICI-118,551 (1μM) - - - + 
 
A 
B 
Figure 21. Role of β2-ARs in the integrity of NHBE cells monolayer in 
response to IL-13:  NHBE cells were grown in the presence of 3 μM 
epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in combination 
with CGP-20712A or ICI-118,551 for 14 days. NHBE cells were grown in the 
presence or absence of 3 μM epinephrine. At ALI, the cells were treated with 20 
ng/ml IL-13 for 14 days. A) Trans-epithelial electrical resistance (TEER) was 
measured throughout the culture period. Data are presented as ohm.cm2 of 
insert surface area. Data are presented as means ± SEM from three donors. B) 
Representative images of immunofluorescence with a rabbit antibody against 
ZO-1 (red) (scale bar = 100 μm). The Transwell® membranes were incubated 
with DAPI to counterstain the nuclei (blue). Data are presented as means ± 
SEM from three donors. * indicates p<0.05 significant difference between +epi 
and +epi+IL-13. 
100 µm 
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Figure 22. Agonist induced β2-AR signaling is required for mucin 5AC 
production in response to IL-13 in NHBE cells: NHBE cells were grown in the 
presence of 3 μM epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in 
combination with 10 μM nadolol (a non-selective β-AR blocker with inverse agonist 
of β2-ARs) or 10 μM alprenolol (a non-selective β-AR blocker with no inverse 
agonist activity) for 14 days. A) MUC5AC transcripts were measured by qRT-PCR. 
Data are presented as fold change compared to cells grown in the presence of 
epinephrine only. B) The Transwell® membranes were incubated with a rabbit 
antibody against human mucin 5AC (red) and DAPI to counterstain the nuclei 
(blue). The ratio of integrated fluorescence density of each group to the integrated 
mucin 5AC density of the corresponding control group was calculated and 
expressed as fold change compared to the corresponding control cells (in the 
absence of IL-13 treatment). Representative images of immunofluorescence are 
shown (scale bar = 100 μm). Data are presented as means ± SEM from three 
donors. * and # indicate p<0.05 significance as compared to +epi and +epi +IL-13 
treated cells respectively. 
A B 
 
 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Agonist induced β2-AR signaling is required for mucin production 
in response to IL-13 in NHBE cells: NHBE cells were grown in the presence of 3 
μM epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in combination 
with 10 μM nadolol (a non-selective β-AR blocker with inverse agonist of β2-ARs) 
or 10 μM alprenolol (a non-selective β-AR blocker with no inverse agonist activity) 
for 14 days.. PAFS staining of NHBE cells to quantify total intracellular mucin 
glycoproteins. Representative images are shown (scale bar = 100 μm). The ratio of 
mucin integrated density and nucleic acid/cytoplasm integrated density was 
calculated and the data presented as fold change compared to the corresponding 
control cells (in the absence of IL-13 treatment). Data are presented as means ± 
SEM from three donors. * and # indicate p<0.05 significance as compared to +epi 
and +epi +IL-13 treated cells respectively. 
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4.3 Mitogen activated protein kinase (MAPK) signaling is involved in mucin 
production in response to IL-13 in NHBE cells  
MAPKs play an important role in inflammation by transmitting 
inflammatory signals from the cell surface into the nucleus (Garrington and 
Johnson 1999). In addition, MAPKs are involved in asthma pathogenesis (Pelaia, 
Cuda et al. 2005). To investigate the role of MAPKs in IL-13 induced mucin 
production in NHBE cells, we evaluated the activation of ERK1/2, JNK and p38 in 
response to IL-13 and whether epinephrine modulated this effect. In the absence 
of epinephrine, IL-13 did not affect the phosphorylation of ERK1/2, c-Jun or p38 
as compared to their corresponding controls (Figure 24A, B and C). When 
epinephrine was included in the medium, IL-13 induced an approximately 3-fold 
increase in the phosphorylation of ERK1/2 and c-Jun when compared to their 
corresponding controls (Figure 24A and B). However, phosphorylation of p38 
was still unaffected by IL-13 even in the presence of epinephrine (Figure 24 C).  
 
4.3.1 Role of ERK1/2 signaling in mucin production in response to IL-13 in 
NHBE cells  
We treated the cells with 3 μM U0126, an inhibitor of MEK1/2 (which 
activates ERK1/2), for 14 days in combination with IL-13. U0126 reduced 
MUC5AC expression significantly in response to IL-13 (17.74± 7.55 fold increase 
by IL-13 vs 2.51 ± 1.67 fold by U0126, p<0.05) (Figure 25A). The effect of U1026 
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was also associated with reduction in ERK1/2 phosphorylation in response to IL-
13 (Figure 25B). 
To further confirm the involvement of ERK1/2, we treated NHBE cells with 
3 μM FR180204, a direct ERK1/2 inhibitor, in combination with IL-13 and 
epinephrine for 14 days.  FR180204 significantly attenuated MUC5AC gene 
expression (15.18 ± 3.76 fold increase by IL-13 vs 1.82 ± 0.68 fold by FR180204, 
p<0.05) (Figure 26A). Moreover, mucin 5AC and mucin glycoproteins were also 
reduced significantly with FR180204 when compared to IL-13 treated cells 
(Figure 26B and Figure 27). The concentration of FR180204 that we used did not 
alter the integrity of NHBE cell monolayer (Figure 28). 
We then tested if FR180204 affected the activation of other MAPKs; 
ERK1/2, p38 and cJun, a marker of JNK activity, in response to IL-13. FR180204 
did not affect ERK1/2 or p38 activation whereas it significantly attenuated cJun 
phosphorylation in response to IL-13 (Figure 29). Furthermore, phosphorylation 
of RSK-1, a substrate of ERK1/2, and CREB transcription factor were not 
affected by IL-13 or by ERK1/2 inhibitor (Figure 30).  
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Figure 24. Effects of epinephrine on 
MAPKs activation in response to IL-13 
in NHBE cells: The cells were grown in 
the presence or absence of epinephrine or 
IL-13 as indicated for 14 days after ALI 
before harvesting for total proteins. 
Immunoblots were performed using 
antibodies to the indicated phosphorylated 
MAP-kinases. The signal densities of the 
phosphorylated proteins were normalized 
to GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data 
are presented as fold change compared to 
the corresponding control cells. A) ERK1/2 
phosphorylation. B) cJun phosphorylation. 
C) p38 phosphorylation. Data are 
presented as means ± SEM from three 
donors. *, † and ¥ indicate p<0.05 
significance as compared to +epi, -epi and 
-epi +IL-13 treated cells respectively. 
pERK 
GAPDH 
p-cJun 
GAPDH 
pp38 
GAPDH 
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Figure 25. Role of MEK1/2 in MUC5AC expression in response to IL-13 in 
NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at 
ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM U0126 
(MEK1/2 inhibitor) for 14 days. A) MUC5AC transcripts were measured by qRT-
PCR, and the data presented as fold change compared to cells grown in the 
presence of epinephrine only. B) Immunoblots were performed using antibodies to 
the indicated phosphorylated ERK1/2. The signal densities of the phosphorylated 
proteins were normalized to total ERK1/2 protein density and the relative intensities 
were reported as the degree of activation of the protein. Data are presented as 
means ± SEM from three donors. * and # indicate p<0.05 significance as compared 
to +epi and +epi+IL-13 treated cells respectively. 
pERK 
Total ERK 
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Figure 26. Role of ERK1/2 signaling in mucin 5AC production in response to 
IL-13 in NHBE cells: The cells were grown in the presence of 3 μM epinephrine, 
then at ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM 
FR180204 (ERK1/2 inhibitor) for 14 days. A) MUC5AC transcripts were measured 
by qRT-PCR, and the data presented as fold change compared to cells grown in 
the presence of epinephrine only. B) The Transwell® membranes were incubated 
with a rabbit antibody against human mucin 5AC (red) and DAPI to counterstain the 
nuclei (blue). The ratio of integrated fluorescence density of each group to the 
integrated mucin 5AC density of the corresponding control group was calculated 
and expressed as fold change compared to the corresponding control cells (in the 
absence of IL-13 treatment). Representative images of immunofluorescence are 
shown (scale bar = 100 μm). Data are presented as means ± SEM from three 
donors. Data are presented as means ± SEM from three donors. * and # indicate 
p<0.05 significance as compared to +epi and +epi+IL-13 treated cells respectively. 
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Figure 27. Role of ERK1/2 signaling in mucin production in response to IL-
13 in NHBE cells: The cells were grown in the presence of 3 μM epinephrine, 
then at ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM 
FR180204 (ERK1/2 inhibitor) for 14 days. PAFS staining of NHBE cells to 
quantify total intracellular mucin glycoproteins. Representative images are 
shown (scale bar = 100 μm). The ratio of mucin integrated density and nucleic 
acid/cytoplasm integrated density was calculated and the data presented as fold 
change compared to the corresponding control cells (in the absence of IL-13 
treatment). Data are presented as means ± SEM from three donors. * and # 
indicate p<0.05 significance as compared to +epi and +epi +IL-13 treated cells 
respectively. 
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Figure 28. Effect of ERK1/2 inhibitor on the integrity of NHBE cells 
monolayer in response to IL-13:  The cells were grown in the presence of 3 μM 
epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in combination 
with 3 μM FR180204 (ERK1/2 inhibitor) for 14 days. A) Trans-epithelial electrical 
resistance (TEER) was measured one day before ALI and throughout ALI period. 
Data are presented as ohm.cm2 of insert surface area. Data are presented as 
means ± SEM from three donors. B) Representative images of 
immunofluorescence with a rabbit antibody against ZO-1 (red) (scale bar = 100 
μm). The Transwell® membranes were incubated with DAPI to counterstain the 
nuclei (blue). Data are presented as means ± SEM from three donors. * indicates 
p<0.05 significant difference between +epi and +epi+IL-13. 
Epi (3µM) + + + 
IL-13 (20ng/ml) - + + 
FR180204 (3μM) - - + 
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Figure 29. Effects of ERK1/2 inhibitor 
on activation of MAPKs in NHBE cells 
in response to IL-13: At ALI, NHBE cells 
were treated with 20 ng/ml IL-13 in 
combination with 3 μM FR180204 (ERK1/2 
inhibitor) for 14 days in the presence of 3 
μM epinephrine. Total proteins were 
harvested and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or GAPDH 
protein density and the relative intensities 
were reported as the degree of 
phosphorylation of the protein. The data 
are presented as fold change compared to 
the corresponding control cells. A) ERK1/2 
phosphorylation. B) cJun phosphorylation. 
C) p38 phosphorylation. Data are 
presented as means ± SEM from three 
donors. *and # indicate p<0.05 
significance as compared to +epi and +epi 
+IL-13 treated cells respectively. 
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Figure 30. Effects of ERK1/2 inhibitor on activation of RSK-1 and CREB in 
NHBE cells in response to IL-13: At ALI, NHBE cells were treated with 20 ng/ml 
IL-13 in combination with 3 μM FR180204 (ERK1/2 inhibitor) for 14 days in the 
presence of 3 μM epinephrine. Total proteins were harvested, and immunoblots 
were performed using antibodies to phosphorylated proteins. The signal densities 
of the phosphorylated proteins were normalized to total protein or GAPDH protein 
density and the relative intensities were reported as the degree of 
phosphorylation of the protein. The data are presented as fold change compared 
to the corresponding control cells. A) RSK-1 phosphorylation in NHBE cells. B) 
CREB phosphorylation. Data are presented as means ± SEM from three donors. * 
and # indicate p<0.05 significance as compared to +epi and +epi +IL-13 treated 
cells respectively. 
pRSK1 pCREB 
GAPDH 
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4.3.2 Role of JNK signaling in mucin production in response to IL-13 in 
NHBE cells  
Since IL-13 increased cJun phosphorylation, we studied the effect of JNK 
on mucin parameters induced by IL-13 only in the presence of epinephrine. We 
treated the cells with 3 μM SP600125, a JNK inhibitor, for 14 days in combination 
with IL-13 in the presence of epinephrine. SP600125 blocked the increase in 
MUC5AC expression by IL-13 (15.18 ± 3.76 fold increase by IL-13 vs 0.77 ± 0.39 
fold by SP600125, p<0.05) (Figure 31A). Moreover, mucin 5AC and mucin 
glycoproteins were also inhibited significantly with SP600125 as compared to the 
levels induced by IL-13 (Figure 31B and Figure 32). 3 μM SP600125 did not 
reduce the integrity of the cultured epithelial monolayer below the control cells, 
as evaluated by measuring TEERs and ZO-1 protein localization (Figure 33A and 
B). 
We then examined the effect of inhibiting JNK activity on several 
downstream signaling molecules that might mediate the effect of IL-13 on mucin 
production in NHBE cells. We found that SP600125 was associated with 
reduction in cJun phosphorylation in response to IL-13 (Figure 34A). However, 
SP600125 did not affect the levels of ERK1/2, p38 or CREB phosphorylation 
when combined with IL-13 as compared to IL-13 treated cells (Figure 34 B, C 
and Figure 35). 
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Figure 31. Role of JNK signaling in mucin 5AC production in response to IL-13 
in NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at 
ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM SP600125 (JNK 
inhibitor) for 14 days. A) MUC5AC transcripts were measured by qRT-PCR, and the 
data presented as fold change compared to cells grown in the presence of 
epinephrine only. B) The Transwell® membranes were incubated with a rabbit 
antibody against human mucin 5AC (red) and DAPI to counterstain the nuclei (blue). 
The ratio of integrated fluorescence density of each group to the integrated mucin 
5AC density of the corresponding control group was calculated and expressed as 
fold change compared to the corresponding control cells (in the absence of IL-13 
treatment). Representative images of immunofluorescence are shown (scale bar = 
100 μm). Data are presented as means ± SEM from three donors. Data are 
presented as means ± SEM from three donors. * and # indicate p<0.05 significance 
as compared to +epi and +epi+IL-13 treated cells respectively. 
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Figure 32. Role of JNK signaling in mucin production in response to IL-13 in 
NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at 
ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM SP600125 
(JNK inhibitor) for 14 days. PAFS staining of NHBE cells to quantify total 
intracellular mucin glycoproteins. Representative images are shown (scale bar = 
100 μm). The ratio of mucin integrated density and nucleic acid/cytoplasm 
integrated density was calculated and the data presented as fold change compared 
to the corresponding control cells (in the absence of IL-13 treatment). Data are 
presented as means ± SEM from three donors. * and # indicate p<0.05 significance 
as compared to +epi and +epi +IL-13 treated cells respectively. 
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Figure 33. Effect of JNK inhibitor on the integrity of NHBE cells monolayer 
in response to IL-13:  The cells were grown in the presence of 3 μM 
epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in combination 
with 3 μM SP600125 (JNK inhibitor) for 14 days. A) Trans-epithelial electrical 
resistance (TEER) was measured one day before ALI and throughout ALI period. 
Data are presented as ohm.cm2 of insert surface area. Data are presented as 
means ± SEM from three donors. B) Representative images of 
immunofluorescence with a rabbit antibody against ZO-1 (red) (scale bar = 100 
μm). The Transwell® membranes were incubated with DAPI to counterstain the 
nuclei (blue). Data are presented as means ± SEM from three donors. * indicates 
p<0.05 significant difference between +epi and +epi+IL-13 treated cells. 
100 µm 
Epi (3µM) + + + 
IL-13 (20ng/ml) - + + 
SP600125 (3μM) - - + 
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Figure 34. Effects of JNK inhibitor on 
activation of MAPKs in NHBE cells in 
response to IL-13: At ALI, NHBE cells 
were treated with 20 ng/ml IL-13 in 
combination with 3 μM SP600125 (JNK 
inhibitor) for 14 days in the presence of 3 
μM epinephrine. Total proteins were 
harvested, and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or GAPDH 
protein density and the relative intensities 
were reported as the degree of 
phosphorylation of the protein. The data 
are presented as fold change compared to 
the corresponding control cells. A) cJun 
phosphorylation in NHBE cells. B) ERK1/2 
phosphorylation and C) p38 
phosphorylation. Data are presented as 
means ± SEM from three donors. * and # 
indicate p<0.05 significance as compared 
to +epi and +epi +IL-13 treated cells 
respectively. 
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Figure 35. Effect of JNK inhibitor on activation of CREB in NHBE cells in 
response to IL-13: At ALI, NHBE cells were treated with 20 ng/ml IL-13 in 
combination with 3 μM SP600125 (JNK inhibitor) for 14 days in the presence of 3 
μM epinephrine. Total proteins were harvested. Immunoblots were performed 
using antibodies to phosphorylated CREB proteins. The signal densities of the 
phosphorylated proteins were normalized to total CREB protein density and the 
relative intensities were reported as the degree of activation of the protein. The 
data presented as fold change compared to the corresponding control cells. 
CREB phosphorylation. Data are presented as means ± SEM from three donors.  
pCREB 
Total CREB 
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4.3.3 Role of p38 signaling in mucin production in response to IL-13 in 
NHBE cells  
Next, we examined the involvement of the third member of the traditional 
MAPK family, p38. IL-13 did not increase p38 phosphorylation either in the 
presence or absence of p38 (Figure 24C). Subsequently, we studied if the basal 
level of phosphorylated p38 plays any role in modulating the mucin parameters 
induced by IL-13 in the presence of epinephrine. We treated the cells with 3 μM 
SB203580, a p38 inhibitor, in combination with IL-13 and in the presence of 
epinephrine for 14 days. SB203580 significantly attenuated the IL-13 induced 
increase in MUC5AC expression (15.18 ± 3.76 fold increase by IL-13 vs 0.80 ±0. 
65 fold by SB203580, p<0.05) (Figure 36A). Intracellular mucin 5AC and mucin 
glycoproteins were also inhibited by SB203580 (Figure 36B and 37).  
SB203580 did not reduce the TEER readings below the control cells, 
instead it increased these values as compared to control or IL-13 treated cells 
(Figure 38A). Morphologically, the localization of ZO-1 at the cell peripheries did 
not change (Figure 38B). 
Inhibiting p38 did not affect the phosphorylation of other MAPKs; p38, 
ERK1/2 or of cJun, a specific substrate of JNK (Figure 39A, B and C). Moreover, 
inhibiting p38 activity by SB203580 did not affect the activation of MAP kinase 
activated protein kinase-2 (MAPKAP kinase-2), a downstream substrate of p38, 
or of the CREB transcription factor (Figure 40A and B).  
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Figure 36. Role of p38 signaling in mucin 5AC production in response to IL-13 in 
NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at ALI, 
they were treated with 20 ng/ml IL-13 in combination with 3 μM SB203580 (p38 inhibitor) 
for 14 days. A) MUC5AC transcripts were measured by qRT-PCR, and the data 
presented as fold change compared to cells grown in the presence of epinephrine only. 
B) The Transwell® membranes were incubated with a rabbit antibody against human 
mucin 5AC (red) and DAPI to counterstain the nuclei (blue). The ratio of integrated 
fluorescence density of each group to the integrated mucin 5AC density of the 
corresponding control group was calculated and expressed as fold change compared to 
the corresponding control cells (in the absence of IL-13 treatment). Representative 
images of immunofluorescence are shown (scale bar = 100 μm). Data are presented as 
means ± SEM from three donors. Data are presented as means ± SEM from three 
donors. * and # indicate p<0.05 significance as compared to +epi and +epi+IL-13 treated 
cells respectively. 
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Figure 37. Role of p38 signaling in mucin production in response to IL-13 
in NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then 
at ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM 
SB203580 (p38 inhibitor) for 14 days. PAFS staining of NHBE cells to quantify 
total intracellular mucin glycoproteins. Representative images are shown (scale 
bar = 100 μm). The ratio of mucin integrated density and nucleic acid/cytoplasm 
integrated density was calculated and the data presented as fold change 
compared to the corresponding control cells (in the absence of IL-13 treatment). 
Data are presented as means ± SEM from three donors. * and # indicate p<0.05 
significance as compared to +epi and +epi +IL-13 treated cells respectively. 
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Figure 38. Effect of p38 inhibitor on the integrity of NHBE cells monolayer in 
response to IL-13:  The cells were grown in the presence of 3 μM epinephrine, 
then at ALI, they were treated with 20 ng/ml IL-13 in combination with 3 μM 
SB203580 (p38 inhibitor) for 14 days. A) Trans-epithelial electrical resistance 
(TEER) was measured one day before ALI and throughout the ALI period. Data 
are presented as ohm.cm2 of insert surface area. Data are presented as means ± 
SEM from three donors. B) Representative images of immunofluorescence with a 
rabbit antibody against ZO-1 (red) (scale bar = 100 μm). The Transwell® 
membranes were incubated with DAPI to counterstain the nuclei (blue). Data are 
presented as means ± SEM from three donors. *, @ indicates p<0.05 significant 
difference between +epi and +epi+IL-13 and between +epi and +epi+IL-
13+SB203580 respectively. 
Epi (3µM) + + + 
IL-13 (20ng/ml) - + + 
SB203580 (3μM) - - + 
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Figure 39. Effects of p38 inhibitor on 
activation of MAPKs in NHBE cells in 
response to IL-13: At ALI, NHBE cells 
were treated with 20 ng/ml IL-13 in 
combination with 3 μM SB203580 (p38 
inhibitor) for 14 days in the presence of 3 
μM epinephrine. Total proteins were 
harvested, and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree 
of phosphorylation of the protein. The 
data are presented as fold change 
compared to the corresponding control 
cells. A) ERK1/2 phosphorylation in 
NHBE cells. B) cJun phosphorylation 
and C) p38 phosphorylation. Data are 
presented as means ± SEM from three 
donors. * and # indicate p<0.05 
significance as compared to +epi and 
+epi +IL-13 treated cells respectively. 
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Figure 40. Effects of p38 inhibitor on activation of MAPKAPK2 and CREB 
in NHBE cells in response to IL-13: At ALI, NHBE cells were treated with 20 
ng/ml IL-13 in combination with 3 μM SB203580 (p38 inhibitor) for 14 days in 
the presence of 3 μM epinephrine. Total proteins were harvested, and 
immunoblots were performed using antibodies to phosphorylated proteins. The 
signal densities of the phosphorylated proteins were normalized to total protein 
or GAPDH protein density and the relative intensities were reported as the 
degree of phosphorylation of the protein. The data are presented as fold change 
compared to the corresponding control cells. A) MAPKAPK2 phosphorylation in 
NHBE cells. B) CREB phosphorylation. Data are presented as means ± SEM 
from three donors. * and # indicate p<0.05 significance as compared to +epi and 
+epi +IL-13 treated cells respectively. 
pCREB 
Total CREB 
pMAPKAPK2 
GAPDH 
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4.4 Role of PKA signaling in mucin production in response to IL-13 in 
NHBE cells  
β2AR can signal through the canonical Gs-AC pathway and β-arrestin 
signaling cascades. The canonical Gs pathway leads to increase intracellular 
cAMP and PKA activation. Here we studied the involvement of PKA and cAMP 
separately and their effect on IL-13 induced mucin production in NHBE cells.  
First, we treated the cells with 3μM H89, a PKA inhibitor, in combination 
with IL-13 and in the presence of epinephrine. H89 reduced MUC5AC expression 
significantly in response to IL-13 (15.02± 8.42 fold by IL-13 vs 2.09± 2.28 fold by 
H89, p<0.05) (Figure 41A). Since PKA activates ERK1/2 (Schmitt and Stork 
2000; Gerits, Kostenko et al. 2008), we measured ERK1/2 phosphorylation in 
response to IL-13 and IL-13+H89. H89 did not reduce ERK1/2 phosphorylation 
as compared to IL-13 induced levels (Figure 41B). 
Due to the several limitations of H89 that will be discussed later, we 
studied the involvement of PKA using a competitive cAMP analogue, Rp-cAMPS, 
in combination with IL-13 and epinephrine. Rp-cAMPS did not significantly 
reduce the levels of MUC5AC expression at 50 μM (5.97 ± 4.29 fold vs 12.50 ± 
5.38 fold increase by IL-13, p>0.05) while at 100 μM, there was a significant 
reduction (2.35 ± 1.63 fold vs 12.50 ± 5.38 fold increase by IL-13, p<0.05) (Figure 
42A). The intracellular mucin 5AC protein level was significantly reduced when 
the cells were treated with 100 μM Rp-cAMPS but not at 50 μM, while mucin 
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glycoproteins levels were reduced at both concentrations (Figure 42B and Figure 
43).  
The two concentrations of Rp-cAMPS that we used in our studies did not 
induce any cytotoxicity to the monolayer, as evaluated by TEER measurement 
and ZO-1 localization (Figure 44 A and B).  
To understand the mechanism by which Rp-cAMPS reduced mucin 
production in NHBE cells, we examined the activity of several PKA downstream 
signaling molecules. Rp-cAMPS at 100 μM increased ERK1/2 phosphorylation as 
compared to control cells or IL-13 treated cells (Figure 44A). However, cJun, 
p38, CREB and STAT6 phosphorylation state by IL-13 was not affected by Rp-
cAMPS (Figure 45B, C and Figure 46A, B).   
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Figure 41. Role of H89 in MUC5AC expression in response to IL-13 in NHBE 
cells: The cells were grown in the presence of 3 μM epinephrine, then at ALI, they 
were treated with 20 ng/ml IL-13 in combination with 3 μM H89 (PKA inhibitor) for 
14 days. A) MUC5AC transcripts were measured by qRT-PCR, and the data 
presented as fold change compared to cells grown in the presence of epinephrine 
only. B) Immunoblots were performed using antibodies to the indicated 
phosphorylated ERK1/2. The signal densities of the phosphorylated proteins were 
normalized to total ERK1/2 protein density and the relative intensities were reported 
as the degree of activation of the protein. Data are presented as means ± SEM 
from three donors. * and # indicate p<0.05 significance as compared to +epi and 
+epi+IL-13 treated cells respectively. 
pERK 
Total ERK 
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Figure 42. Role of PKA signaling in mucin 5AC production in response to IL-13 in 
NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at ALI, 
they were treated with 20 ng/ml IL-13 in combination with either 50 μM or 100 μM Rp-
cAMPS (cAMP dependent protein kinase inhibitor) for 14 days. A) MUC5AC transcripts 
were measured by qRT-PCR, and the data presented as fold change compared to 
cells grown in the presence of epinephrine only. B) The Transwell® membranes were 
incubated with a rabbit antibody against human mucin 5AC (red) and DAPI to 
counterstain the nuclei (blue). The ratio of integrated fluorescence density of each 
group to the integrated mucin 5AC density of the corresponding control group was 
calculated and expressed as fold change compared to the corresponding control cells 
(in the absence of IL-13 treatment). Representative images of immunofluorescence are 
(scale bar = 100 μm). Data are presented as means ± SEM from three donors. Data 
are presented as means ± SEM from three donors. * and # indicate p<0.05 significance 
as compared to +epi and +epi+IL-13 treated cells respectively. 
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Figure 43. Role of PKA signaling in mucin production in response to IL-13 in 
NHBE cells: The cells were grown in the presence of 3 μM epinephrine, then at ALI, 
they were treated with 20 ng/ml IL-13 in combination with either 50 μM or 100 μM Rp-
cAMPS (cAMP dependent protein kinase inhibitor) for 14 days. PAFS staining of 
NHBE cells to quantify total intracellular mucin glycoproteins. Representative images 
are shown (scale bar = 100 μm). The ratio of mucin integrated density and nucleic 
acid/cytoplasm integrated density was calculated and the data presented as fold 
change compared to the corresponding control cells (in the absence of IL-13 
treatment). Data are presented as means ± SEM from three donors. * and # indicate 
p<0.05 significance as compared to +epi and +epi +IL-13 treated cells respectively. 
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Figure 44. Effect of PKA inhibitor on the integrity of NHBE cells monolayer 
in response to IL-13:  NHBE cells were grown in the presence of 3 μM 
epinephrine, then at ALI, they were treated with 20 ng/ml IL-13 in combination 
with either 50 μM or 100 μM Rp-cAMPS (cAMP dependent protein kinase 
inhibitor) for 14 days. A) Trans-epithelial electrical resistance (TEER) was 
measured one day before ALI and throughout ALI period. Data are presented as 
ohm.cm2 of insert surface area. Data are presented as means ± SEM from three 
donors. B) Representative images of immunofluorescence with a rabbit antibody 
against ZO-1 (red) (scale bar = 100 μm). The Transwell® membranes were 
incubated with DAPI to counterstain the nuclei (blue). Data are presented as 
means ± SEM from three donors. * indicates p<0.05 significant difference 
between +epi and +epi+IL-13. 
Epi (3µM) + + + + 
IL-13 (20ng/ml) - + + + 
Rp-cAMPS (50μM) - - + - 
Rp-cAMPS (100μM) - - - + 
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Figure 45. Effects of PKA inhibitor on 
activation of MAPKs in NHBE cells in 
response to IL-13: NHBE cells were grown 
in the presence of 3 μM epinephrine, then at 
ALI, they were treated with 20 ng/ml IL-13 in 
combination with either 50 μM or 100 μM 
Rp-cAMPS (cAMP dependent protein kinase 
inhibitor) for 14 days. Total proteins were 
harvested, and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or GAPDH 
protein density and the relative intensities 
were reported as the degree of 
phosphorylation of the protein. The data are 
presented as fold change compared to the 
corresponding control cells. A) ERK1/2 
phosphorylation in NHBE cells. B) cJun 
phosphorylation and C) p38 
phosphorylation. Data are presented as 
means ± SEM from three donors. * and # 
indicate p<0.05 significance as compared to 
+epi and +epi +IL-13 treated cells 
respectively. 
 
C 
pERK 
Total ERK GAPDH 
pp38 
GAPDH 
 
 
111 
 
 
A B 
Figure 46. Effects of PKA inhibitor on activation of CREB and STAT6 in NHBE 
cells in response to IL-13: At ALI, NHBE cells were treated with 20 ng/ml IL-13 in 
combination with either 50 μM or 100 μM Rp-cAMPS (cAMP dependent protein 
kinase inhibitor) for 14 days in the presence of 3 μM epinephrine. Total proteins 
were harvested, and immunoblots were performed using antibodies to 
phosphorylated proteins. The signal densities of the phosphorylated proteins were 
normalized to total protein or GAPDH protein density and the relative intensities 
were reported as the degree of phosphorylation of the protein. The data are 
presented as fold change compared to the corresponding control cells. A) CREB 
phosphorylation in NHBE cells. B) STAT6 phosphorylation. Data are presented as 
means ± SEM from three donors. * and # indicate p<0.05 significance as compared 
to +epi and +epi +IL-13 treated cells respectively. 
pCREB 
Total CREB 
pSTAT6 
GAPDH 
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4.5 Effect of cAMP elevating agents in mucin production in response to IL-
13 in NHBE cells  
4.5.1 Effect of forskolin+IBMX in mucin production in response to IL-13 in 
NHBE cells 
We evaluated the effect of elevating intracellular cAMP Levels on mucin 
parameters in response to IL-13. For this purpose, we treated cells with 10 μM 
forskolin combined with 100 μM 3-isobutyl-l-methylxan-thine (IBMX), in the 
absence of epinephrine for 14 days. This treatment caused a dramatic increase 
in MUC5AC expression (75.73 ± 66.59 fold vs 0.56 ± 0.40 fold by IL-13, p<0.05) 
(Figure 47A). Then we tested if the forskolin+IBMX combination potentiates the 
effect of IL-13 on mucin production in the presence epinephrine. MUC5AC 
expression was increased in response to IL-13 in the presence of epinephrine 
+forskolin+IBMX combination (120.29 ± 85.5 fold vs 12.29 ± 7.55 fold increase 
by IL-13, p<0.05) (Figure 47B). The forskolin+IBMX combination also increased 
intracellular mucin 5AC and mucin glycoproteins accumulation in response to IL-
13 either in the presence or absence of epinephrine (Figure 48A, B and Figure 
49A, B).  
The effect of forskolin+IBMX combination did not alter the barrier function 
and the integrity of NHBE monolayer, as evaluated by TEERs measurements 
and ZO-1 apical localization (data not shown) (Figure 50A and B). 
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We next measured intracellular cAMP levels to evaluate the effectiveness 
of forskolin+IBMX combination in raising cAMP. The forskolin+IBMX combination 
resulted in an increased accumulation of intracellular cAMP under all conditions 
(Figure 51A and B). We then studied the involvement of different signaling 
molecules that could be activated by increasing intracellular cAMP levels and 
thereby mediate the increase in mucin production in response to IL-13. ERK1/2 
phosphorylation in response to IL-13 did not change with forskolin+IBMX 
combination, either in the presence or absence of epinephrine (Figure 52A and 
Figure 53A). p38 and cJun activation were also not affected by forskolin+IBMX 
combination (Figure 52B, C and Figure 53B,C), while CREB activation was 
significantly increased by forskolin+IBMX and IL-13 treatment but only in the 
presence of epinephrine (Figure 54A,B). This increase was significant as 
compared to cells grown in the presence of epinephrine.  Moreover, the 
phosphorylation of STAT6, an effector of IL-13 signaling cascade, was also 
increased by IL-13 in the presence of forskolin+IBMX and epinephrine (Figure 
54C).   
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Figure 47. cAMP potentiates MUC5AC expression in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI 
(A) or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 10 μM forskolin and 100 μM IBMX for 14 
days. MUC5AC transcripts levels were measured by qRT-PCR and the data 
presented as fold change compared to corresponding control cells grown in the 
absence of IL-13, IBMX and forskolin. Data are presented as means ± SEM from 
three donors. †, ¥,$ and *, #, @ indicate p<0.05 significance as compared to -epi, -
epi+ IL-13,-epi+forskolin+IBMX, +epi and +epi+IL-13, +epi+forskolin+IBMX treated 
cells respectively.  
 
A 
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Figure 48. cAMP potentiates mucin 5AC production in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI 
(A) or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 10 μM forskolin and 100 μM IBMX for 14 
days. The Transwell® membranes were incubated with a rabbit antibody against 
human mucin 5AC (red) and DAPI to counterstain the nuclei (blue). The ratio of 
integrated fluorescence density of each group to the integrated mucin 5AC 
density of the corresponding control group was calculated and expressed as fold 
change compared to the corresponding control cells (in the absence of IL-13 
treatment). Representative images of immunofluorescence are shown (scale bar 
= 100 μm). Data are presented as means ± SEM from three donors. †, ¥,$ and *, 
#, @ indicate p<0.05 significance as compared to -epi, -epi+ IL-13,-
epi+forskolin+IBMX, +epi and +epi+IL-13, +epi+forskolin+IBMX treated cells 
respectively.  
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Figure 49. cAMP potentiates mucin production in response to IL-13 in NHBE 
cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) or in 
the presence of epinephrine (B), then at ALI, they were incubated with or without 20 
ng/ml IL-13 with or without 10 μM forskolin and 100 μM IBMX for 14 days. PAFS 
staining of NHBE cells to quantify total intracellular mucin glycoproteins. 
Representative images are shown (scale bar = 100 μm). The ratio of mucin 
integrated density and nucleic acid/cytoplasm integrated density was calculated 
and the data presented as fold change compared to the corresponding control cells 
(in the absence of IL-13 treatment). Data are presented as means ± SEM from 
three donors. †, ¥,$ and *, #, @ indicate p<0.05 significance as compared to -epi, -
epi+ IL-13,-epi+forskolin+IBMX, +epi and +epi+IL-13, +epi+forskolin+IBMX treated 
cells respectively.  
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Figure 50. Effect of cAMP elevating agents on the integrity of NHBE cell 
monolayers: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or without 
20 ng/ml IL-13 with or without 10 μM forskolin and 100 μM IBMX for 14 days. Trans-
epithelial electrical resistance (TEER) was measured throughout the culture period. 
Data are presented as ohm.cm2 of insert surface area. Data are presented as means ± 
SEM from three donors. * and # indicate p<0.05 significance between -epi and -
epi+forskolin+IBMX+IL-13, and between +epi and +epi+IL-13 treated cells respectively. 
B 
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Figure 51. Effect of forskolin+IBMX combination on intracellular cAMP levels in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 10 μM forskolin and 100 μM IBMX for 14 days. 
Intracellular cAMP was measured in pmol and presented as pmol/mg after 
normalizing to total protein concentration. Data are presented as means ± SEM from 
three donors.  
A 
B 
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 52. Effects of elevated intracellular 
cAMP on MAPK activation in NHBE cells in 
response to IL-13 in the absence of 
epinephrine: Cells were grown in the absence 
of epinephrine 72 hours before ALI, then at 
ALI, they were incubated with or without 20 
ng/ml IL-13 with or without 10 μM forskolin and 
100 μM IBMX for 14 days. Total proteins were 
harvested and immunoblots were performed 
using antibodies to phosphorylated proteins. 
The signal densities of the phosphorylated 
proteins were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data are 
presented as fold change compared to the 
corresponding control cells. A) ERK1/2 
phosphorylation in NHBE cells. B) cJun 
phosphorylation and C) p38 phosphorylation. 
Data are presented as means ± SEM from 
three donors. † and ψ indicate p<0.05 
significance as compared to -epi and -
epi+forskolin+IBMX respectively. 
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Figure 53. Effects of elevated intracellular 
cAMP on MAPK activation in NHBE cells in 
response to IL-13 in the presence of 
epinephrine: Cells were grown in the 
presence of epinephrine, then at ALI, they 
were incubated with or without 20 ng/ml IL-13 
with or without 10 μM forskolin and 100 μM 
IBMX for 14 days. Total proteins were 
harvested and immunoblots were performed 
using antibodies to phosphorylated proteins. 
The signal densities of the phosphorylated 
proteins were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data are 
presented as fold change compared to the 
corresponding control cells. A) ERK1/2 
phosphorylation in NHBE cells. B) cJun 
phosphorylation and C) p38 phosphorylation. 
Data are presented as means ± SEM from 
three donors. @ indicate p<0.05 significance 
as compared to +epi+forskolin+IBMX treated 
cells respectively. 
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Figure 54. Effects of elevated 
intracellular cAMP on CREB, STAT6 
activation in NHBE cells in response to 
IL-13: Cells were grown in the absence of 
epinephrine 72 hours before ALI (A), or in 
presence of epinephrine (B, C), then at 
ALI, they were incubated with or without 
20 ng/ml IL-13 with or without 10 μM 
forskolin and 100 μM IBMX for 14 days. 
Total proteins were harvested and 
immunoblots were performed using 
antibodies to phosphorylated proteins. 
The signal densities of CREB 
phosphorylation in NHBE cells (A, B) and 
STAT6 phosphorylation (C) were 
measured and normalized to total protein 
or GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data 
are presented as fold change compared 
to the corresponding control cells. Data 
are presented as means ± SEM from 
three donors. *,# and @ indicate p<0.05 
significance as compared to +epi, 
+epi+IL-13 and +epi+forskolin+IBMX 
treated cells respectively. 
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4.5.2 Role of a specific PDE inhibitor in mucin production in response to IL-
13 in NHBE cells  
Besides studying the global intracellular cAMP elevation induced by 
forskolin+IBMX combination, we used roflumilast, a specific PDE4 inhibitor, to 
study the involvement of compartmentalized cAMP signaling. Subcellular 
compartmentalization of cAMP is responsible for spatially and temporally 
controlling the generation and degradation of cAMP (Arora, Sinha et al. 2013) 
and consequently phosphorylation of specific downstream substrates (Di 
Benedetto, Zoccarato et al. 2008). We treated NHBE cells with 100 nM 
roflumilast in combination with IL-13 in the presence or absence of epinephrine. 
In the absence of epinephrine, roflumilast did not increase MUC5AC expression 
(1.57 ± 1.61 fold vs 0.72 ± 0.47 fold by IL-13, p>0.05) (Figure 55A). Intracellular 
accumulation of mucin 5AC and mucin glycoproteins were also not increased by 
roflumilast under the same conditions (Figure 56A and Figure 57A). Also, 
roflumilast did not alter the levels of MUC5AC transcripts that were induced by 
IL-13 and in the presence of epinephrine (3.48 ± 3.57 fold vs 12.29 ± 7.55 fold 
increase by IL-13, p>0.05) (Figure 55B). Intracellular accumulation of mucin 5AC 
and mucin glycoproteins were reduced in roflumilast+ IL-13 treated cells as 
compared to IL-13 treated cells (Figure 56B and Figure 57B). Roflumilast did not 
affect the integrity of epithelial cells monolayer, as evaluated by TEER 
measurements (Figure 58A and B).  
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Intracellular cAMP levels were not elevated in roflumilast+IL-13 treated 
cells as compared to cells grown in the absence or presence of epinephrine 
(Figure 59A and B).  
We examined the activation state of several downstream signaling 
molecules to identify the involved signaling molecules in mediating the effect of 
roflumilast. Roflumilast did not alter the levels of activated ERK1/2, p38, cJun 
and CREB in response to IL-13, either in the presence or absence of epinephrine 
(Figure 60A-C, Figure 61A-C, Figure 62A and B). Furthermore, STAT6 
phosphorylation was also not altered by roflumilast in the presence of 
epinephrine (Figure 62C).  
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Figure 55. Effect of roflumilast on MUC5AC transcripts in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI 
(A) or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 nM roflumilast for 14 days. MUC5AC 
transcripts levels were measured by qRT-PCR and the data presented as fold 
change compared to corresponding control cells grown in the absence of IL-13 and 
roflumilast. Data are presented as means ± SEM from three donors.* indicates 
p<0.05 significance as compared to +epi treated cells. 
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Figure 56. Effect of roflumilast on mucin 5AC production in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 nM roflumilast for 14 days. The Transwell® 
membranes were incubated with a rabbit antibody against human mucin 5AC (red) 
and DAPI to counterstain the nuclei (blue). The ratio of integrated fluorescence 
density of each group to the integrated mucin 5AC density of the corresponding 
control group was calculated and expressed as fold change compared to the 
corresponding control cells (in the absence of IL-13 treatment). Representative 
images of immunofluorescence are shown (scale bar = 100 μm). Data are presented 
as means ± SEM from three donors. * indicates p<0.05 significance as compared to 
+epi treated cells. 
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Figure 57. Effect of roflumilast on mucin production in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or without 
20 ng/ml IL-13 with or without 100 nM roflumilast for 14 days. PAFS staining of NHBE 
cells to quantify total intracellular mucin glycoproteins. Representative images are 
shown (scale bar = 100 μm). The ratio of mucin integrated density and nucleic 
acid/cytoplasm integrated density was calculated and the data presented as fold 
change compared to the corresponding control cells (in the absence of IL-13 
treatment). Data are presented as means ± SEM from three donors. Data are 
presented as means ± SEM from three donors. * and # indicate p<0.05 significance as 
compared to +epi and +epi+IL-13 treated cells. 
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Figure 58. Effect of roflumilast on the integrity of NHBE cell monolayers: Cells 
were grown in the absence of epinephrine 72 hours before ALI (A) or in the 
presence of epinephrine (B), then at ALI, they were incubated with or without 20 
ng/ml IL-13 with or without 100 nM roflumilast for 14 days. Trans-epithelial electrical 
resistance (TEER) was measured throughout the culture period. Data are 
presented as mean ohm.cm2 of insert surface ± SEM from three donors. * and $ 
indicate p<0.05 significance between -epi and -epi+roflumilast+IL-13, and between 
-epi and -epi+IL-13 treated cells respectively.  
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Figure 59. Effect of roflumilast on intracellular cAMP levels in NHBE cells: Cells 
were grown in the absence of epinephrine 72 hours before ALI (A) or in the presence 
of epinephrine (B), then at ALI, they were incubated with or without 20 ng/ml IL-13 
with or without 100 nM roflumilast for 14 days. Intracellular cAMP was measured in 
pmol and presented as pmol/mg after normalizing to total protein concentration. Data 
are presented as means ± SEM from three donors.  
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Figure 60. Effects of roflumilast on 
activation of MAPKs in NHBE cells in 
response to IL-13 in the absence of 
epinephrine:  Cells were grown in the 
absence of epinephrine 72 hours before ALI, 
then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 
nM roflumilast for 14 days. Total proteins 
were harvested and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or GAPDH 
protein density and the relative intensities 
were reported as the degree of 
phosphorylation of the protein. The data 
presented as fold change compared to the 
corresponding control cells. A) ERK1/2 
phosphorylation in NHBE cells. B) cJun 
phosphorylation and C) p38 phosphorylation. 
Data are presented as means ± SEM from 
three donors. # and † indicate p<0.05 
significance as compared to -epi+IL-13 and -
epi respectively. 
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Figure 61. Effects of roflumilast on 
activation of MAPKs in NHBE cells in 
response to IL-13 in the presence of 
epinephrine:  Cells were grown in the 
presence of epinephrine then at ALI, 
they were incubated with or without 20 
ng/ml IL-13 with or without 100 nM 
roflumilast for 14 days. Total proteins 
were harvested and immunoblots were 
performed using antibodies to 
phosphorylated proteins. The signal 
densities of the phosphorylated proteins 
were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree 
of phosphorylation of the protein. The 
data are presented as fold change 
compared to the corresponding control 
cells. A) ERK1/2 phosphorylation in 
NHBE cells. B) cJun phosphorylation 
and C) p38 phosphorylation. Data are 
presented as means ± SEM from three 
donors. @ indicate p<0.05 significance 
as compared to +epi+roflumilast treated 
cells respectively. 
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Figure 62. Effects of roflumilast on CREB 
and STAT6 activation in NHBE cells in 
response to IL-13:  Cells were grown in the 
absence of epinephrine 72 hours before ALI 
(A) or in the presence of epinephrine (B and 
C), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 nM 
roflumilast for 14 days. Total proteins were 
harvested and immunoblots were performed 
using antibodies to phosphorylated proteins. 
The signal densities of the phosphorylated 
proteins were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data are 
presented as fold change compared to the 
corresponding control cells. A and B) CREB 
phosphorylation in NHBE cells. C) STAT6 
phosphorylation. Data are presented as 
means ± SEM from three donors.  
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4.6 Role of β-arrestin signaling in mucin production in response to IL-13 in 
airway epithelial cells 
4.6.1 Effect of carvedilol on mucin production in response to IL-13 in NHBE 
cells 
After evaluating the involvement of β2-AR canonical Gs/adenylyl cyclase 
pathway, we assessed the role of β-arrestin signaling on mucin parameters and 
signaling cascades induced by IL-13. For this purpose, we treated NHBE cells 
with 100 nM carvedilol, a β-blocker that blocks the Gs/ adenylyl cyclase signaling 
while activating the β-arrestin pathway, for 14 days in the presence and absence 
of epinephrine. MUC5AC expression was not changed with carvedilol in the 
absence of epinephrine (2.20 ± 1.76 fold vs 0.72 ± 0.47 fold by IL-13, p>0.05) 
(Figure 63A). Also, in the presence of epinephrine, carvedilol did not alter the 
levels of MUC5AC expression induced by IL-13 (5.04 ± 8.50 fold vs 13.6 ± 5.72 
fold by IL-13, p>0.05) (Figure 63B). Similar trends were also observed at the 
level of intracellular mucin 5AC accumulation and mucin glycoproteins either in 
the absence or presence of epinephrine (Figure 64A, B and Figure 65A, B). 
Carvedilol did not alter the barrier function of cultured NHBE cells, as assessed 
by measuring the TEER and ZO-1 localization (Figure 66A, B and 67A, B).  
The accumulation of intracellular cAMP induced by carvedilol did not differ from 
control or IL-13 treated cells either in the presence or absence of epinephrine 
(Figure 68A, B). Next, we examined the levels of activated signaling molecules 
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downstream of β-arrestin signaling cascade. Carvedilol reduced ERK1/2 
phosphorylation when combined with IL-13 in the absence of epinephrine as 
compared to control cells, whereas it did not affect ERK1/2 phosphorylation in 
the presence of epinephrine (Figure 69A and Figure 70A). On the other hand, 
carvedilol + IL-13 treatment increased cJun phosphorylation as compared to 
control cells only in the pesence of epinephrine (Figure 70B). p38 and CREB 
phosphorylation states were not changed by carvedilol either in the presence or 
absence of epinephrine (Figure 69C, Figure 70C and Figure 71A,B).
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Figure 63. Effect of carvedilol on MUC5AC transcripts in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or without 
20 ng/ml IL-13 with or without 100 nM carvedilol for 14 days. MUC5AC transcripts 
levels were measured by qRT-PCR and the data presented as fold change compared 
to corresponding control cells grown in the absence of IL-13 and carvedilol. Data are 
presented as means ± SEM from three donors.* and ψ indicate p<0.05 significance as 
compared to +epi and +epi+carvedilol treated cells respectively.  
A 
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Figure 64. Effect of carvedilol on mucin 5AC production in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or without 
20 ng/ml IL-13 with or without 100 nM carvedilol for 14 days. The Transwell® 
membranes were incubated with a rabbit antibody against human mucin 5AC (red) and 
DAPI to counterstain the nuclei (blue). The ratio of integrated fluorescence density of 
each group to the integrated mucin 5AC density of the corresponding control group 
was calculated and expressed as fold change compared to the corresponding control 
cells (in the absence of IL-13 treatment). Representative images of 
immunofluorescence are shown (scale bar = 100 μm). Data are presented as means ± 
SEM from three donors. .* and ψ indicate p<0.05 significance as compared to +epi and 
+epi+carvedilol treated cells respectively.  
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Figure 65. Effect of carvedilol on mucin production in response to IL-13 in 
NHBE cells: Cells were grown in the absence of epinephrine 72 hours before ALI (A) 
or in the presence of epinephrine (B), then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 nM carvedilol for 14 days. PAFS staining 
of NHBE cells to quantify total intracellular mucin glycoproteins. Representative 
images are shown (scale bar = 100 μm). The ratio of mucin integrated density and 
nucleic acid/cytoplasm integrated density was calculated and the data presented as 
fold change compared to the corresponding control cells (in the absence of IL-13 
treatment). Data are presented as means ± SEM from three donors. Data are 
presented as means ± SEM from three donors. * indicates p<0.05 significance as 
compared to +epi treated cells. 
A B 
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Epi (3µM) - - - - 
IL-13 (20ng/ml) - + + + 
Carvedilol (100nM) - - + - 
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Figure 66. Effect of carvedilol on the integrity of NHBE cells monolayer in 
response to IL-13 in the absence of epinephrine:  NHBE cells were grown in the 
absence of epinephrine 72 hours before ALI, then at ALI, they were treated with 20 
ng/ml IL-13 in combination with 100 nM carvedilol for 14 days. A) Trans-epithelial 
electrical resistance (TEER) was measured thought the culture period one day before 
ALI and throughout ALI period. Data are presented as ohm.cm2 of insert surface 
area. Data are presented as means ± SEM from three donors. B) Representative 
images of immunofluorescence with a rabbit antibody against ZO-1 (red) (scale bar = 
100 μm). The Transwell® membranes were incubated with DAPI to counterstain the 
nuclei (blue). Data are presented as means ± SEM from three donors. * and $ 
indicate p<0.05 significant difference between -epi and -epi+IL-13 and between -epi 
and -epi+carvedilol+IL-13 treated cells respectively. 
B 
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Epi (3µM) + + + + 
IL-13 (20ng/ml) - + + + 
Carvedilol (100nM) - - + - 
 
Figure 67. Effect of carvedilol on the integrity of NHBE cells monolayer in 
response to IL-13 in the presence of epinephrine:  NHBE cells were grown in 
the presence of 3 μM epinephrine, then at ALI, they were treated with 20 ng/ml IL-
13 in combination with 100 nM carvedilol for 14 days. A) Trans-epithelial electrical 
resistance (TEER) was measured throughout the culture period. Data are 
presented as ohm.cm2 of insert surface area. Data are presented as means ± SEM 
from three donors. B) Representative images of immunofluorescence with a rabbit 
antibody against ZO-1 (red) (scale bar = 100 μm). The Transwell® membranes 
were incubated with DAPI to counterstain the nuclei (blue). Data are presented as 
means ± SEM from three donors. * indicates p<0.05 significant difference between 
+epi and +epi+carvedilol+IL-13 treated cells respectively. 
A 
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Figure 68. Effect of carvedilol on intracellular cAMP levels in NHBE cells: 
Cells were grown in the absence of epinephrine 72 hours before ALI (A) or in the 
presence of epinephrine (B), then at ALI, they were incubated with or without 20 
ng/ml IL-13 with or without 100 nM carvedilol for 14 days. Intracellular cAMP was 
measured in pmol and presented as pmol/mg after normalizing to total protein 
concentration. Data are presented as means ± SEM from three donors. 
A 
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Figure 69. Effects of carvedilol on 
activation of MAPKs in NHBE cells in 
response to IL-13 in the absence of 
epinephrine:  Cells were grown in the 
absence of epinephrine 72 hours before ALI, 
then at ALI, they were incubated with or 
without 20 ng/ml IL-13 with or without 100 nM 
carvedilol for 14 days. Total proteins were 
harvested and immunoblots were performed 
using antibodies to phosphorylated proteins. 
The signal densities of the phosphorylated 
proteins were normalized to total protein or 
GAPDH protein density and the relative 
intensities were reported as the degree of 
phosphorylation of the protein. The data are 
presented as fold change compared to the 
corresponding control cells. A) ERK1/2 
phosphorylation in NHBE cells. B) cJun 
phosphorylation and C) p38 phosphorylation. 
Data are presented as means ± SEM from 
three donors. # indicates p<0.05 significance 
as compared to -epi cells. 
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4.6.2 Effect of β-arrestin-2 on mucin production in response to IL-13 from 
isolated mouse tracheal epithelial cells (mTECs) 
We next examined if the loss of β-arrestin-2 from airway epithelial cells 
affects the response to IL-13 by using a mouse with a knockout of β-arrestin-2. 
We isolated mTECs from β-arrestin-2 KO mice and WT mice and treated them 
with murine IL-13 for 14 days after establishing ALI for 14 days. The intracellular 
mucin 5ac content of mTECs from β-arrestin-2 KO was induced by IL-13 as 
compared to untreated cells from β-arrestin-2 KO. However, this increase was 
significantly lower as compared to IL-13 treated cells from WT mice (Figure 72).  
In addition, we examined the total mucin glycoprotein accumulation in 
these treated cells. Intracellular mucin glycoprotein was induced by IL-13 in cells 
from WT mice, but not in cells from β-arrestin-2 KO mice (Figure 73).  
Incubation of mTECs from β-arrestin-2 KO mice with IL-13 resulted in 
increased permeability of the monolayer, as evaluated by TEER measurement 
and ZO-1 localization after 14 days of IL-13 treatment (ALI day 28) (Figure74A, 
B). There was also a reduction in TEERs from IL-13 treated mTECs from WT 
mice, but it was not significant (Figure74A, B). 
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Figure 72. Role of β-arrestin-2 signaling in mucin 5ac production in response 
to IL-13 in cultured mTECs: Cells from WT and β-arrestin-2 KO mice were grown 
14 days at ALI, then treated with or without 20 ng/ml IL-13 in the presence of 
epinephrine for another 14 days. The Transwell® membranes were incubated with 
mucin 5ac (red) antibody and DAPI to counterstain the nuclei (blue). The integrated 
fluorescence density of each group was calculated and expressed as arbitrary 
units. Representative images of immunofluorescence are shown (scale bar = 100 
μm). Data are presented as means ± SEM from three inserts from N=3-4. *, $, @ 
and # indicate p<0.05 significance as compared to WT-IL-13, β-arrestin-2 KO-IL-13, 
β-arrestin-2 KO+IL-13 and β-arrestin-2 KO-IL-13 treated cells respectively. 
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Figure 73. Role of β-arrestin-2 signaling in mucin production in response to 
IL-13 in cultured mTECs: Cells from WT and β-arrestin-2 KO mice were grown 
14 days at ALI, then treated with or without 20 ng/ml IL-13 in the presence of 
epinephrine for another 14 days. PAFS staining of mTECs to quantify total 
intracellular mucin glycoproteins. Representative images are shown (scale bar = 
100 μm). The ratio of mucin integrated density and nucleic acid/cytoplasm 
integrated density was calculated and the data presented as fold change 
compared to the corresponding control cells (in the absence of IL-13 treatment). 
Data are presented as means ± SEM from three inserts from N=3-4. *, $ and @ 
indicate p<0.05 significance as compared to WT-IL-13, β-arrestin-2 KO-IL-13 and 
β-arrestin-2 KO+IL-13 treated cells respectively. 
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Figure 74: Effect of β-arrestin-2 signaling on the integrity of mTECS 
monolayer in response to IL-13:  Cells were grown 14 days at ALI, then treated 
with or without 20 ng/ml IL-13 in the presence of epinephrine for another 14 days.  
A) Trans-epithelial electrical resistance (TEER) was measured on ALI day 28 (14 
days after starting IL-13 treatment). Data are presented as mean ohm.cm2 of insert 
surface area± SEM from three inserts from N=3-4. B) Representative images of 
immunofluorescence with a rabbit antibody against ZO-1 (red) (scale bar = 100 
μm). The Transwell® membranes were incubated with DAPI to counterstain the 
nuclei (blue). Data are presented as means ± SEM from three donors. $ indicates 
p<0.05 significance as compared to β-arrestin-2 KO-IL-13 cells. 
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4.7 Effect of β2-AR signaling in IL-13 modulation of mucociliary 
differentiation of NHBE cells. 
We then assessed if β2-AR signaling is involved in the 
transdifferentiation from ciliated cells to goblet cells induced by IL-13 and if this is 
the site of cross-talk between β2-AR and IL-13 signaling pathways. For this 
purpose, we measured the expression level of FOXJ1, a marker for ciliated cells. 
Cells that were grown in the absence of epinephrine and treated with IL-13 
showed a higher levels of FOXJ1, but this difference was not significant as 
compared to cells grown in the presence of epinephrine (Figure 75A). NHBE 
cells were treated with IL-13 and 1 μM ICI-118,551 (a highly preferential β2-AR 
antagonist) or 3 μM CGP-20712A (a highly preferential β1-AR antagonist) for 14 
days in the presence of epinephrine. IL-13 did not alter FOXJ1 expression as 
compared to control cells. Moreover, CGP-20712A (0.60±0.27 fold vs 1.39±1.46 
fold by IL-13, p>0.05) and ICI-118,551 (2.39±3.09 fold vs 1.39±1.46 fold by IL-13, 
p>0.05) did not affect the expression level in response to IL-13 (Figure 75B).  
We next examined if the increase in mucin production in response to 
IL-13 in the presence of epinephrine is due to cell proliferation. We used DAPI 
staining of cell nuclei as a marker for cell number. IL-13 increased the cell 
number only in the presence of epinephrine (Figure 76A). Also, when treating the 
cells with CGP-20712A+IL-13, the cell number was significantly increased and 
ICI-118,551+ IL-13 significantly reduced the cell number as compared to CGP-
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20712A+IL-13 (Figure 76B). In addition, elevated intracellular cAMP by 
forskolin+IBMX combination resulted in significant increase in cell number in 
response to IL-13 either in the absence or presence of epinephrine (Figure77A 
and B). 
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Figure 75. Role of β2-AR signaling in FOXJ1 expression in response to IL-13 in 
NHBE cells: A) NHBE cells were grown in the absence of epinephrine 72 hours 
before ALI or in the presence of epinephrine, then at ALI, they were incubated with or 
without 20 ng/ml IL-13 for 14 days. FOXJ1 transcripts levels were measured by qRT-
PCR and the data presented as fold change compared to cells grown in the presence 
of epinephrine. B) NHBE cells were grown in the presence of epinephrine, then at 
ALI, they were incubated with or without 20 ng/ml IL-13 with CGP-20721A or ICH-
118,551 for 14 days. FOXJ1 was measured and the data presented as fold change 
compared to cells grown in the presence of epinephrine. Data are presented as 
means ± SEM from three donors.  
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Figure 76. Role of β2-AR signaling in cell proliferation in response to IL-13 in 
NHBE cells: A) NHBE cells were grown in the absence of epinephrine 72 hours before 
ALI or in the presence of epinephrine, then at ALI, they were incubated with or without 
20 ng/ml IL-13 for 14 days. B) NHBE cells were grown in the presence of epinephrine, 
then at ALI, they were incubated with or without 20 ng/ml IL-13 with CGP-20721A or ICI-
118,551 for 14 days. DAPI count was used as a marker of the cell number and the data 
presented as fold change compared to cells grown in the presence of epinephrine. Data 
are presented as means ± SEM from three donors. *, @ and # indicate p<0.05 
significant difference between +epi and –epi and +epi+IL-13+ CGP-20721A treated cells 
respectively. 
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Figure 77. Role of intracellular cAMP elevation on cell proliferation in 
response to IL-13 in NHBE cells: Cells were grown in the absence of 
epinephrine 72 hours before ALI (A) or in the presence of epinephrine (B), then at 
ALI, they were incubated with or without 20 ng/ml IL-13 with or without 10 μM 
forskolin and 100 μM IBMX for 14 days. DAPI count was used as a marker of the 
cell number and the data presented as fold change compared to cells grown in 
the presence of epinephrine. Data are presented as means ± SEM from three 
donors. †, ¥,$ and *, #, @ indicate p<0.05 significance as compared to -epi, -epi+ 
IL-13,-epi+forskolin+IBMX, +epi and +epi+IL-13, +epi+forskolin+IBMX treated 
cells respectively. 
A B 
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5. Discussion: 
Asthma, a chronic airway inflammatory condition, affects around 300 
million people worldwide (Masoli, Fabian et al. 2004; 2007). Though there are 
several treatment modalities for asthma, it accounts for 250,000 deaths per year 
(2007). β2-AR agonists are among the most widely used medications for asthma, 
both for acute relief and long term maintenance therapy. The chronic use of β2-
AR agonists is associated with increased risk of severe exacerbations and 
overall asthma related death (Currie, Lee et al. 2006; Nelson, Weiss et al. 2006; 
Salpeter, Buckley et al. 2006). Acute administration of β-AR blockers is 
associated with airway narrowing in asthmatic patients (Singh, Whitlock et al. 
1976; Boskabady and Snashall 2000) and in murine model of asthma (Callaerts-
Vegh, Evans et al. 2004). However, chronically blocking β2-ARs by nadolol 
resulted in reduction in inflammation and mucus metaplasia in allergen driven 
murine model of asthma (Nguyen, Lin et al. 2009). Thus, β2-AR signaling 
appears to contribute to asthma through its pro-inflammatory potential, and 
blocking these receptors may contribute to improvement in the disease status. 
Airway inflammation results in changes in airway epithelium that eventually 
causes mucus metaplasia. The increased mucus production that is associated 
with asthma and other airway inflammatory diseases, such as COPD, contributes 
significantly to airway obstruction and AHR. Autopsies of patients who died of 
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severe asthma attacks revealed goblet cell hyperplasia and mucus accumulation 
in peripheral airways (Aikawa, Shimura et al. 1992).  
 In our studies, we wanted to examine the role of β2-AR signaling in mucus 
metaplasia. Due to the complexity of understanding the signaling pathways that 
are involved in mediating mucus production and the involvement of several 
inflammatory cells in vivo, it was essential to study the involvement of airway 
epithelial cells independent from other inflammatory and structural cells. In this 
study, we investigated the requirement for β2-ARs in the expression of MUC5AC, 
the major mucin producing gene, and intracellular mucin accumulation in 
response to IL-13 in NHBE cells. Also, we further delineated the key signaling 
components involved such as MAPKs, CREB and STAT6. The major findings in 
this study are: 1) epinephrine-induced β2-AR signaling is required for mucin 
production in NHBE cells in response to IL-13. 2) MAPKs are part of the required 
signaling cascade in IL-13 responses. 3) Signaling pathways downstream of 
cAMP and PKA play a role in mediating the effect of IL-13 on mucin parameters. 
4) β-arrestin-2 signaling pathway does not modulate the effect of IL-13 on mucin 
parameters in NHBE cells. 5) β2-AR signaling is not involved in IL-13 induced 
mucuciliary shift from ciliated cells to goblet cells in NHBE cells. 
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5.1 Epinephrine is required for mucin production in response to IL-13 in 
NHBE cells  
Epinephrine, the endogenous ligand that activates all α and β 
adrenoceptors (Ahlquist 1948), is added to the culture medium of NHBE cells in 
most published studies (Atherton, Jones et al. 2003; Yoshisue and Hasegawa 
2004; Fulcher, Gabriel et al. 2005; Zhen, Park et al. 2007; Kono, Nishiuma et al. 
2010). When we removed epinephrine from the culture media 72 hours before 
cells reached ALI and throughout the treatment period, IL-13 was not able to 
induce MUC5AC expression or the accumulation of intracellular mucin 5AC and 
mucin glycoproteins in NHBE cells (Figure 15 and 16). On the other hand, in the 
presence of epinephrine, IL-13 significantly induced these three parameters of 
mucin expression (Figure 15 and 16).  These data are consistent with our recent 
animal studies where genetic or pharmacological depletion of epinephrine in 
mice attenuated mucous metaplasia in an antigen-driven murine model of 
asthma (Thanawala, Forkuo et al. 2013).  
Growing the NHBE cells at ALI caused an increase in the trans-epithelial 
electrical resistance (TEER) that peaked at ALI day 7 and then declined 
gradually (Figure 17A). TEER is an indirect indicator for the tight junction 
formation between cells and epithelial layer integrity (Stewart, Torr et al. 2012).  
This bell-shaped curve has been observed when retinoic acid is absent from the 
culture media (Murgia, Grosser et al. 2011), whereas most other papers used a 
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50 nM concentration of retinoic acid (Atherton, Jones et al. 2003; Fulcher, 
Gabriel et al. 2005; Zhen, Park et al. 2007). In our studies, we used 0.1 ng/ml 
(0.3 nM) retinoic acid, which is the concentration that is recommended by the 
vendor (Lonza®), and other studies have used this low concentration to support 
cell differentiation (Kafoury, Pryor et al. 1999; Lee, Yoo et al. 2005; Damera, 
Zhao et al. 2009). Moreover, The formation of tight junctions was also evaluated 
by showing the presence of ZO-1, a tight junction protein marker, on cell-junction 
by immunofluorescence (Stewart, Torr et al. 2012) (Figure 17B). IL-13 did not 
reduce TEERs values below control cells that were grown in the presence or 
absence of epinephrine. 
We examined if the absence of epinephrine affected cell differentiation 
and if that was the underlying reason for MUC5AC expression not responding to 
IL-13 stimulation. Cells that were grown in the absence or presence of 
epinephrine have properties of airway epithelium at baseline (without IL-13 
stimulation) at the level of MUC5AC transcripts, mucin 5AC and intracellular 
mucin glycoprotein expression (Figure 18A and B). Moreover, there was no 
significant difference at the level of FOXJ1 expression (hepatocyte nuclear factor 
homolog (HFH-4)/forkhead box protein J1), an early marker for ciliogenesis 
(Figure 18A). FOXJ1 is a transcription factor that is localized to proximal ciliated 
epithelial cells of the airways, as assessed by colocalization of FOXJ1 and β-
tubulin IV (Blatt, Yan et al. 1999). Much evidence indicates that FOXJ1 plays a 
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central role in the process of ciliogenesis and it is expressed before the 
appearance of cilia during murine lung development (Tichelaar, Wert et al. 1999). 
The barrier function of cells grown in the presence or absence of epinephrine, as 
evaluated by TEER measurements and the cellular localization of ZO-1, were 
also at similar levels (Figure 17A and B). Differentiated airway bronchial epithelial 
cells secrete several characteristic chemokines such as TSLP, a well-studied 
epithelial cytokine, MCP-1 and MIP3α, and the production of these were also 
unaffected by the presence or absence of epinephrine (Figure 18C). Taken 
together, these cells have levels of mucociliary differentiation that do not depend 
on the presence of epinephrine. 
Our in vitro results are also consistent with our recent data where genetic 
or pharmacological depletion of epinephrine in mice resulted in attenuation of 
inflammation and mucous metaplasia in an antigen-driven model of asthma 
(Thanawala, Forkuo et al. 2013). 
 
5.2 Epinephrine induced-β2-AR signaling is required for mucin production 
in response to IL-13 in NHBE cells  
β2-AR is the principal subtype present in human airway epithelium (Davis, 
Silski et al. 1990). To verify the involvement of this subtype in the effects of IL-13 
in cultured NHBE cells, we used ICI-118,551 and CGP 20712A. CGP 20712A is 
a highly preferential β1-AR antagonist; its selectivity toward β1-AR is ~500 fold 
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over β2-AR and ~4000 over β3-AR (Baker 2005). On the other hand, ICI-118,551 
is a preferential β2-AR antagonist; its selectivity to β2-AR as compared to β1-AR 
is ~500 fold and ~600 fold as compared to β3-AR (Baker 2005). Treating NHBE 
cells with the preferential β2-AR antagonist almost completely abolished 
MUC5AC expression in response to IL-13 and epinephrine (Figure 19A). On the 
contrary, the preferential β1-AR antagonist did not alter the expression level 
under the same conditions. Also IL-13 induced accumulation of intracellular 
mucin 5AC and mucin glycoproteins were reduced by ICI-118,551 but not by 
CGP 20712A treatment (Figure 19B and Figure 20). Thus, β2-AR activation is 
required in IL-13 induced mucin accumulation in NHBE cells. Our results are 
consistent with the murine model of asthma, in which blocking β2-AR with ICI-
118,551 (Nguyen, Omoluabi et al. 2008) or genetically ablating β2-AR (Nguyen, 
Lin et al. 2009) resulted in attenuated mucus metaplasia in response to allergen. 
The concentrations of ICI-118,551 and CGP 20712A that were used in our 
studies did not affect the integrity of the monolayer, as evaluated by TEER 
measurement and ZO-1 apical localization, when compared to untreated control 
cells (Figure 21A and B). 
Previous studies of the role of β2-ARs in mucous secretion in the airways 
have produced varying results. An earlier study had shown that β-AR activation, 
through cAMP/PKA dependent mechanisms, enhanced the secretion of mucus 
cells from cat trachea in vitro (Liedtke, Rudolph et al. 1983). Moreover, 
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salbutamol, a β2-AR agonist, increased the rate of mucus output from human 
bronchi in vitro (Phipps, Williams et al. 1982). In contrast, other in vitro studies on 
human bronchial airway preparations showed that β-AR stimulation, via 
isoproterenol (Shelhamer, Marom et al. 1980; Abdullah, Conway et al. 1997), or 
increasing the level of intracellular cAMP were not associated with increase in 
the release of mucin (Abdullah, Conway et al. 1997). It is noteworthy to mention 
that these studies focused on mucin secretion rather than on intracellular mucin 
accumulation, which we studied. Increased mucin accumulation possibly resulted 
from a change in the relative rates of mucin production and secretion. At the level 
of secretion, there appears to be no change in the molecular components or the 
rate of the secretion during mucus metaplasia (Evans, Kim et al. 2009). 
Therefore, the increase in mucin accumulation is most likely a reflection of 
increased mucin production (Young, Williams et al. 2007), specifically MUC5AC 
(Kirkham, Sheehan et al. 2002).  
β2-AR signaling can proceed from agonist-activated receptors and from 
constitutively active receptors (Bond, Leff et al. 1995). In two state receptor 
model receptors are at equilibrium between two conformations, active (R*) and 
inactive (R) (Kenakin 2001; Bond and Ijzerman 2006). The receptor in its active 
confirmation couples to G-protein and activates downstream signaling pathways 
in a ligand-independent fashion (Seifert and Wenzel-Seifert 2002; Milligan 2003). 
Ligands are classified based on their ability to bind and enrich one of these 
 
 
159 
conformations as outlined in Figure 78. An agonist binds and enriches the active 
conformation while an inverse agonist binds and stabilizes the inactive 
conformation, and thus it reduces the signaling induced by the constitutive active 
receptor (Milligan, Bond et al. 1995; Milligan 2003). A neutral antagonist 
theoretically binds without preference to both conformations (Parra and Bond 
2007).  
 
Figure 78. Two state model of receptor theory: The receptor exists in 
equilibrium between active (R*) and inactive state (R). Full agonist stabilizes 
more receptors in the active confirmation than the partial agonist. Full inverse 
agonist binds to and enriches the inactive conformation at a higher level as 
compared to partial inverse agonist. Antagonist  binds to both receptor 
conformations and does not affect the equilibrium. Reproduced from Seifert and 
Wenzel-Seifert (2002). 
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We have shown that epinephrine activation of β2-AR is required to induce 
mucin production in response to IL-13. To further evaluate whether agonist 
induced signaling or constitutive β2-AR activity is sufficient for this effect, we 
treated the cells with nadolol and alprenolol in the presence of epinephrine.  
Nadolol is a non-selective β-AR blocker that has full inverse agonist activity at β2-
ARs (Callaerts-Vegh, Evans et al. 2004; Wisler, DeWire et al. 2007), thus it 
blocks both induced and constitutive β2-AR signaling. Alprenolol lacks inverse 
agonist activity (Bond, Leff et al. 1995) and has weak β2-AR agonist activity 
(Brodde, Daul et al. 1985; Lima 1996; Wisler, DeWire et al. 2007) behaving as an 
antagonist in the presence of epinephrine, thus preserving constitutive β2-AR 
signaling. Both nadolol and alprenolol blocked the effect of IL-13 on the three 
parameters of mucin production to similar extents (Figure 22 and Figure 23).  
The role of nadolol in reducing the mucin content of airway epithelium is 
consistent with our group’s findings in the allergen driven murine model of 
asthma (Nguyen, Omoluabi et al. 2008). In contrast, alprenolol did not reduce 
mucus metaplasia in this model (Nguyen, Lin et al. 2009) while it reduced all 
three measured parameters (MUC5AC expression, intracellular mucin 5AC and 
mucin glycoproteins accumulation) in NHBE cells. This discrepancy in the results 
could be explained by differences between the in vitro and in vivo models. In the 
mouse model, mucus metaplasia is dependent on different mediators and 
 
 
161 
cytokines released from recruited inflammatory cells and not only on the direct 
effect of the ligand on airway epithelial cells. In our isolated system, we studied 
the effect of each ligand on NHBE cells independent from other cell types, either 
hematopoietic or parenchymal. The effect of alprenolol in NHBE cells may be 
explained based on its weak agonist properties. One proposed scenario is that 
alprenolol, the partial agonist, competes with epinephrine, full agonist, and 
displaces epinephrine from its binding sites on β2-ARs. The resulting weak β2-AR 
signaling may be insufficient for increased mucin expression in response to IL-
13.  
Thus, we provide evidence that constitutive β2-AR receptor activity is not 
sufficient to drive the increase in mucin in response to IL-13 in human bronchial 
epithelial cells. Our in vitro results are also consistent with our recent animal data 
where genetic depletion of epinephrine resulted in attenuated mucus metaplasia 
which was restored by formoterol, a β2-AR agonist, an antigen-driven murine 
model of asthma (Thanawala, Forkuo et al. 2013). More work in future is required 
to evaluate the contribution of different β2-AR agonists in mediating the effect of 
IL-13 in NHBE cells. 
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5.3 MAPK signaling is involved in mucin production in response to IL-13 in 
NHBE cells  
MAPKs play a major role in inflammation (Garrington and Johnson 1999), 
asthma pathogensis and in airway remodeling (Pelaia, Cuda et al. 2005). There 
are three principal families of MAPKs: ERK 1/2, JNK and p38. ERK 1/2 is mainly 
involved in cell growth and differentiation, while JNK and p38 play major roles in 
stress, inflammation and apoptosis signaling (Schaeffer and Weber 1999).  
All MAPK pathways are activated through three core activation steps as 
summarized in Figure 79. We studied the involvement of the three MAPKs in 
mucin production in response to IL-13. 
Figure 79. Activation of MAPKs. Briefly, different activators activate MAPK-kinase-
kinases (MAPKKKs). These kinases activate MAPK-kinase (MAPKKs) which in turn 
phosphorylate MAPKs. The three major MAPKs, JNK, p38 and ERK1/2, then activate 
downstream substrates and eventually induce different cell responses. Reproduced and 
modified from Cargnello and Roux (2011). 
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5.3.1 Role of ERK1/2 signaling in mucin production in response to IL-13 in 
NHBE cells  
In asthmatic patients, elevated levels of phosphorylated ERK1/2 were 
detected in airway epithelium and correlated positively with disease severity (Liu, 
Liang et al. 2008). Moreover, elevated levels of lung phosphorylated ERK1/2 are 
found in a murine model of asthma (Kumar, Lnu et al. 2003). IL-13 significantly 
increased ERK1/2 phosphorylation in the presence, but not in the absence, of 
epinephrine (Figure 24A). U0126, a specific MEK1/2 inhibitor, significantly 
downregulated ERK1/2 phosphorylation and MUC5AC expression induced by IL-
13 (Figure 25A and B). U0126 is a selective non-ATP competitive inhibitor 
(Favata, Horiuchi et al. 1998) that binds to a pocket of MEK1/2 adjacent to ATP-
binding site and thus inactivates its catalytic activity (Sebolt-Leopold and English 
2006). Our result is consistent with a study by Atherton and colleagues in which 
IL-13 induced mucous hypersecretion manifested as an increase in goblet cell 
density and MUC5AC protein expression in NHBE cells, and these effects were 
attenuated with the use of MEK1/2 inhibitor (Atherton, Jones et al. 2003). In 
addition, U0126 lowered the level of mucus metaplasia in allergen driven murine 
model of asthma (Duan, Chan et al. 2004; Chialda, Zhang et al. 2005). Moreover, 
U0126 treatment reduces MUC5AC expression and the number of goblet cells in 
response to IL-13 in cultured mouse tracheal epithelial cells (mTECs), though 
ERK1/2 phosphorylation was not affected by IL-13 (Fujisawa, Ide et al. 2008). 
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These differences could be due to the differences in primary cells source as well 
the treatment protocol.  
To confirm our finding of ERK-1/2 involvement, we also used FR180204, 
an ATP-competitive direct inhibitor of ERK1/2 (Ohori, Kinoshita et al. 2005). 
FR180204 reduced MUC5AC expression, intracellular mucin 5AC and mucin 
glycoprotein content in response to IL-13 (Figure 26A, B and Figure 27). 
Moreover, FR180204 did not affect the integrity of the monolayer as 
demonstrated by TEERs and ZO-1 localization (Figure 28 A and B). Thus, this is 
the second line of evidence toward the involvement of ERK1/2 signaling cascade 
in mediating IL-13 response.  
ERK1/2 is activated by GPCRs, cytokines and growth factors such as 
epidermal growth factor (EGF) (Cargnello and Roux 2011). Also, IL-13 activates 
ERK1/2 through IRS1/2 /Grb-2 /SOS /Ras pathway (Jiang, Harris et al. 2000; 
Hershey 2003). cAMP causes phosphorylation of Rap-1/B-Raf, through PKA 
(Vossler, Yao et al. 1997) and Epac (Gerits, Kostenko et al. 2008), and 
consequently ERK1/2 activation (Busca, Abbe et al. 2000). β-arrestin, as a 
scaffolding protein, binds directly to Raf-1 and ERK1/2 and indirectly to MEK1 
and consequently activates ERK1/2 (Pierce and Lefkowitz 2001; DeWire, Ahn et 
al. 2007). Moreover, β-arrestin recruits Src, a non-receptor tyrosine kinase, to the 
phosphorylated β2-AR and phosphorylates ERK1/2 (Sun, McGarrigle et al. 2007; 
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Defea 2008). Src also activates ERK1/2 indirectly through transactivation of 
EGFR (Prenzel, Zwick et al. 1999). 
Activated ERK1/2 phosphorylates a number of downstream substrates 
including membrane proteins such as calnexin (Roux and Blenis 2004) and other 
kinases such as the 90 kDa ribosomal S6 kinase (RSK) (Anjum and Blenis 
2008). Of interest, ERK2 phosphorylates PDE4D3 and significantly reduces its 
activity (Hoffmann, Baillie et al. 1999), thus ERK2 can modify cAMP signaling. 
FR180204 did not influence ERK1/2 or p38 activation (Figure 29 A and C).  
Of greatest relevance to our studies is that ERK1/2 has been shown to 
activate downstream signaling cascades that lead to activation or translocation of 
several transcriptional factors to bind to the MUC5AC promoter region and 
enhance MUC5AC transcription (Thai, Loukoianov et al. 2008) as outlined in 
Figure 80.  
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Figure 80. Schematic illustration of MUC5AC expression by activated 
ERK1/2: Several upstream signaling pathways result in ERK1/2 activation. 
Phosphorylated ERK1/2 activates several transcription factors, such as CREB, 
SP-1, AP-1 and NF-kB that bind to the MUC5AC promoter region and enhance 
its transcriptional activity.  
 
ERK1/2 activation in bronchial epithelial cells results in phosphorylation of 
CREB via RSK (Kim, Hong et al. 2007) or mitogen- and stress-
activated protein kinase 1 (MSK1) dependent signaling (Song, Lee et al. 2003). 
SP-1 (Hewson, Edbrooke et al. 2004) and NF-κB (Thai, Loukoianov et al. 2008) 
are also activated by ERK1/2. Moreover, ERK1/2 activates fos family proteins, 
 
 
167 
which are part of the AP-1 transcription factor complex with c-Jun proteins (Karin 
1996; Gensch, Gallup et al. 2004).  
In our studies, the level of phosphorylated RSK-1 or CREB were not 
affected by either IL-13 or FR180204 (Figure 30 A and B). The MUC5AC 
promoter region contains a TGACGTCA sequence (Johannessen, Delghandi et 
al. 2004) that is called the cAMP-response element (CRE) motif (Song, Lee et al. 
2003; Kim, Hong et al. 2007; Thai, Loukoianov et al. 2008). Phosphorylation of 
the Serine-133 residue of CREB enhances its interaction with CREB-binding 
protein (CBP) and p300 transcriptional co-activators. The CREB /co-activator 
complex in turn enhances RNA polymerase complex assembly at the CRE motif 
of the MUC5AC promoter (Johannessen, Delghandi et al. 2004) and hence 
enhances gene transcription. The role of pCREB in mucous hypersecretion was 
suggested by the observation of elevated levels of pCREB in bronchial epithelial 
cells in asthma patients compared to normal individuals (Chiappara, Chanez et 
al. 2007). It has been shown that MUC5AC expression was induced in normal 
human bronchial cells by retinoic acid and prostaglandin F2α, via CREB 
dependent mechanisms and that MUC5AC expression was abolished by 
knocking down CREB (Kim, Hong et al. 2007; Chung, Ryu et al. 2009).  In 
contrast, c-Jun phosphorylation was significantly induced by IL-13 and was 
inhibited by FR180204 treatment (Figure 29B). Thus, our results support the role 
of ERK1/2 in mediating IL-13 effect on mucin production through AP-1 nuclear 
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translocation and subsequent activation of MUC5AC transcription. Further 
studies are required to dissect the involvement of other transcription factors that 
might be downstream of ERK1/2 such as NF-κB and SP-1. 
 
5.3.2 Role of JNK signaling in mucin production in response to IL-13 in 
NHBE cells  
JNK is activated by environmental stress and pro-inflammatory cytokines 
(Pelaia, Cuda et al. 2005) such as TNF and IL-1 (Kyriakis and Avruch 2001). JNK 
is involved in regulating pro-inflammatory genes and airway remodeling in airway 
diseases (Bennett 2006). Three JNK isoforms are present in mammalian cells; 
JNK1, 2 and 3. JNK1 and 2 are expressed in most tissues, while JNK3 is only 
expressed in heart, brain and testes (Cargnello and Roux 2011). The most 
important substrate for activated JNK is the AP-1 transcription factor complex, 
composed of members of the fos and Jun families of transcription factors (Karin 
1995). Different scaffold proteins are known to modulate JNK activity and target 
JNK to specific cellular locations. JNK-interacting protein (JIP1/2) and β-arrestin-
2 are examples (Qi and Elion 2005). Several studies have shown that JNK plays 
a role in MUC5AC expression in response to cigarrete smoke extract (Yu and 
Zhou 2010), live Legionella pneumophila (Morinaga, Yanagihara et al. 2012) and 
Streptococcus pneumoniae pneumolysin (Ha, Lim et al. 2008) in cultured airway 
epithelial cells.  
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Phosphorylated JNK activates different transcription factors that belong to 
AP-1 transcription factor family (Gensch, Gallup et al. 2004) such c-Jun 
(Cargnello and Roux 2011), JunB and JunD (Davis 2000). In our study, IL-13 
induced the phosphorylation of c-Jun, a distinct JNK downstream target, only in 
the presence of epinephrine (Figure 24B). These data point towards the 
involvement of IL-13 in stimulating the kinase activity of JNK. In the absence of 
epinephrine, IL-13 did not increase the phosphorylation of c-Jun (Figure 24B). 
Treating NHBE cells with 3 µM SP600125, an inhibitor of all three isoforms of 
JNK, reduced MUC5AC expression and mucin content in response to IL-13 in the 
presence of epinephrine (Figure 31A, B and Figure 32). This inhibitory effect of 
SP600125 on mucin production is mediated by downregulating c-Jun 
phosphorylation (Figure 34A). Our result is consistent with the attenuation of 
mucus metaplasia by SP600125, in an allergen driven murine model of asthma 
(Chialda, Zhang et al. 2005; Nath, Eynott et al. 2005). Moreover, SP600125 did 
not affect the integrity of the NHBE monolayer as demonstrated by TEERs and 
ZO-1 localization (Figure 33A and B). SP600125, at high concentrations, affects 
p38 activation through inhibiting the upstream MAPKKs (Cui, Zhang et al. 2007). 
Thus, it was necessary to evaluate the effect of SP600125 on p38 and ERK1/2 
activation. SP600125 did not inhibit the phosphorylation of these MAPKs in 
response to IL-13 (Figure 34 B and C). Moreover, SP600125 did not affect CREB 
phosphorylation (Figure 35). 
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JNK is activated by β2-AR via Gs-AC/cAMP dependent activation of the 
Rho family of small GTPases (Yamauchi, Hirasawa et al. 2001) and also by G 
protein-independent, βarrestin-2-dependent pathways (Defea 2008). In addition 
to AP-1 transcription factor family, JNK also activates SP-1 (Benasciutti, Pages 
et al. 2004). These transcription factors bind to specific sequences on MUC5AC 
promoter and enhance gene expression as outlined in Figure 81. Testing the 
involvement of SP-1 transcription factor is required in future studies. 
 
 
Figure 81.  Possible action of JNK on the MUC5AC promoter: Several upstream 
signaling pathways activate JNK. Phosphorylated JNK activates a number of 
transcription factors, such as SP-1 and AP-1, that bind to the MUC5AC promoter 
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5.3.2 Role of p38 signaling in mucin production in response to IL-13 in 
NHBE cells  
Elevated levels of  phosphorylated p38, α, β and γ isoforms, are detected 
in the airway epithelium of asthmatic patients and the levels correlate with 
disease severity (Liu, Liang et al. 2008). Previous studies have illustrated the 
involvment of p38 in regulating MUC5AC expression in response to several 
inflammatory mediators such as IL-1β (Kim, Kwon et al. 2002), interleukin-17A 
(IL-17A) (Fujisawa, Velichko et al. 2009) and TNF-α (Song, Lee et al. 2003).  
In our study, the phosphorylation of p38 was not induced by IL-13 either in 
the presence or absence of epinephrine (Figure 24C). The inability of IL-13 to 
induce p38 phosphorylation is inconsistent with other studies. In one study, 
incubation of NHBE cells with 20 ng/ml IL-13 for 20 and 60 minutes resulted in 
increased p38 phoshorylation (Kono, Nishiuma et al. 2010). Moreover, 10 ng/ml 
IL-13 treatment for 48 hours produced an increase in p38 phosphorylation in 
cultured primary mTECs (Fujisawa, Ide et al. 2008). The difference bewteen our 
results and theirs could be attributed to species differences, or to donors profiles.  
To further explore a role for p38, NHBE cells were treated with 3μM 
SB203580, a specific ATP-competeitive inhibitor of both α and β isoforms of p38 
(Lisnock, Tebben et al. 1998; English and Cobb 2002; Chung 2011) in 
combination with IL-13 and epinephrine. Among the four p38 isoforms, α (Rouse, 
Cohen et al. 1994), β (Jiang, Chen et al. 1996), γ (Li, Jiang et al. 1996) and δ 
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(Wang, Diener et al. 1997), the transcript levels of α and β isoforms in the human 
lung  are higher than the other isoforms (Jiang, Gram et al. 1997). SB203580 
significantly reduced MUC5AC expression, intracellular mucin 5AC and mucin 
glycoprotein content in response to IL-13 (Figure 36 A, B and Figure 37). Our 
result is consistent with other studies where inhibiting p38 activity resulted in 
attenuated IL-13 induced goblet cell density in NHBE cells (Atherton, Jones et al. 
2003), mucin 5AC positive cells and MUC5AC expression in  cultured mTECs 
(Fujisawa, Ide et al. 2008).  
All MAPKs inhibitors that we used in our studies did not reduce the 
monolayer integrity compared to control cells that were grown in the presence of 
epinephrine, however SB203580 appeared to increase the barrier function of 
cultured NHBE cells (Figure 38A and B).   
The role of p38 is also suggested in an allergen driven murine model of 
asthma, in which inhaled p38 α antisense oligonucleotide (Duan, Chan et al. 
2005) or inhibiting p38α with a specific p38α inhibitor, SD-282,(Ma, Medicherla et 
al. 2008) attenuated mucus production in response to allergen and IL-13 
adminstration respectively. The level of p38 phosphorylation was not affected by 
SB203580 since this inhibitor inhibits the kinase activity of p38 rather than its 
upstream activators (Kumar, Jiang et al. 1999) (Figure 39C). Thus, we tested the 
phosphorylation of MAP kinase activated protein kinase-2 (MAPKAP kinase-2) 
(Cuenda, Rouse et al. 1995), a downstream subtstrate of p38, and its 
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phosphorylation level was not affected by IL-13 or by the p38 inhibitor (Figure 
40A). SB203580 did not affect the activation of other MAPKs such as ERK1/2 or 
cJun, the specific JNK downstream target (Figure 39A and B). 
p38 is activated by β2AR in a Gs-AC (Zheng, Zhang et al. 2000) and 
βarrestin-2 dependent fashion (DeWire, Ahn et al. 2007). The effect of p38 on 
MUC5AC gene expression is mediated by activation of different transcription 
factors that bind to MUC5AC promoter. Of these transcription factors; CREB 
(Song, Lee et al. 2003), NF-κB (Pelaia, Cuda et al. 2005) and SP-1 (Thai, 
Loukoianov et al. 2008) as outlined in Figure 82. CREB phosphorylation was not 
affected by p38 inhibitor (Figure 40B). Thus, we were not able to determine the 
mechanism by which p38 affect mucin production in response to IL-13 and more 
studies are required to examine the involvement of SP-1 as a downstream target 
of p38. 
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Figure 82. Schematic illustration of p38 activity on MUC5AC promoter: 
Several upstream signaling pathways activate p38. Phosphorylated p38 activates 
several transcription factors, such as CREB, SP-1 and NF-kB, that bind to the 
MUC5AC promoter region and enhance its transcriptional activity. 
 
5.4 Role of PKA signaling in mucin production in response to IL-13 in 
NHBE cells  
β2-AR can signal through heterotrimeric G-proteins, and also through β-
arrestin. The Gs pathway increases adenylyl cyclase activity and thereby 
intracellular cAMP concentrations, leading to activation of cAMP-dependent 
protein-kinase A (PKA) and exchange protein activated by cAMP (Epac). To test 
for a possible role of cAMP in mediating the effect of IL-13 + epinephrine, we first 
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tried a widely-used inhibitor of PKA, H89. This drug binds to the ATP binding site 
in the catalytic subunit of PKA and thus inhibits its activity (Chijiwa, Mishima et al. 
1990; Lochner and Moolman 2006; Cho, Woo et al. 2009). Treating NHBE cells 
with 3μM H89 in combination with IL-13 and epinephrine resulted in a reduction 
in MUC5AC expression (Figure 41A). However, H89 did not reduce ERK1/2 
phosphorylation (Figure 41B), thus either ERK1/2 is not a downstream substrate 
of PKA or the effect of H89 on MUC5AC expression is mediated by inhibiting 
MSK-1, which is downstream of ERK1/2, rather than PKA. Though H89 is used 
widely as PKA inhibitor, with a Ki ~48 nM (Chijiwa, Mishima et al. 1990), it also 
blocks β2-AR, at Ki ~180 nM (Penn, Parent et al. 1999). Moreover, H89 inhibits 
MSK-1 and other kinases with almost with simliar potency as compared to PKA 
inhibition (Penn, Parent et al. 1999; Lochner and Moolman 2006). Therefore, 
another PKA inhibitor was utilized to study the involvement of PKA.  
Rp-cAMPS is a cAMP analog that binds to cAMP binding site on PKA’s 
regulatory subunit, preventing the dissociation of the catalytic subunits and 
inhibiting PKA activity (Botelho, Rothermel et al. 1988; Dostmann 1995; Lochner 
and Moolman 2006). MUC5AC expression and intracellular mucin 5AC protein 
levels induced by IL-13 and epinephrine were inhibited by 100 µM Rp-cAMPS, 
but not 50 µM Rp-cAMPS, while the mucin content of NHBE cells was inhibited at 
both concentrations (Figure 42A, B and Figure 43). Though Rp-cAMPS is 
believed  to be specific toward PKA, it may also inhibit Epac, though the data are 
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contradictory (Christensen, Selheim et al. 2003; Rehmann, Schwede et al. 2003; 
Holz 2004).  Therefore, we can not completely exclude the role of Epac in 
mediating the effect on MUC5AC expression induced by IL-13 and further studies 
are required utilizing reagents, such as the Epac activator 8-pCPT-2-O-Me-cAMP 
(Gloerich and Bos 2010).  
The effect of Rp-cAMPS on MUC5AC expression may be explained by 
reference to the pathways shown in  Figure 83.  
 
Figure 83. Schematic diagram of possible PKA effects on MUC5AC 
promoter: Activated PKA in the Gs/AC pathway may lead to activation of several 
downstream transcription factors that bind to MUC5AC promoter region and 
enhance its transcriptional activity.  
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The two concentrations of Rp-cAMPS that we used in our studies did not 
affect the integrity of NHBE cells monolayer as evaluated by TEER and ZO-1 
localization (Figure 44A and B). 
Inhibiting PKA by 100 µM Rp-cAMPS increased ERK1/2 phosphorylation 
in NHBE cells in response to IL-13 in the presence of epinephrine (Figure 45A). 
Therefore, PKA activation has an inhibitory effect on ERK1/2 phosphorylaion. 
PKA can either activate or inhibit ERK1/2 phosphorylation based on the isoform 
of interacting Raf and the cell type (Gerits, Kostenko et al. 2008). Activation of 
PKA, by β2-AR, activates Rap-1/B-Raf signaling cascade and results in ERK1/2 
activation (Schmitt and Stork 2000). Raf-1 is expressed in most tissues while A-
Raf and B-Raf are restricted in their expression (Chen, Gibson et al. 2001). B-Raf 
is expressed at low levels in the lung (Stork and Schmitt 2002). On the other 
hand, PKA reduces ERK1/2 activation through phosphorylating and inactivating 
Raf-1 which reduces ERK1/2 phosphorylation (Cook and McCormick 1993; 
Mischak, Seitz et al. 1996). Moreover, Rap-1 activation by PKA enhances its 
association with Raf-1 and this complex sequesters Raf-1 and reduces its 
availability to bind and to Ras and consequently reduces ERK activation (Schmitt 
and Stork 2001). It’s important to note that activation of Rap-1 can stimulate B-
Raf and increase ERK phosphorylation (Gerits, Kostenko et al. 2008). The cross-
talk between ERK1/2 and PKA is complex: ERK1/2 can modify the activity of 
cAMP/PKA through affecting the activity of PDE4 (Gerits, Kostenko et al. 2008). 
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In our hands, Rp-cAMPS inhibited MUC5AC expression while it increased 
ERK1/2 phosphorylation. This discrepancy could be due to the complexity of the 
signaling pathways that are involved in regulating MUC5AC promoter activity. For 
example, even though ERK1/2 phosphorylation was increased with Rp-cAMPS, it 
is possible that Rp-cAMPS inhibited other signaling pathways that we did not 
examine in this study and these pathways have greater influence on MUC5AC 
promoter than ERK1/2. In addition to that, the cellular localization, in the 
cytoplasm or translocated to the nucleus, of phosphorylated ERK1/2 by Rp-
cAMPS could affect the cellular response.  
PKA also affects p38 activity through different complex mechanisms such 
as regulating Rap-1 and different phosphatases that affect kinases upstream of 
p38 (Gerits, Kostenko et al. 2008). PKA not only affects ERK1/2 and p38 
activation, but also JNK. The effect of PKA on JNK is not yet completely 
resolved, but cAMP/PKA might inhibit JNK activity through inducing the synthesis 
of JNK inhibitors while Epac could activate JNK-1(Gerits, Kostenko et al. 2008). 
But in our studies, inhibiting PKA did not alter the effect of IL-13 on p38 or JNK 
activity Figure 45B and C). Additionally, CREB or STAT6 phosphorylation were 
not affected by Rp-cAMPS (Figure 46A and B). Therefore, we were not able to 
determine the signaling pathway downstream of PKA. 
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5.5 Effect of cAMP elevating agents in mucin production in response to IL-13 in 
NHBE cells 
5.5.1 Effect of forskolin+IBMX in mucin production in response to IL-13 in NHBE 
cells 
To further establish the involvment of cAMP, forskolin and IBMX in 
combination were used to raise intracellular cAMP levels independent of β2AR 
activity. Forskolin activates the catalytic activity of all AC isoforms except AC9 
(Hurley 1999), through assembling the catalytic domains of AC (Zhang, Liu et al. 
1997) and hence increasing intracellular cAMP levels (Seamon and Daly 1981). 
IBMX reduces the degradation of cAMP by inhibiting all PDEs isoenzymes 
except PDE8 (Bender and Beavo 2006).  Combining both reagents substantially 
increases the intracellular cAMP levels, and this treatment increased mucin 
production in response to IL-13 even in the absence of epinephrine (Figure 47, 
Figure 48 and Figure 49).  
In patients with mild to moderate asthma, forskolin is effective in 
preventing the acute attacks and did not cause any worsening in pulmonary 
function, as evaluated by forced expiratory volume in 1 second (FEV1) 
(Gonzalez-Sanchez, Trujillo et al. 2006). This effect of forskolin is due to its 
ability in reducing the release of inflammatory mediators from several structural 
and inflammatory cells that are present in the airways. For example, forskolin 
reduces the release of eotaxin from human ASM cells (Pang and Knox 2001), IL-
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13 from peripheral blood mononuclears cells (Yoshida, Shimizu et al. 2001), 
leukotriene B4 from alveolar macrophages (Fuller, O'Malley et al. 1988). 
However, in our in vitro studies, forskolin resulted in an increase in mucin 
production in response to IL-13. Our in vitro model studied the direct effect of 
forskolin+IBMX on one specific parenchymal cell type, independent from other 
types of cells, and under the influence of one cytokine. Therefore, the results that 
are obtained from whole body or murine models should not be compared side by 
side to in vitro cultures. Forskolin+IBMX concentrations that we used in our study 
did not alter the barrier function of cultured NHBE cells in the presence or 
absence of epinephrine (Figure 50A, B). In NHBE cells, the forskolin+IBMX 
combination caused an increase in accumulated intracellular cAMP levels, by 
more than 400 fold as compared to cells grown in the presence or absence of 
epinephrine (Figure 51). However, this increase in cAMP does not mimic the 
effect mediated by epinephrine. Intracellular cAMP levels in cells grown in the 
absence or presence of epinephrine were not different. In our studies, cAMP 
levels were measured 48 hours after the last treatment point on ALI day 12. It 
has been shown previously that 10 µM isoproterenol treatment for 5 minutes 
results in significant increase in cAMP accumulation in cultured cell lines. 
However, when these cells were incubated with 10 µM isoproterenol for 24 hours 
the cAMP level was similar to untreated cells, probably due to receptor 
desensitization (Peng, Bond et al. 2011). Moreover, treating human bronchial 
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epithelial cells with salbutamol results in increased accumulation of cAMP that 
reaches maximum between 30-60 minutes (Dent, White et al. 1998). Formeterol, 
which has similar efficacy to epinephrine (Moore, Millman et al. 2007), increases 
cAMP levels in NHBE cells within 10 minutes (Korn, Jerre et al. 2001). Thus, 
epinephrine is expected to increase cAMP levels transiently and initiate a 
downstream signaling cascade that eventually affects MUC5AC expression. It is 
possible that chronically incubating NHBE cells with epinephrine causes 
downregulation and loss of β2-ARs, but enough receptors remain to drive 
MUC5AC expression in response to IL-13. Additionally, phosphorylated β2-ARs 
can affect MUC5AC expression by activation of other signaling cascades. β2-ARs 
phosphorylated by PKA at serine 262, couple to Gi which activates ERK1/2 
whereas phosphorylation of β2-ARs by GRK at other receptor sites initiates a 
second wave of signaling through β-arrestin. Additional studies are required to 
evaluate the receptor levels after chronic exposure to epinephrine in NHBE cells. 
It is important to mention that it has been reported recently that internalized β2-
AR are capable in inducing a second wave of cAMP signaling through activation 
of Gs pathway from the endosome (Irannejad, Tomshine et al. 2013).  
Increased intracellular cAMP affects several downstream targets that can 
eventually increase MUC5AC expression as outlined in Figure 84. 
Forskolin+IBMX did not affect the level of ERK1/2, p38 or c-Jun phosphorylation 
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in response to IL-13 as compared to cells treated with IL-13 alone (Figure 52 and 
Figure 53).  
 
Figure 84. Possible action of cAMP on the MUC5AC promoter: Increased 
intracellular cAMP activates PKA and Epac signaling molecules.  PKA and Epac 
phosphorylate several downstream signaling proteins that activate several 
transcription factors that are capable to enhance MUC5AC transcriptional 
activity. CREB, SP-1, AP-1 and NF-kB are examples of these transcription 
factors. 
 
Only in the presence of epinephrine did forskolin+IBMX in combination 
with IL-13 increase CREB phosphorylation (Figure 54A and B). Other candidates 
that might mediate the effect of forskolin+IBMX in combination with IL-13 in the 
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absence of epinephrine and require further examination include HIF-1, SMAD-4 
and NF-κB.  
Additionally, the forskolin+IBMX combination increases STAT6 
phosphorylation in response to IL-13 in the presence of epinephrine (Figure 
54C). Since the MUC5AC promoter region lacks a STAT6 consensus motif, 
STAT6 may indirectly contribute to MUC5AC expression through the activation of 
other transcription factors such as HIF-1 and SMAD4 (Young, Williams et al. 
2007; Thai, Loukoianov et al. 2008). It is noteworthy that even though 
forskolin+IBMX increased cAMP levels in the presence or absence of IL-13, 
mucin parameters only increased in the presence of IL-13. Thus, cAMP by itself 
is not enough to drive MUC5AC expression, and IL-13 activation of other 
signaling pathways is necessary. This interaction might be at the level of STAT6, 
thus an inhibitor of STAT6 could be used in future studies to further delineate the 
cross-talk between β2-AR and IL-13 signaling. 
 
5.5.2 Effect of a specific PDE inhibitor on mucin production in response to 
IL-13 in NHBE cells  
One major limitation of forskolin+IBMX is that these agents result in a 
global and diffuse increase in intracellular cAMP levels throughout cells. 
Recently, it has become appreciated that compartmentalized factors are 
responsible for spatially and temporally controlling the generation and 
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degradation of cAMP (Arora, Sinha et al. 2013). This compartmentalization 
phenomenon is the underlying reason for the differences in cell responses to 
variety of ligands that work through the same second messenger. For example, 
differences in the effect of β2-AR ligands and prostaglandin on heart contractility 
are due to differences in the compartmentalization of cAMP and consequently 
the phosphorylation of specific downstream substrates (Di Benedetto, Zoccarato 
et al. 2008). The spatially confined subcellular compartmentalization of cAMP 
signaling elements includes PKA, PDEs, phosphatases, specific substrates 
(Wong and Scott 2004) and ACs (Dessauer 2009) that are anchored to A kinase 
anchoring proteins (AKAPs). This compartmentalization creates different cAMP 
pools, each with its specific set of substrates and unique cell responses, as 
shown in the Figure 85.  For all of the aforementioned reasons, we used a more 
specific PDE inhibitor. 
cAMP compartmentalization in the subcortical region of human airway 
epithelial cells has been reported to be involved in PKA mediated control of cystic 
fibrosis transmembrane conductance regulator (CFTR) activity, and alteration in 
this compartmentalization has been reported in cystic fibrosis (CF) (Monterisi, 
Favia et al. 2012).  
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Figure 85. Schematic illustration of compartmentalized cAMP signaling: 
Two different cAMP pools (red) are generated by AC based on the localization of 
the enzyme (anchored to plasma membrane or attached to the internalized 
receptor), GPCR (on the cells surface or internalized) and PDEs where they 
degrade the cAMP to prevent its leak to other compartments. Each compartment 
activates different subsets of substrates.  Moreover, the differences in the 
localization of different PKA (PKAI and PKAII) and their variability in cAMP 
sensitivity contribute to activation of different subset of substrates. Adapted from 
Zaccolo (2011). 
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In humans, there are 11 different families of PDEs (Omori and Kotera 
2007). In the airways, each cell type expresses a predominant PDE isoenzyme. 
For example, ASM cells express PDE3, 4, and 5 while airway epithelial cells and 
inflammatory cells express mainly PDE4 (Barnes 1995). Most inhibitors that act 
on PDE4 interfere with the catalytic activity of the enzyme (Page and Spina 
2012). The compartmentalization of PDEs is especially important to degrade 
cAMP in specific microdomains and prevent the spread of cAMP to other 
compartments which might affect other substrates. The importance of this is 
revealed by an elegant study by Jurevicius and Fischmeister, where they 
measured L-type calcium current (ICa) by whole-cell patch-clamp recording in 
cardiac myocytes. Exposing half of the cell surface to isoproterenol or forskolin 
resulted in a local and global effect on ICa respectively. However, isoproterenol 
combined with IBMX resulted in a global effect, indicating the importance of PDE 
in compartmentalized β2-AR signaling (Jurevicius and Fischmeister 1996).  
Beside the role of each PDE isoenzyme in compartmentalized signaling, there 
are different PDE4 isoforms (PDEA, B, C and D) and at least 18 splice variants 
(Kodimuthali, Jabaris et al. 2008). The main isoform that mediates anti-
inflammatory effects is PDE4B while PDE4D contributes to the adverse effects, 
mainly emesis and nausea (Lipworth 2005). Roflumilast inhibits all PDE4 
isoforms (Lipworth 2005). Thus, it is expected that each of these isoforms have 
its role in a specific compartmentalized signaling.  
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Treating NHBE cells with 100 nM roflumilast in the absence of epinephrine 
did not increase MUC5AC expression, intracellular mucin 5AC or mucin 
glycoproteins in response to IL-13 (Figure 55A, Figure 56A and Figure 57A). 
In the presence of epinephrine, roflumilast did not affect MUC5AC 
expression in response to IL-13 (Figure 55B).  However, mucin 5AC and 
intracellular mucin were reduced significantly in response to IL-13 (Figure 56B 
and Figure 57B). The levels of cAMP were not increased in roflumilast treated 
cells in response to IL-13 either in the presence or absence of epinephrine 
(Figure 59A and B). Human primary bronchial epithelial cells show similar 
activities of both PDE4 and PDE1 and lower activity of PDE3 and PDE5 isoforms 
(Dent, White et al. 1998). However, in another study, cultured human epithelial 
cells showed the presence of the PDE4 and 5 isoenzymes (Fuhrmann, Jahn et 
al. 1999). Therefore, it is possible that inhibiting PDE4 only is not enough to 
increase intracellular cAMP levels. In addition, the effect of roflumilast on 
intracellular mucin 5AC and mucin glycoproteins production induced by IL-13 in 
the presence of epinephrine could be cAMP independent.  
Roflumilast reduced muc5ac expression and mucus producing cells, in a 
dose-dependent fashion, in mouse lungs in response to bleomycin (Cortijo, 
Iranzo et al. 2009). Thus, it is possible that we could observe more reduction of 
MUC5AC expression if we used higher concentrations of roflumilast. 
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The discrepancy in the effect of PDE4 inhibition on mucus is also 
observed in in murine models. Roflumilast did not affect mucus metaplasia in 
chronic murine model of asthma (Kumar, Herbert et al. 2003). In contrast, 
rolipram, another PDE4 inhibitor, decreased mucus metaplasia in an acute 
murine model of asthma (Kanehiro, Ikemura et al. 2001). In vitro studies with 
roflumilast have revealed its inhibitory effects toward human inflammatory cells 
such as eosinophils, neutrophils and macrophages (Hatzelmann and Schudt 
2001). Moreover, it has been shown that the increase in cAMP concentration 
caused by PDE4 inhibition suppresses eosinophil activity (Dent, Giembycz et al. 
1994). The use of roflumilast in inflammatory airway diseases, such as asthma 
and COPD, results in a significant improvement in the disease condition (Cowan 
2005; van Schalkwyk, Strydom et al. 2005; Bateman, Izquierdo et al. 2006). 
Roflumilast attenuated sputum levels of eosinophils and neutrophils (Gauvreau, 
Boulet et al. 2011) and also reduced AHR (Louw, Williams et al. 2007; Gauvreau, 
Boulet et al. 2011) in mild asthmatic patients. Thus, it is possible that the 
usefulness of PDE4 inhibitors in vivo is mediated by the reduction in the 
inflammatory mediators released from parenchymal cells and inflammatory cells. 
This could explain the discrepancy between in vivo results and our in vitro 
results, where we focused on one cell type and studied the direct effect of 
roflumilast independent from its other anti-inflammatory effects on other cells. 
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Roflumilast did not reduce the barrier function as compared to cells grown 
in the presence or absence of epinephrine (Figure 59A and B). 
Examining the signaling pathways (Figure 84) downstream of roflumilast 
revealed that the roflumilast and IL-13 combination did not affect ERK1/2 or cJun 
phosphorylation in the absence or presence of epinephrine (Figure 60A, B and 
Figure 61A, B). On the other hand, the roflumilast and IL-13 combination 
increased p38 phosphorylation in the absence of epinephrine as compared to 
control cells, yet this increase was not associated with any effect on MUC5AC 
transcription (Figure 60C). Other studies have shown that the anti-inflammatory 
effect of roflumilast in A549 cells is mediated by inhibition of ERK1/2 and p38 
activation (Mata, Sarria et al. 2005) and, in a murine macrophage cell line, 
through inhibiting NF-κB, p38 and JNK (Kwak, Song et al. 2005). In our study, we 
were not able to determine how roflumilast inhibits mucin production in response 
to L-13. Therefore, testing the involvement of NF-κB is required and further 
studies using donors whose cells respond to IL-13 by increasing MAPKs 
phosphorylation are required.    
Roflumilast did not increase STAT6 or CREB phosphorylation in response 
to IL-13 in the presence of epinephrine (Figure 62B-C), in contrast to the 
forskolin+IBMX combination. This provides an explanation for the differences in 
mucin parameters that we saw with the global increase in cAMP by 
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forskolin+IBMX combination versus roflumilast, though both are expected to 
increase intracellular cAMP levels in NHBE cells.                                                                                                                                              
 
5.6 Role of β-arrestin signaling in mucin production in response to IL-13 in 
airway epithelial cells 
5.6.1 Effect of carvedilol on mucin production in response to IL-13 in NHBE 
cells 
In addition to its signaling action through G proteins, β2ARs also signal 
through β-arrestin dependent pathways. We performed studies which were 
intended to provide evidence for or against a role of β-arrestin in the promotion of 
mucin production by β2ARs. For this purpose, we employed a biased β2AR 
agonist. 
Biased agonism describes the ability of a ligand to preferentially activate a 
specific signaling pathway that is known to be activated by the receptor 
(Rajagopal, Rajagopal et al. 2010; DeWire and Violin 2011; Kenakin and 
Christopoulos 2013), as shown in Figure 86A below. This modifies the two state 
receptor theory, in which there are a number of unique active conformations (R*), 
each having its own preferential stimulation of G-protein or β-arrestin signaling 
(Walker, Penn et al. 2011), as outlined in Figure 86B.  
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Figure 86. Biased agonism concept:  A) Agonist, antagonist and biased 
ligand concept. a) Binding of non-biased agonist to the receptor activates all 
downstream signaling cascades, in this example, β-arrestin and G-protein 
signaling. b) Non-biased antagonist binds receptors and inhibits all pathways. 
c) G-protein biased ligand binds to the receptor and only activates G-protein 
signaling. d) β-arrestin biased ligand binds to the receptor and only activates 
β-arrestin and inhibits G-protein signaling. Adapted from Whalen, Rajagopal 
(2011) . 
B) Proposed conformations of β2-AR based on biased agonism concept. 
The receptor exists at equilibrium between the inactive conformation (R) and 
different active conformations (R*). R* could be unbiased and signal through 
G-protein or β-arrestin signaling (R* G-active and β-arrestin active), or biased toward 
G-protein (R* G-active) or β-arrestin signaling (R* β-arrestin active).  Reproduced 
from Walker, Penn et al. (2011). 
A B 
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Different β-AR ligands have different signaling profiles. Alprenolol is a 
weak partial agonist on both the Gs/AC and β-arrestin-2 pathways (Wisler, 
DeWire et al. 2007). Nadolol is an inverse agonist with respect to Gs/AC 
signaling, while not affecting β-arrestin signaling (as assessed by ERK1/2 
phosphorylation) (Wisler, DeWire et al. 2007). Carvedilol and propranolol, non-
selective β-AR blockers, are inverse agonists of the Gs/AC pathway and agonists 
of the β-arrestin-2 pathway (Galandrin and Bouvier 2006; Wisler, DeWire et al. 
2007; Stallaert, Dorn et al. 2012). Carvedilol induces β2-AR phosphorylation, 
recruitment of β-arrestin-2 and internalization of the receptors to initiate ERK1/2 
activation through β-arrestin-2 dependent mechanisms (Wisler, DeWire et al. 
2007). Carvedilol neither increased mucin production in NHBE cells in response 
to IL-13 in the absence of epinephrine nor altered the mucin production induced 
by IL-13 in the presence of epinephrine (Figure 63A, B, Figure 64A, B and Figure 
65A, B). Though carvedilol is a full inverse agonist at Gs/AC pathway, 
intracellular cAMP levels in carvedilol treated groups were not lower than control 
cells (Figure 68A, B). This could be due to the time point at which we measured 
cAMP levels in these cells as discussed previously. 
We then studied the effect of carvedilol on different downstream signaling 
molecules, as outlined in Figure 87. Unexpectedly, carvedilol did not increase 
ERK1/2 phosphorylation either in the presence/absence of epinephrine or 
presence/absence of IL-13 (Figure 69A and 70A). Instead, carvedilol in 
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combination with IL-13 reduced ERK1/2 phosphorylation as compared to cells 
grown in the absence of epinephrine (Figure 9A). Carvedilol activates ERK1/2 
through Gs-independent and β-arrestin-2 dependent pathway (Galandrin and 
Bouvier 2006; Wisler, DeWire et al. 2007; Stallaert, Dorn et al. 2012). Thus, 
variability in donors’ responses and profiles could be the underlying reason for 
not observing any difference in ERK1/2 activation by IL-13 or IL-13+carvedilol 
treatment. Further studies using donors whose cells respond to IL-13 by 
increasing ERK1/2 phosphorylation are required. Phosphorylation of cJun, the 
downstream substrate of JNK, was not affected by carvedilol in the absence of 
epinephrine (Figure 69B). However, in the presence of epinephrine, carvedilol + 
IL-13 treatment increased cJun phosphorylation as compared to cells grown in 
the presence of epinephrine (Figure 70C). The phosphorylation of cJun could be 
the underlying reason for the lack of difference in mucin production between cells 
treated with epinephrine+IL-13 and epinephrine+IL-13+carvedilol. It is 
noteworthy, that all signaling molecules that were affected by different activators 
or inhibitors did not affect MUC5CA expression in the absence of IL-13.  
The levels of p38 or CREB phosphorylation were not affected by carvedilol 
either in the presence or absence of epinephrine (Figure 69C, Figure 70C and 
Figure 71A, B), though it has been reported that β-arrestin-2 activates ERK1/2 
and CREB through PKA independent pathways in CF (Manson, Corey et al. 
2011). Thus, we could not establish a role for β-arrestin-2 in mediating the IL-13 
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response and further experiments on NHBE cells from different donors may be 
required, as well as reducing the expression of β-arrestin-2 using shRNA or 
knockdown similar approach 
 
Figure 87. Schematic illustration of possible action of β-arrestin-2 on 
MUC5AC promoter: Activated β-arrestin-2 signaling cascade result in 
phosphorylation of MAPKs. Activated MAPKs in turn activate several 
transcription factors, such as CREB, SP-1, AP-1 and NF-kB,that enhance 
MUC5AC transcriptional activity.  
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5.6.2 Effect of β-arrestin-2 on mucin production in response to IL-13 from isolated 
mouse tracheal epithelial cells (mTECs). 
The intracellular content of mucin 5ac in mTECs cultured from β-arrestin-2 
KO mice was increased in response to IL-13 as compared to untreated cells from 
β-arrestin-2 KO, while it was significantly lower as compared to IL-13 treated 
cells from WT mice (Figure 72). On the other hand, intracellular mucin 
glycoprotein was significantly higher in IL-13 treated cells from WT mice as 
compared to IL-13 treated cells from β-arrestin-2 KO (Figure 73). Several studies 
suggest the involvement of β-arrestin-2 in a murine model of asthma. β-arrestin-2 
KO mice fail to develop AHR and airway inflammation in response to allergen 
(Walker, Fong et al. 2003). Additionally, chimeric mice with β-arrestin-2 
expression in hematopoietic cells but not in structural cells (S-/H+) did not show 
any decrease in mucus metaplasia, as reported by periodic acid-Schiff score, in 
response to IL-13 or ovalbumin challenge compared to wild type mice 
(Hollingsworth, Theriot et al. 2010). Also, exclusive β-arrestin-2 expression in 
structural cells but not in hematopoietic cells (S+/H-) revealed a reduction in 
mucus metaplasia in response to IL-13 or ovalbumin challenge compared to wild 
type mice (Hollingsworth, Theriot et al. 2010). These data illustrate the 
importance of β-arrestin-2 signaling in hematopoietic cells in mediating mucus 
metaplasia in response to IL-13 or allergen. One suggested scenario is that the 
inflammatory mediators released from hematopoietic cells, via β-arrestin-2 
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dependent mechanisms, act on airway epithelial cells to enhance mucus 
metaplasia. β-arrestin-2 in mouse airway epithelial cells do not appear to have a 
direct involvement in mediating mucus production in response to IL-13 in vivo, 
consistent with our NHBE cells findings but not with mTECs results. This 
discrepancy could be due to differences between in vitro and in vivo models. In 
mTECs studies, the isolated cells were cultured in the absence of any other 
inflammatory cell types and were treated for 14 days with IL-13 while it was for 7 
days in in vivo study.  
The inconsistency of the findings from NHBE cells and mTECs can be 
attributed to differences in species, culture media and growth supplements and 
most importantly, the starting time point of IL-13 treatment. IL-13 treatment 
started on ALI day 1 in NHBE cells and on ALI day 14 in mTECs after the cells 
were fully differentiated. Starting the IL-13 treatment after the cells are fully 
differentiated resembles the situation in vivo, in which the cells are already 
differentiated and the treatment does not affect the differentiation process.  
Finally, it may be that the KO mice have adapted to the absence of β-arrestin-2 
and β-arrestin1 or other proteins were capable in mediating the increase in mucin 
5ac levels in response to IL-13 but to a significantly lower levels as compared to 
IL-13 treated mTECs from WT mice. 
Evaluating the barrier function revealed that treating mTECs from β-
arrestin-2 KO mice had lower TEER values after 14 days of treatment as 
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compared to untreated cells (Figure 74A), with leaking of the media from the 
basal compartment of the insert to the apical compartment. Moreover, ZO-1 
apical and cell-cell junction localization was also disturbed in these cells (Figure 
74B). A smaller, but not significant, reduction in TEERs was observed in IL-13 
treated mTECs from WT as compared to untreated cells. However, in cultured 
NHBE cells we did not observe this difference. This increase in epithelial 
permeability by IL-13 in cells from β-arrestin-2 KO means that β-arrestin-2 
molecule might play a role in maintaining the integrity of the monolayer. 
Therefore, it is necessary to evaluate the expression and localization other 
molecules that are known to be involved in the formation of tight junction such as 
occluding and claudin (Shin, Fogg et al. 2006).  During inflammation, cytokines 
such as IL-4 and IL-13, reduce the barrier function of epithelial cells (Forster 
2008). Moreover, airway epithelial cells from asthmatic patients have a disrupted 
barrier function and lower TEER measurements as compared to cells from 
normal individuals (Xiao, Puddicombe et al. 2011). However, in cultured NHBE 
cells we did not observe any reduction in TEER of IL-13 treated cells as 
compared to control cells. This difference in the IL-13 effect on the integrity of the 
monolayer between cultured mTECs and NHBE cells could be explained by 
differences at the level of cell culture.  mTECs were fully differentiated when IL-
13 was administered. The response of fully differentiated cells mimic the 
behavior of in vivo bronchial epithelial cells. Whereas IL-13 was added at the 
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beginning of the differentiation phase in NHBE cells and hence IL-13 affects the 
differentiation of these cells and the way these cells respond to IL-13. Thus, 
evaluating the barrier function in fully differentiated NHBE cells in response to IL-
13 is important for establishing a better in vitro model for studying asthma.  
 
5.7 Effect of β2-AR signaling on IL-13 modulation of mucociliary 
differentiation of NHBE cells.  
Growing NHBE cells to ALI provokes polarization and differentiation to 
form pseudostratified epithelium with tight junctions. Airway epithelium is 
composed of a heterogeneous population of basal, ciliated and goblet cells. The 
goblet cell phenotype can be assessed by immunohistochemical detection of 
mucin 5AC or MUC5AC expression, the main mucin-producing gene (Atherton, 
Jones et al. 2003; Yoshisue, Puddicombe et al. 2004). The ciliated cell 
phenotype can be assessed by the expression of specific markers such as tektin, 
FOXJ1 and β-tubulin IV. Previous reports pointed toward an effect of IL-13 in 
upregulating goblet cell numbers at the expense of ciliated cells and causing the 
ciliated cells to transdifferentiate to mucin-producing cells. Chronic administration 
of IL-13 during mucociliary differentiation resulted in increased goblet cell 
numbers in cultured bronchial epithelium leading to mucous hypersecretion 
(Atherton, Jones et al. 2003; Yoshisue, Puddicombe et al. 2004).  However, this 
increase in goblet cells was associated with a reduction in ciliated cell population 
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as represented by downregulation of tektin (Yoshisue, Puddicombe et al. 2004) 
and FOXJ1 (Yoshisue, Puddicombe et al. 2004; Turner, Roger et al. 2011) 
expression.  
To examine if epinephrine is necessary for mediating the shift of ciliated 
cells to goblet cells, we correlated MUC5AC and FOXJ1 expression in response 
to IL-13 in the presence and absence of epinephrine.  In the presence of 
epinephrine, IL-13 induced MUC5AC expression in NHBE cells, but the 
expression of FOXJ1 was not downregulated (Figure 75 A). Our results are 
inconsistent with other reports that demonstrated the downregulation of FOXJ1 
expression in response to IL-13 (Yoshisue, Puddicombe et al. 2004; Turner, 
Roger et al. 2011). In the absence of epinephrine, IL-13 did not induce MUC5AC 
expression and FOXJ1 expression showed a non-significant increase (Figure 
75A).  
Next, we examined if the reduction in MUC5AC expression during 
blockade of β2-ARs was associated with upregulation of FOXJ1. Specifically, we 
asked if β2-AR signaling is required for the mucociliary shift that is induced by IL-
13. In the presence of epinephrine, IL-13 or CGP 20712A did not affect FOXJ1 
expression. Moreover, ICI-118,551 did not increase the FOXJ1 expression 
significantly (Figure 75B). Though previous reports showed that IL-13 decreased 
FOXJ1 on day 14 ALI (Turner, Roger et al. 2011), but donor variations might 
attribute to these differences.  
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Other cells that could transdifferentiate to mucus producing cells are basal 
cells and club cells. Several studies have shown that goblet cells originate 
directly from club cells in a murine model of asthma (Reader, Tepper et al. 2003; 
Evans, Williams et al. 2004; Hayashi, Ishii et al. 2004; Chen, Korfhagen et al. 
2009; Pardo-Saganta, Law et al. 2013). Club cells are the main non-ciliated 
secretory cells throughout mouse airways but these cells are found only in the 
bronchioles in human lungs (Liu, Driskell et al. 2006). Therefore, the involvement 
of club cells in goblet cell formation is not expected and testing whether basal 
cells play a role is recommended.  
The increase in mucus production could be due goblet cell hyperplasia, 
which is the increase in goblet cell numbers in areas where goblet cells are 
usually present (Rogers 2003; Mary Mann-Jong Chang 2008). Accordingly, the 
proliferation of existing goblet cells causes an increase in mucin production. 
Since the cell seeding density for all treatment groups were the same, counting 
the cell nuclei provides a clue as to whether β2-AR signaling is involved in cell 
proliferation. In the presence of epinephrine, IL-13 significantly increased the cell 
number as compared to cells grown in the presence or absence of epinephrine 
(Figure 76A). Treating NHBE cells with IL-13 and CGP 20712A resulted in a 
significant increase in the cell number. ICI-118,551 reduced the cell number as 
compared to CGP 20712A + IL-13 treated cells (Figure 76B). Therefore, a more 
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specific way to evaluate cell proliferation may be required, such as assessing 
proliferating cell nuclear antigen (PCNA).  
Forskolin+IBMX in combination with IL-13 increased the DAPI count 
significantly compared to all other groups, either in the absence or presence of 
epinephrine (Figure 77A and B). Interestingly, forskolin+IBMX alone without IL-13 
did not induce an increase in cell number. IL-13 can initiate cell proliferation 
through releasing transforming growth factor-alpha (TGF-α) from airway epithelial 
cells, which then activates EGFR signaling (Booth, Adler et al. 2001; Booth, 
Sandifer et al. 2007). Moreover, it has been reported that epinephrine and cAMP 
elevating agents enhance cell division and proliferation and inhibit squamous cell 
differentiation (Pfeifer, Lechner et al. 1989). Thus, a global increase in cAMP 
may result in a synergistic increase in the IL-13 effect on cell proliferation and 
mucociliary differentiation toward more goblet cells. Nonetheless, we cannot 
assume that goblet cells are the proliferating cells and not the precursor cells that 
differentiate/transdifferentiate to mucus producing cells. 
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6. Summary and Conclusions: 
Our study examined the involvement of β2-ARs signaling in mucin production 
parameters (MUC5AC expression, intracellular mucin 5AC and mucin 
glycoproteins accumulation) that are induced by IL-13 in NHBE cells. The main 
findings in our study are: 
1. IL-13 induces mucin production in NHBE cells only in the presence of 
epinephrine. Growing the cells in the absence or presence of epinephrine 
throughout ALI does not affect the levels of expressed mucociliary differentiation 
markers, the released chomkines or the barrier function. The only difference is 
their response to IL-13. 
2. Epinephrine-induced β2-AR signaling is required for IL-13 induced mucin 
production in NHBE cells. Whereas constitutive β2-AR signaling is not sufficient 
to mediate the effect of IL-13 on mucin production in bronchial airway epithelial 
cells. 
3. Mitogen activated protein kinases (MAPKs) are involved in mucin production in 
NHBE cells in response to IL-13. Only in the presence of epinephrine, IL-13 
induces ERK1/2 phosphorylation and JNK activity, but does not alter p38 
activation. ERK1/2 and JNK signaling molecules affect MUC5AC expression 
through activating cJun, a member of AP-1 transcription factor family.  
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4. Protein Kinase A (PKA), as a part of the canonical Gs/adenylyl cyclase 
pathway of β2-AR signaling, is involved in IL-13 induced mucin production in 
NHBE cells.  
5. cAMP elevating agents potentiates mucin production in response to IL-13 in 
NHBE cells, in the presence or absence of epinephrine. In the presence of 
epinephrine, forskolin+IBMX combination enhances MUC5AC expression 
through CREB and STAT6 signaling molecules. However, in the absence of 
epinephrine, forskolin+IBMX combination does not alter the levels of CREB 
phosphorylation. 
6. Roflumilast, a PDE4 inhibitor, does not reduce MUC5AC expression, but it 
attenuates intracellular mucin accumulation in the presence of epinephrine. 
Whereas it has no effect on mucin parameters in response to IL-13 in the 
absence of epinephrine.  
7. Activation of β-arrestin signaling, by carvedilol, does not alter the induced 
levels of mucin parameters in response to IL-13 in the presence of epinephrine 
but it induces cJun phosphorylation. In the absence of epinephrine, carvedilol 
neither induces mucin production in response to IL-13 nor affects MAPKs or 
CREB activation. Therefore, β-arrestin does not seem to be involved in IL-13 
induced mucin in NHBE cells. 
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8. IL-13 treatment of mouse tracheal epithelial cells (mTECs) from β-arrestin-2 
KO mice results in a lower level of mucin production as compared to IL-13 
treated cells from WT mice. Therefore, β-arrestin-2 is involved in mediating the 
cell response to IL13 in mice airway epithelium. 
9. Epinephrine, epinephrine-induced β2-AR signaling or IL-13 are not involve in 
mucocilary shift from ciliated cells to goblet cells in IL-13 treated NHBE cells. 
10. IL-13 increases cell proliferation only in the presence of epinephrine. 
However, β2-AR signaling does not seem to be involved in this effect. Increasing 
intracellular cAMP by forskolin+IBMX combination induces cells proliferation in 
response to IL-13, either in the presence or absence of epinephrine.  
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8. Appendix: 
The requirement of epinephrine in inducing mucin production in response 
to IL-13 in NHBE cells is consistent with our recent data where genetic or 
pharmacological depletion of epinephrine in mice resulted in attenuation of 
inflammation and mucous metaplasia in an antigen-driven allergic model of 
asthma (Thanawala, Forkuo et al. 2013). To determine if this requirement for 
epinephrine is specific to the TH2 driven model of asthma, we tested the 
involvement of epinephrine in innate immunity model, induced by toll-like 
receptor (TLR) ligands (Pam2CSK4, TLR2/6 agonist, and ODN2395, TLR9 
agonist) (Duggan, You et al. 2011). TLRs recognize pathogen-associated 
molecular patterns (PAMPs) (Medzhitov 2001),  conserved features of pathogens 
(Takeda, Kaisho et al. 2003), and induce innate immune responses. Activation of 
TLR upon its binding to PAMPs results in a initiating downstream signaling 
cascade through the Toll/IL-1 receptor (TIR) domain and results ultimately in 
inducing the expression of inflammatory mediators and antimicrobial proteins 
(Takeda and Akira 2004). Recently, a synergistic interaction between TLR2/6 
and TLR9 has been reported to provide a protection against lung infections 
(Duggan, You et al. 2011; Tuvim, Gilbert et al. 2012). 
For establishing an innate immunity model, we treated WT mice and 
epinephrine-ablated mice (these mice lack phenylethanolamine N-
methyltransferase (PNMT) enzyme which is required for epinephrine synthesis) 
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with 4µM Pam2CSK4 and 1µM ODN2395 for 20 minutes by nebulization and 
then sacrificed 24 hours after the treatment. Total inflammatory cells and 
neutrophil numbers in bronchoalveolar lavage fluid were counted. 
In our study, neither the total inflammatory cells nor neutrophils 
recruitment to the airways was affected by the presence or absence of 
epinephrine (Figure A1). In contrast to the previously published data, where 
epinephrine ablated mice had complete attenuated asthma phenotype, airway 
eosinophilic inflammation beside AHR and mucus metaplasia, in an antigen-
driven allergic model of asthma (Thanawala, Forkuo et al. 2013). Therefore, we 
cannot extrapolate the requirement of epinephrine to other murine models of 
airway inflammation besides those driven by TH2 lymphocytes. 
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Figure A1. Role of epinephrine in a neutrophil model of airway 
inflammation.  Wild type (WT) and epinephrine knockout (Epi KO) mice 
were treated with PBS (vehicle) or toll-like receptor (TLR) ligands (4µM 
Pam2CSK4, TLR2/6 agonist, and 1µM ODN2395, TLR9 agonist) for 20 
minutes by nebulization and then sacrificed 24 hours after the treatment. 
Bronchoalveolar lavage was performed and the recovered total cells (A) 
and differential neutrophil count (B) were counted. Data are presented as 
means ± SEM from N=4-5 mice. * and # indicate p<0.05 significance 
between WT/vehicle and Epi KO/vehicle respectively. 
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